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ABSTRACT 
 Poly(ADP-ribose) synthesis and degradation are important cellular processes associated 
with the DNA damage response and many other pathways. Traditionally, these processes have 
been challenging to study due to the heterogeneity associated with the synthesis of poly(ADP-
ribose). Discussed here are methods for the synthesis of homogeneous poly(ADP-ribose) as well 
as the biology that is enabled by these synthetic efforts.  
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Chapter 1. Poly(ADP-ribose): Opportunities and Challenges 
 
1.1 Introduction to Poly(ADP-ribose) Synthesis and Degradation 
Poly(ADP-ribosyl)ation is a common post-translational modification mediated by the 
poly(ADP-ribose) polymerase (PARP) protein family and the enzyme poly(ADP-ribose) 
glycohydrolase (PARG). A family of 17 PARP enzymes exists with 12 of these enzymes 
possessing mono ADP-ribosyl transferase activity and five possessing the ability to synthesize 
poly(ADP-ribose) (PAR)1. PARP-1 is the most ubiquity expressed of the PARP family and is 
responsible for the majority of PAR synthesis2. When cells undergo DNA damage, PARP-1 
associates to the damaged sites and begins the synthesis of PAR. In this process, PARP-1 
converts the molecule β-NAD+ to polymers of PAR, modifying both itself as well as other 
acceptor proteins (Figure 1.1). The polymers act as a scaffold to recruit a host of non-covalent, 
PAR-binding, DNA-damage repair proteins such as X-ray cross complementing protein-1 
(XRCC1) (Figure 1.1). Ultimately, recruitment of these proteins results in repair of the damaged 
DNA. Upon successful DNA repair, the glycohydrolase enzyme (PARG) cleaves the polymers to 
ultimately form monomeric ADP-ribose3 (Figure 1.1). In addition to PARG, other enzymes are 
responsible for PAR processing including ARH3, which is the primary enzyme for PAR 
processing in the mitochondria of the cell4. Though much less active toward PAR than PARG, 
ARH3’s role in PAR metabolism is still being elucidated and is perhaps greater than initially 
thought5. Also, PARG and ARH3 are unable to remove the final ADP-ribose unit from acceptor 
proteins, and several enzymes (MacroD1, MacroD2 and TARG1) exist that possess this 
capability6,7.  
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Enzymatic degradation of PAR chains is an important process, as long chain PAR can 
trigger cell death through a process known as parthanatos in the event of extensive DNA damage 
or PARG deficiency8-11.  While PAR’s role in the DNA damage response has been the most well 
characterized and delineated, it is a post-translational modification with roles in other cellular 
processes such as replication, transcription, and chromatin regulation12. As a result, the list of 
PAR-binding proteins and protein domains is ever-growing; PAR has been shown or predicted to 
interact non-covalently with over 500 proteins through at least four distinct protein-binding 
domains13-17.  	
	
Figure 1.1. Poly(ADP-ribose) synthesis and degrdation in response to DNA damage. PARP: 
poly(ADP-ribose) polymerase. PARG: poly(ADP-ribose) glycohydrolase. XRCC1: X-ray cross 
complementing protein 1. 
 
Chemically, PAR is a highly heterogeneous and polydisperse polymer of ADP-ribose 
with units of ADP-ribose linked via an α-glycosidic linkage between the 2’ position of adenosine 
and the 1’’ position of ribose (Figure 1.2). The polymer can be 2 to greater than 200 units in 
length. The two negative charges per monomeric unit results in polymers with high negative 
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charge, an aspect believed to be an important factor in the mediation of PAR-protein 
interactions18. A branching process in the polymer occurs with some regularity (about every 20-
30 residues), forming an α-glycosidic linkage between the ribose 2’’ and 1’’’ positions19. 
Interestingly, both the polymerization process of branched PAR and the catabolism process to 
degrade it are mediated by the same enzymes (PARP and PARG) that modulate the synthesis and 
processing of linear PAR. That is, enzymes that specifically carry out the formation or 
degradation of branched PAR do not exist.  
 
Figure 1.2. Chemical structure of poly(ADP-ribose) 
 Therapeutic targeting of the PAR cycle has been of interest for several decades20,21. 
Inhibitors of PARP have been pursued extensively as an anti-cancer strategy and have made 
good progress in the clinic, culminating in the recent approval of Olaparib for advanced ovarian 
cancers with BRCA mutations22 as well as castration resistant prostate cancer23. A number of 
clinical trials are currently ongoing pursuing PARP inhibition both as a single agent (primarily in 
BRCA deficient patients) as well as in combination with DNA damaging agents. Targeting of 
PARG in the treatment of cancers is another promising approach. However, despite being 
pursued for some time, PARG inhibition is much less advanced than inhibition of PARP. While 
good in vitro inhibitors of PARG such as ADP-HPD24-26 and the RBPIs27 have been discovered, 
to date no compounds that specifically inhibit PARG activity in whole cells have been described.  
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1.2 Heterogeneity of PAR as Produced by PARP  
The heterogeneity of PAR when produced by PARP has been an impediment to the 
overall study of PAR metabolism. As previously mentioned, PAR is a heterogeneous and 
branched polymer produced in lengths ranging from 2 to over 200 monomeric units. PAR is most 
frequently used as a heterogeneous mixture for in vitro studies, and is sometimes fractionated 
down to narrow distributions by ion exchange chromatography for more exact work. The 
challenges with accessing homogeneous PAR have been lamented1 especially in the structural 
biology literature where co-crystallography of PAR oligomers and polymers with binding 
proteins is desired28-30. Unfortunately, PAR produced in vitro is generally long (2-200 units, with 
the bulk of the distribution being >60), though studies show that the PAR produced in whole 
cells is often shorter (<20 units)31. Therefore, PAR accessed via in vitro synthesis may not 
always be the most relevant for study of biological phenotypes. 
 
1.3 Methods to Address PAR Heterogeneity  
 
1.3.1 Isolation of PAR by Enzymatic Synthesis and Fractionation 
PAR oligomers have long been isolated from synthesis by PARP-1 and fractionation by 
HPLC to provide small amounts of polymers of narrow distribution in length. The use of HPLC 
for analysis and isolation of PAR synthesized in vitro by PARP-1 was first described by Hakam 
and Kun32 and further demonstrated by Jacobson33. These general procedures have been repeated 
over the years with very little modification to isolate PAR for use in many studies9,34-36. 
However, the process of PAR production by PARP-1 and fractionation rarely provides polymers 
of homogeneous length in large quantities for two main reasons. First, expression and 
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purification of large amounts of PARP-1 is challenging37. Second, isolation of polymers of 
homogenous length by anion exchange chromatography after their synthesis by PARP-1 is a 
tedious process. 
The Mitchison lab attempted to solve the problem of PARP-1 scarcity by using tankyrase, 
another enzyme with PARP activity, instead of PARP-1 for the synthesis of PAR37. This 
important work showed that tankyrase is easier to express and can be obtained in about 45 fold 
higher yield than PARP-1. Though tankyrase was shown to be about six fold less active towards 
PAR synthesis than PARP-1, the higher yields of protein expression more than made up for this 
difference. Mitchison and coworkers showed that relatively homogeneous PAR oligomers and 
polymers can be obtained in greater yields using this method than with PARP-1. Others have 
used this method to obtain the first co-crystal structure of PAR oligomers and a protein38 as well 
as to understand the binding profile of XRCC-1 to PAR of different lengths39. However, one 
major drawback of this method is that it does not solve the problem of polymer fractionation 
following synthesis and this remains the major bottleneck in the process. For instance, while the 
Mitchison group reported isolation of over 400 mg of unfractionated “bulk” PAR, they were only 
able to fractionate this amount in 3 mg increments. Therefore, to get meaningful amounts of a 
polymer of a given length, the purification process needs to be repeated many times. Also, HPLC 
methods generally do not allow for baseline resolution of polymers of all sizes. Generally, one 
must design separations of PAR oligomers to get sufficient resolution of a certain distribution of 
PAR sizes. Resolution of long polymers is rarely achieved.  
Control or manipulation of enzymatic synthesis of PAR to selectively provide polymers 
of defined length has largely been unsuccessful. Varying experimental factors in enzymatic 
synthesis can have an effect on polymer length, where factors such as substrate concentration, 
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reaction time, and reaction temperature can all bias formation of shorter or longer polymers. For 
instance, the Mitchison work demonstrated that by extending reaction times using tankyrase-1, 
higher amounts of longer polymers could be generated than were present at short times37. Still, 
even at short reaction times, about 50% of the PAR produced is >34 units in length. The addition 
of an in trans acceptor (histones) biased this distribution very little. Also, the Ahel lab has 
described PARP from the organism H. aurantiacus, which produces PAR of shorter lengths (<15 
units)40. Still, these processes have not been successful in producing homogeneous PAR of 
defined length and at best provide distributions. To perform a controlled enzymatic synthesis of 
PAR, one would need to strike a delicate balance between attenuation of PARP activity to 
prevent runaway polymerization, while maintaining sufficient enzymatic activity so as to provide 
meaningful amounts of product.  
Additionally, one could envision a controlled degradation process where enzymatically 
synthesized PAR polymers are treated with PARG to afford predominantly short polymers (<10 
units). While this approach has not been successfully described in the literature, small amounts 
of ADP-ribose oligomers (2-4 units in length) have been seen by LCMS after treatment of PAR 
with human PARG in some studies38. Potentially, optimization of this process could enable 
polymers of a desired length. This approach would face the same hurdles as controlled 
polymerization (attenuating enzyme activity to yield short oligomers without complete 
degradation, but retaining enough enzymatic activity such that processing of oligomers takes 
place). 
 
 
 
	 7 
1.3.2 Chemical Synthesis as a Solution to PAR Heterogeneity 
 An orthogonal approach to enzymatic synthesis of PAR oligomers is accessing such 
compounds by total chemical synthesis. While chemical synthesis of PAR could be a solution to 
the issue of PAR heterogeneity, it is not without its challenges. First, the structure of PAR 
requires the construction of an α-glycosidic ribofuranose linkage, a major challenge in 
carbohydrate chemistry41. Second, and perhaps more challenging, is the presence of the multiple 
pyrophosphates in the PAR structure. Construction of multiple pyrophosphates in the same 
molecule was essentially unknown when we began the project detailed in chapter 2. The 
chemical synthesis of pyrophosphates is synthetically challenging with most literature conditions 
involving phosphorimidiazolides or phosphomorphilodates (compounds in the P(V) oxidation 
state) as activating groups42 (Figure 1.3a). These methods often involve long reaction times and 
low yields. Use of the P(III) oxidation state for pyrophosphate formation (Figure 1.3b) was only 
described in a very few cases43 when we began the project in chapter 2, but this method has more 
recently been shown to work with some advantages over the P(V) phosphorimidiazolide and 
phosphomorphilodate couplings44,45. Although a single group has used P(III) pyrophosphites 
(Figure 1.3c) as a method for pyrophosphate formation46, we and others44 have found this 
method to be irreproducible.  
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Figure 1.3. Methods for pyrophosphate formation. a. coupling between compounds of the P(V) 
oxidation state using the common imidazolide or morphilodate methods. b. P(V)-P(III) 
methods43 to overcome long reaction times and low yields of a). c. P(III)-P(III) methods 
described by Parang, et al46. We and others44 have found the method in Figure 1.3c not to work 
as described. 
 
A variety of approaches towards the chemical synthesis of PAR oligomers have been 
published. In 2008, Mikhailov and coworkers47 published a synthesis of the PAR disaccharide 
(Figure 1.4) involving a key glycosylation between an adenosine protected with the Markiewicz 
reagent48 (1-1)  and a protected arabinofuranose (1-2). This strategy uses neighboring group 
participation of the arabinose benzoyl group to efficiently form disaccharide 1-3. Unfortunately, 
the use of the arabinose glycosyl donor (1-2) to give efficient glycosylation comes with the 
drawback of the necessity of substantial adjustment after the glycosylation to provide the correct 
stereochemistry at the c-2’’ alcohol. After freeing this position for reaction by debenzoylation 
and Markiewicz reagent installation, the inversion was performed by a two step oxidation and 
reduction sequence to give 1-4. A price was also paid for this procedure, as the use of the 
Markiewicz reagent to protect both the adenosine 5’ and ribose 5’’ alcohols means that a strategy 
for further elaboration of compounds 1-4 or 1-5 to oligomers of PAR in a controlled manner is 
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needed. Elaboration would require the differentiation of the 5’ and 5’’ primary alcohols and a 
strategy for doing this is not obvious.   
  
Figure 1.4. Synthesis of the PAR disaccharide (1-5) by Mikhailov and coworkers47. 
 In an effort to overcome the orthogonality problems of the Mikhailov route, Filippov and 
coworkers disclosed a route to an orthogonally protected disaccharide to be used as a building 
block for PAR synthesis49 (Figure 1.5). Their route relied on the synthesis of an adenosine 
protected by the Markiewicz reagent as the glycosyl acceptor (1-6) and the imidate of tribenzyl 
ribose as a glycosyl donor (1-7). Both the glycosyl donor and glycosyl acceptor can be 
synthesized in one or two steps from commercial materials. This route provided disaccharide 1-8 
in reasonable yields upon glycosylation. Unfortunately, and analogous to the Mikhailov route, 
the use of the Markiewicz reagent and tribenzyl ribose results in the necessity of a number of 
post-glycosylation protecting group manipulations. In this case, three steps are required to 
establish the orthogonality of the 5’’ position to give 1-9, and an additional four are needed to 
establish full orthogonality in 1-10. Installation of the requisite phosphorous functionality for 
fragment coupling reactions from 1-10 would likely require four additional steps. This route does 
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demonstrate the feasibility of and provide precedent for an α-selective glycosylation to form the 
desired disaccharide, though it also details the challenges of doing so in light of substantial N-
glycosylation and poor reactivity depending on the identity of the glycosyl donor as reported by 
the authors.         
 
Figure 1.5. Filippov’s initial approach to an orthogonally protected disaccharide (1-10) for PAR 
synthesis49. 
 
 Simultaneous to our publication of the material detailed in chapters 2 and 3, Filippov and 
coworkers disclosed the synthesis of unnatural ADP-ribose, as well as unnatural ADP-ribose 
dimers and trimers containing a methoxy acetal group on the reducing sugar45. This route was 
enabled by a new synthetic approach to the iterative building block involving a clever 
Vorbrüggen glycosylation50 for installation of the nucleobase (Figure 1.6). Glycosyl donor 1-11 
was synthesized using a known procedure51 and glycosyl acceptor 1-12 is commercially 
available. Formation of the ribose-ribose glycosidic linkage proceeded smoothly to provide 
disaccharide 1-13. Vorbrüggen glycosylation with N6-benzoyladenine (1-14) installed the 
nucleobase of disaccharide 1-15. A series of five steps provided disaccharide 1-16 with the 
requisite phosphorous functionality for fragment couplings.    
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Figure 1.6. Second-generation synthesis of a disaccharide (1-16) for fragment couplings by the 
Filippov group45. 
 
 Formation of the unnatural ADP-ribose dimer and trimer by Filippov and coworkers was 
performed using a solid phase approach (Figure 1.7). Coupling between ribose phosphate 1-17 
and phosphoramidite 1-18 provided O-methoxy ADP-ribose (1-19) after deprotection from the 
resin. A first coupling of disaccharide building block 1-16 in place of adenosine phosphoramidite 
1-18 followed by phosphate deprotection and a second coupling with adenosine 1-18 provided 
O-methoxy ADP-ribose dimer (1-20). The analogous trimer (1-21) could be synthesized in a 
similar manner by two couplings with 1-16 and a single one with 1-18. This approach has the 
key advantage that the couplings are performed on the solid phase and therefore the purification 
of intermediates is relatively straightforward. The drawbacks are that the deprotection of the 
methoxy acetal of compounds 1-19, 1-20, and 1-21 to give natural oligomers was not 
demonstrated in the work, likely because of the challenge of such a reaction. Acetal containing 
oligomers, such as 1-19, 1-20, and 1-21, are not found in any biological source. The choice of 
this group was likely due to synthetic ease, and protection of this position with the proper group 
that would allow for subsequent removal was a major challenge in our work as discussed in 
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chapter 2. The strongly acidic conditions to affect phosphate deprotection in this work coupled 
with the acid-lability of anomeric substituents likely precludes the use of many potential 
protecting group for this position and may explain the choice of the acetal. Additionally, if 
unnatural oligomers are to be synthesized, the most logical and enabling choice for the unnatural 
position might be a functionality that allows for probe synthesis, such as the alkyne we 
synthesized in chapter 2. The methoxy group, however, provides no such advantage. Finally, the 
stoichiometry of the coupling reactions employed by Filippov require three equivalents of the 
synthetically most challenging substrate (1-16) for each coupling.           
 
Figure 1.7. Solid phase fragment couplings as described by Filippov and coworkers45. 
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used to form branched oligomers containing pyrophosphates, as the work did show the ability to 
deprotect the TBDPS group in the presence of the TIPS groups. However, selective deprotection 
of the 5’ benzoyl group was not shown and would likely require three additional steps. Selective 
formation of PAR oligomers containing the branched trisaccharide would also require orthogonal 
protection of the phosphate groups if oligomers containing different substitution on the 5’’ and 
5’’’ groups were desired, though the setup employed could be easily extended to 5’’ and 5’’’ 
groups containing the same substitution.  
 
Figure 1.8. The route by Filippov et al. to a PAR trisaccharide (1-26)52 
 
1.3.3 Chemoenzymatic Approaches to PAR Synthesis 
 In principle, one could imagine a variety of methods through which polymers could be 
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substrates has been used for applications mostly involving protein labeling53,54. The collection of 
non-natural β-NAD+ analogs demonstrated to be PARP-1 substrates are depicted in Figure 1.9. 
Importantly, one of these approaches describes the ability of PARP-1 to terminate PAR chains 
by chemical modification of the 2’ position of β-NAD+54. Could this termination be performed 
and subsequently reversed, in principle an approach to homogeneous PAR production and 
homogeneous PAR polymers could be developed. Efforts towards such an approach are 
described in chapter 4. 
 
Figure 1.9. β-NAD+ and analogs that have been shown to be PARP-1 substrates in the literature. 
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1.4 Conclusions and Outlook 
 PAR biology has been the subject of intense focus in the past decade, in large part due to 
the progression of PARP inhibitors, such as Olaparib, through the clinic. While most researchers 
began study of PARylation due to the therapeutic potential of the process with respect to DNA 
damage repair, the increased attention to PARylation has uncovered the role of this post-
translational modification in a wide range of cellular contexts and processes. Therefore, as 
knowledge of the role of PAR in the cell continues to grow, the need and desire for tools to 
understand these processes will as well. The desire for one such tool, homogeneous PAR 
polymers and oligomers, has been clearly articulated in the literature1,28-30,55. 
 To access homogeneous ADP-ribose oligomers, both chemical and enzymatic synthesis 
approaches have been described. New enzymatic approaches that utilize tankyrase instead of 
PARP-1 show promise in generation of larger amounts of PAR than was obtainable previously37. 
Unfortunately, these approaches still require tedious fractionation of oligomers and polymers, 
and therefore do not overcome the major bottleneck in the processes of accessing homogeneous 
PAR. On the other hand, chemical approaches to PAR synthesis have shown the ability to 
synthesize short oligomers in greater yield and purity than what is obtainable by enzymatic 
synthesis. The drawback to such approaches, however, is the number of steps required to access 
the target compounds. The large number of steps and inefficient fragment coupling reactions 
associated with them likely precludes the synthesis of long oligomers.   
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 Chapter 2. Chemical Synthesis of the Natural and Propargyl ADP-Ribose Dimers  
 
Portions of this chapter are reprinted with permission from: Lambrecht, M. J.; Brichacek, M.; 
Barkauskaite, E.; Ariza, A.; Ahel, I.; and Hergenrother, P. J. J. Am. Chem. Soc. 2015, 137, 3558-
3564. This work was performed in close collaboration with Dr. Matthew Brichacek. 
 
2.1 Synthesis of the Natural ADP-ribose Dimer 
 
2.1.1 The ADP-ribose Dimer as a Model ADP-ribose Oligomer 
ADP-ribose oligomers and polymers are produced upon DNA damage and can have 
many binding partners in cells (>500 proteins with at least four different PAR binding motifs 
have been predicted or shown to bind PAR)1-4. For some PAR binding proteins, the length of the 
PAR oligomer is an important factor for binding affinity5. However, for other classes of proteins 
the polymer-binding motif is hypothesized to be a much reduced portion of the polymer1,6. 
Determination of the binding unit of the polymer to the protein in these cases is done with simple 
PAR fragments (ADP-ribose and iso-ADP-ribose). Generally, if a protein binds to one of these 
fragments, it is concluded that the portion of the PAR polymer represented by the fragment 
composes the binding motif of the polymer to the protein. However, such molecules do not retain 
certain key components of the PAR polymer as a whole (multiple pyrophosphates and the α-
glycosidic linkage).  Therefore, while useful in many studies, model compounds such as ADP-
ribose or iso-ADP-ribose lack the structural complexity and important aspects of the PAR 
polymer and therefore may not represent PAR with sufficient rigor. Homogeneous PAR 
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oligomers themselves are of course challenging to access by enzymatic synthesis as detailed in 
chapter 1.   
It was therefore envisioned that the simplest ADP-ribose oligomer, the ADP-ribose 
dimer, would be of value in biochemical studies where ADP-ribose and iso-ADP-ribose fall 
short. The ADP-ribose dimer contains all the key structural features of the full polymer (the 
glycosidic linkage and multiple pyrophosphates), and the molecule has been described in the 
literature as an “ideal ligand for x-ray co-crystal structure determination.”7 While the ADP-
ribose dimer has been detected by a variety of methods including MS analysis8, this compound 
has not been isolated and handled as a pure substance due to its low levels of production by 
enzymatic synthesis9 and challenging preparative separation and isolation. The ADP-ribose 
dimer was therefore an appropriate and attractive target for total chemical synthesis. If the ADP-
ribose dimer could be accessed by a modular chemical route, the compound could be obtained in 
quantities and purities that are not currently available by enzymatic synthesis and fractionation. 
Additionally, its synthesis could serve as a template for the synthesis of longer or unnatural 
oligomers.         
2.1.2 Retrosynthetic Analysis and Strategy  
Despite the synthetic challenges associated with the α-selective ribose glycosylation and 
pyrophosphate formation (as detailed in chapter 1), retrosynthetically these disconnections 
remained the most logical when considering routes to the ADP-ribose dimer (Figure 2.1). The 
ADP-ribose dimer (2-1) was therefore envisioned to originate from pyrophosphate couplings 
between protected ribose phosphate 2-2, orthogonally protected disaccharide 2-3 containing the 
synthetically challenging α-ribose glycosidic linkage, and protected adenosine monophosphate 
2-4. All these precursors were unknown when this project began, with disaccharide 2-3 
	 21 
representing the greatest synthetic challenge. While protected adenosine monophosphate 2-4 had 
not been previously prepared, its synthesis was conceptually similar to that of a known 
compound10. Ribose phosphate 2-2, while relatively simple, provided a challenge with respect to 
the selection of the proper protecting group for the anomeric position. It was envisioned that 
setting the α-glycosidic linkage would be the key step for disaccharide 2-3 and that this linkage 
could be installed via a 1,2-cis-selective glycosylation of an orthogonally protected adenosine (2-
5) by an appropriately protected ribose (2-6). Synthesis of the glycosyl donor (2-6) and glycosyl 
acceptor (2-5) would commence from ribose and adenosine, respectively. Strategically, for the 
synthesis as a whole, it was envisioned that the secondary alcohols would ideally be protected as 
silyl ethers and the nitrogenous bases would be protected with the benzoyl group. These groups 
were chosen for their stability as well as their ability to be removed quickly, in good yield, and 
under mild conditions at the end of the synthesis.  
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Figure 2.1. Retrosynthetic analysis of natural ADP-ribose dimer (2-1). 
2.1.3 Selective Synthesis of the Glycosyl Acceptor 2-5 
 In the forward sense, the first challenge encountering the synthesis of disaccharide 2-3 
was the creation of an appropriately protected adenosine with the 2’ alcohol free for chemical 
glycosylation (such as alcohol 2-5). While protection of the 3’ and 5’ alcohols in nucleic acids is 
commonly carried out using the Markiewicz Reagent11 to form a cyclic silyl ether, this approach 
was ruled out due to problems in selectively deprotecting the 5’ alcohol in the presence of the 3’ 
alcohol. Therefore, a challenge existed in how to selectively silylate the 5’ and 3’ alcohols 
without silylation of the 2’ alcohol. Traditionally, conditions have existed for selective 2’ 
silylation with a variety of groups though selective 3’ protection is less established. Additionally, 
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we found the yields and selectivities reported for silver promoted 3’ silylation12 to not be 
robustly reproducible in our hands. 
 
Figure 2.2. a) Unselective synthesis and isomerization of glycosyl acceptor 2-5 b) selective two 
step synthesis of glycosyl acceptor 2-5 i. TBSCl (2.8 eq), imidazole (6 eq), DMF, 0oC to rt, 1 h, 
13% 2-8, 41% 2-9, 36% 2-5. ii. imidazole (2 eq), DMF, 30oC, 50% iii. TBSCl (1.5 eq), 
imidazole (3 eq), DMF, 0oC, 1 h, 77%. iv. TBSOTf (1.7 eq), THF, -78oC, 1 h, 91% 2-5, 6% 2-9. 
 
To preliminarily access such a compound, a known procedure was followed and a non-
selective mixture of compounds 2-8, 2-9, and the desired 2-5 was obtained (Figure 2.2a)13. It had 
been noted in the literature that isomerization of constitutional isomers 2-9 and 2-5 was 
possible14 and indeed this was found to be a reasonable approach to procure more of the desired 
2-5. While this unselective silylation and isomerization approach was useful to provide the 
alcohol 2-5 in reasonable quantities, scaling the procedure up was quite cumbersome due to the 
difficulties associated with separating 2-9 and 2-5. Additionally, amounts of trisilyl 2-8 increased 
on larger scale. Ultimately, it was found that compound 2-5 could be synthesized with >15:1 
selectivity over compound 2-9 by a two step process (Figure 2.2b). First, compound 2-7 was 
treated with a small excess of tert-butyldimethylsilyl chloride (TBSCl) to afford the 
monosilylated 2-10. Next, compound 2-10 could be treated with TBSOTf in the absence of base 
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to afford the desired compound 2-5 in 91% yield, and the undesired 2-9 in an isolated yield of 
6%. This approach provided compound 2-5 on multi-gram scale and was key for the synthesis 
moving forward. The exact origins of the observed selectivity for the 3’ silylated product are still 
not well understood, though under conditions involving base an isomerization likely happens 
based on analysis of the reaction at early time points. This isomerization is obviously diminished 
in the optimized procedure without added base.   
 
2.1.4 Synthesis of Glycosyl Donor 
 
2.1.4.1 Glycosyl Donor Synthesis with Chromatography 
Upon synthesis of protected adenosine 2-5, attention was turned to creation of an 
orthogonally protected ribose for chemical glycosylation. After several unsuccessful approaches, 
glycosyl donor 2-6 was ultimately arrived at and was determined to possess the appropriate 
characteristics with which to move forward (Figure 2.3). The glycosylation was found to be 
sensitive to steric effects, especially with respect to the protecting groups on the C-2 and C-3 
alcohols. For instance, glycosyl donors such as 2-11 with bulky groups on the C-2 and C-3 
alcohols were found to glycosylate poorly. Most glycosyl donors where the alcohols were 
protected with ethers, such as 2-12, 2-13, and 2-14, glycosylated with reasonable efficiency. 
Compounds 2-12, 2-13, and 2-14 suffer from a lack of orthogonality of the protection of the C-5 
position relative to the C-2 and C-3 alcohols and their further elaboration was found to be 
challenging.   
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Figure 2.3. Structures of successful (2-6) and unsuccessful (2-11, 2-12, 2-13, and 2-14) glycosyl 
donors used in these studies. 
 
Therefore, the rationale of the final design of compound 2-6 was as follows. For the C-2 
and C-3 positions, the small and non-participating allyl protecting group (All) was chosen. For 
protection of the C-5 alcohol, the 2-naphthylmethyl ether group (Nap) was chosen due to its 
ability to be removed under either mildly oxidizing or mildly reducing conditions. Protection of 
the C-2 and C-3 alcohols is therefore orthogonal to protection to the C-5 alcohol in this system; 
either can be deprotected in the presence of the other. Finally, the glycosyl fluoride was chosen 
as the activating group for the anomeric position due to its mild activation by fluorophilic 
promoters15 and literature reports of high selectivity for producing α-furanoses16.  
 
Figure 2.4. Synthesis of glycosyl donor 2-6. i. HCl, MeOH, acetone, reflux, 4 h, 84% ii. NapBr 
(1 eq), NaH (1.5 eq), DMF, 0oC to rt, 36 h, 88% iii. H2SO4, MeOH, 100oC, 5 h, 99% iv. AllBr (4 
eq), NaH (4 eq), DMF, 0oC to rt, 12 h, 89% v. HCl, dioxane, 140oC, 2 h, 86% vi. Et2NSF3 (1.2 
eq), THF, -50oC to rt, 1 h, 89%. 
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17. To install the desired allyl groups on the C-2 and C-3 alcohols, the acetonide of compound 2-
17 was methanolyzed to form 2-18. Compound 2-18 was efficiently bis-allylated in the next step 
using allyl bromide and sodium hydride to afford 2-19. Hydrolysis of the acetal protecting C-1 of 
compound 2-19 was performed in aqueous dioxane to give lactol 2-20. Finally, lactol 2-20 could 
be easily converted to the desired glycosyl fluoride 2-6 by treatment with diethylamino 
sulfurtrifluoride (DAST), giving very high selectivity for the β-fluoride.  
 
2.1.4.2 Streamlined Synthesis without Chromatography 
The route described in section 2.1.3.1 was sufficient to access gram scale quantities of 
glycosyl donor 2-6, but was found to be somewhat laborious due to the number of steps. As all 
the steps proceeded in good yield with minimal byproducts, it was thought that perhaps a route 
that omitted silica column chromatography purification steps could be developed. This goal was 
ultimately achieved (Figure 2.5). D-ribose (2-11) could be converted to alcohol 2-16 as 
described, and alcohol 2-16 could be distilled at high temperature under vacuum to give a single 
β-anomer. The subsequent C-5 naphthyl group installation, isopropylidene cleavage, and C-2 and 
C-3 allyl group installation could be performed without purifying the intermediates by column 
chromatography. Chromatography was only performed after hydrolysis to lactol 2-20 and the 
yields of lactol 2-20 from D-ribose (2-15) were in some cases higher using the chromatography 
free procedure (see Figure 2.4).  
 
 
 
	 27 
 
Figure 2.5. Streamlined (chromatography free) synthesis of glycosyl donor 2-6. i. HCl, MeOH, 
acetone, reflux, 4 h, 84% (distill) ii. NapBr (1 eq), NaH (1.2 eq) DMF, 0oC to rt, 72 h. iii. H2SO4, 
MeOH, 110oC, 4 h. iv. AllBr (4.8 eq), NaH (5 eq), DMF, 0oC to rt, 3 h. v. aq. HCl, dioxane, 
reflux, 5 h, 74% (from 2-16). vi. Et2NSF3 (1.2 eq), THF, -50oC to rt, 1 h, 89%.   
 
2.1.5 Chemical Glycosylation to form Disaccharide 2-21 
  Upon synthesis of compounds 2-5 and 2-6, the formation of the desired disaccharide 2-21 
via chemical glycosylation (Figure 2.6) presented the next challenge of the synthesis. As 
mentioned above, activation of glycosyl fluorides is frequently accomplished by use of 
fluorophilic promoter/co-promoter systems and a brief screen was performed to identify 
conditions ideal for this transformation. As a starting point, traditional systems15 employing 
tin(II) chloride and silver(I) triflate or silver(I) perchlorate were examined. It was surprising to 
find that these conditions gave little to none of the desired product despite their use in the 
literature to form α-ribosyl linkages. Gratifyingly, when silver hexafluorophosphate was used in 
place of the other silver(I) salts, it was found that the desired disaccharide was formed in 
synthetically useful yields (initially about 50%). Silver hexafluorophosphate has been described 
as an excellent activator of thioglycosides18, but such properties had not previously been 
described for glycosyl fluorides. As this procedure was scaled up, higher yields (around 70%) 
were obtained likely due to several factors. First, it is likely that the starting materials and 
reagents were rendered more anhydrous on larger (>1 g) scales than on the scales in which 
screening experiments were performed (>10 mg). Additionally, it was found that protecting the 
AgPF6 from light and segregating AgPF6 and SnCl2 while drying the reaction components was 
crucial to maximize product formation. 
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Formation of disaccharide 2-21 and verification of synthesis of the desired steroisomer 
was confirmed by global deprotection to form the known compound 2-22. Compound 2-22 was 
fully consistent with previously reported data19,20. It should be noted that in the synthesis of 
disaccharide 2-21, none of the undesired β-isomer could be identified and characterized. This 
result is consistent with previous reports showing high α-selectivity in ribose systems with 
simpler glycosyl acceptors16. An “inside attack” model developed by Woerpel21 and 
computational studies by Codee22 suggesting that ribofuranosyl oxocarbenium ions likely adopt 
an E3 conformation provide the rationale for the high stereochemical selectivity observed in our 
system.   
 
Figure 2.6. Chemical glycosylation to form disaccharide 2-21 and global deprotection to confirm 
its structure. i. SnCl2/AgOTf (2.2/2.2 eq), CH2Cl2, 4 A MS, -78oC to 4 oC, 12 h, 72%. ii. 
Pd(PPh3)4 (20 mol%), 1,3-dimethylbarbituric acid (10 eq), MeOH, rt, 16 h. 99% iii. DDQ (1.1 
eq), CH2Cl2/H2O, 0oC, 5 h iv. Et3N.3HF (5 eq), CH2Cl2, rt, 5 h. v. NH3/MeOH, rt, 12 h, 42% for 
3 steps. Inset: transition state rationalization for the observed α-stereochemistry. 
 
2.1.6 Elaboration of Disaccharide 2-21 to a Suitable Coupling Piece 
Upon synthesis of the key disaccharide 2-21 and verification of its structure, elaboration 
of this compound to form disaccharide 2-3, the molecule possessing the requisite phosphorous 
functionality for fragment couplings, was undertaken (Figure 2.7). Towards this end, compound 
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2-21 was deallylated using Pd(PPh3)4 to afford diol 2-23. Silylation of 2-23 using TBSOTf 
afforded 2-24 resulting in a net exchange of the allyl groups of 2-21 for TBS groups in 2-24. 
This exchanged was performed to facilitate a global desilylation at the end of the synthesis. 
Tetrasilyl disaccharide 2-24 was selectivity deprotected to form a free 5’ hydroxyl group by 
treatment with trichloroacetic acid in THF/H2O to give alcohol 2-25. Phosphoramidite coupling 
and oxidation formed phosphate 2-26. The desired H-phosphonate 2-3 was then synthesized in a 
three-step process. First, the 2-naphthylmethyl group was removed from the 5’’ alcohol under 
mildly oxidative conditions using DDQ to afford alcohol 2-27. Treatment of alcohol 2-27 with 
the chlorophosphoramidite 2-28 effected formation of phosphoramidite 2-29. Hydrolysis of 
phosphoramidite 2-29 gave the desired H-phosphonate 2-3 for use in the fragment couplings. 
 
Figure 2.7. Elaboration of disaccharide 2-21 to phosphorylated disaccharide 2-3. i. Pd(PPh3)4 
(20 mol%), 1,3-dimethylbarbituric acid (10 eq), MeOH, rt, 16 h, 99%. ii. TBSOTf (3 eq), DMAP 
(1 eq), EtNiPr2 (6 eq), CH2Cl2, 0oC to rt, 2 h, 75%. iii. Cl3CCO2H (46 eq), THF/H2O, 0oC, 5 h, 
85%. iv. i-Pr2NP(OBn)2 (1.2 eq), dicyanoimidazole (1.2 eq), CH2Cl2/CH3CN, 2 h, rt, then: 
tBuOOH (5 eq), 0oC to rt, 3 h, 91%. v. DDQ (1.5 eq), CH2Cl2/H2O, 0oC, 6 h, 92%. vi. 2-28 (1.2 
eq), EtNiPr2 (1.2 eq), THF, -78oC to rt, 3 h, 99%. vii. dicyanoimidazole (1.2 eq), H2O (3 eq), 
CH3CN, rt, 2 h, 99%. 
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2.1.7 Synthesis of Protected Adenosine Monophosphate 2-4 
 With the challenging disaccharide 2-3 in hand, attention was turned to the synthesis of 
protected adenosine monophosphate 2-4 and was accomplished in a five-step sequence as 
follows (Figure 2.8). First, N-benzoyl adenosine (2-7) was trisilylated with TBSCl and imidazole 
via a known procedure23 to form 2-8. Deprotection of the primary silyl group had been 
previously reported and was accomplished using trichloroacetic acid in THF/water to afford 
alcohol 2-3024. Phosphoramidite coupling of alcohol 2-30 and phosphoramidite 2-31 afforded 
biscyanoethyl phosphate 2-32.  Deprotection to form the initiator phosphate 2-4 was 
accomplished with DBU and TMSCl, with TMSCl being required to effect cleavage of both 
cyanoethyl groups.  
 
Figure 2.8. Synthesis of adenosine monophosphate 2-4. i. TBSCl (5 eq), imidazole (5 eq), DMF, 
0oC to rt, 1 h, 90%. ii. Cl3CCO2H (46 eq), THF/H2O, 0oC, 3 h, 93%. iii. 2-31 (1.2 eq), 
dicyanoimidazole (1.2 eq), CH2Cl2/CH3CN, 1.5 h, rt, then: tBuOOH (5 eq), 0oC to rt, 3 h, 98%. 
iv. DBU (10 eq), TMSCl (6 eq), CH3CN, 0oC to rt, 12 h, reverse phase chromatography, ion 
exchange, 66%.    
 
2.1.8 Synthesis of Protected ribose Phosphate 2-2  
In contrast to the initiator phosphate 2-4, accessing a terminating ribose phosphate proved 
to be more challenging. Several protecting group schemes were attempted (Figure 2.9) and the 
combination shown for compound 2-2 was ultimately successful. Use of 2-33 led to low 
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coupling yields, while the benzyl groups on the secondary alcohols of 2-34 were hard to remove 
by hydrogenolysis. The TBS group was found to be too labile for protection of the anomeric 
position as in 2-35. Ultimately, compound 2-2 was determined to be ideal. The choice of TBS 
groups for protection of the C-2 and C-3 alcohols was clear due to their presence on the other 
alcohols of the molecule. The tert-butyldiphenylsilyl (TBDPS) group was chosen for the 
anomeric position due to its increased acid stability relative to the TBS group, and the propensity 
for anomeric substituents to be labile under acidic conditions as was seen for 2-35. 
 
Figure 2.9. Structures of ribose phosphates used for this route. 2-2 was ultimately successful, 
while 2-33, 2-34, and 2-35 failed for various reasons. 
 
The route to synthesize compound 2-2 (Figure 2.10) commenced from commercially 
available D-ribonolactone (2-36). The C-5 alcohol was protected with a trityl group using a 
known procedure,25 followed by silylation with TBSOTF to afford the known lactone 2-3726. 
Reduction using iBu2AlH gave lactol 2-38, and the TBDPS group was installed using TBDPSCl 
and imidazole in DMF. Deprotection of 2-39 to afford alcohol 2-40 was accomplished using 
using trifluoroacetic acid with triethylsilane as a trityl scavenger. Phosphoramidite coupling of 
alcohol 2-40 with dibenzyl diisopropylphosphoramidite afford protected phosphate 2-41 and 
hydrogenolysis gave the desired ribose terminator 2-2 in good yield. 
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Figure 2.10. Synthesis of ribose phosphate 2-2. i. Ph3CCl (1.2 eq), DMAP (0.2 eq), pyridine, 
70oC, 16 h, 61%. ii. TBSOTf (3 eq), 2,6-lutidine (6 eq), CH2Cl2, 0oC, 1.5 h, 90%. iii. iBu2AlH 
(1.3 eq), CH2Cl2, -78oC, 1 h, 94%. iv. TBDPSCl (2 eq), imidazole (2.5 eq), DMF, 70oC, 18 h, 
80%. v. CF3CO2H (2 eq), Et3SiH (4 eq), CH2Cl2, 0oC, 1 h, 75%. vi. i-Pr2NP(OBn)2 (1.4 eq), 
dicyanoimidazole (1.4 eq), CH3CN, 1.5 h, rt, then: tBuOOH (5 eq), rt, 1 h, 98%. vii. H2, Pd/C, 
Et3N (10 eq), tBuOH/H2O, rt, 16 h, 75%.  
 
2.1.9 Fragment Couplings and Completion of the ADP-ribose Dimer  
With the requisite coupling partners in hand, the fragment coupling reactions (Figure 
2.11) were performed. Treatment of H-phosphonate 2-3 with N-chlorosuccinimide in the 
presence of phosphate 2-4 and Hunig’s base followed by DBU afforded pyrophosphate 2-42. 
This reaction likely proceeds through an oxidative chlorination to form a highly electrophilic 
chlorophosphate, followed by condensation with the phosphate to form a pyrophosphate triester. 
Deprotection of the pyrophosphate triester with DBU gives the desired pyrophosphate diester. 
We found this method to be a rapid and high-yielding method for pyrophosphate formation, and 
believe that it is superior to most methods for pyrophosphate synthesis in the literature. This 
method has been broadly used in our lab for the synthesis of pyrophosphates in molecules such 
as ADP-HPD and also ADP-ribose-based probes.  
With the first pyrophosphate of dimeric ADP-ribose formed, the benzyl phosphate 2-42 
was deprotected by hydrogenolysis to give deprotected phosphate 2-43. Attempts to couple 
phosphate 2-43 with a terminating H-phosphonate under the oxidative chlorination conditions 
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described above were unsuccessful. Subsequently, similar methods that rely on highly 
electrophilic phosphorous species for coupling in the presence of another pyrophosphate have 
also been reported to be unsuccessful in the solution phase27. As a result, a more traditional 
phosphorimidazolide coupling was used. In this procedure, phosphate 2-2 was activated as a 
phosphorimidazolide using carbonyl diimidazole and coupled with phosphate 2-43 in DMF using 
zinc(II) chloride as a promoter. Removal of the zinc salts using EDTA and reverse phase 
purification gave protected ADP-ribose dimer 2-44 in acceptable yield. Deprotection of 
compound 2-44 with methanolic ammonia (to remove the benzoyl groups) and 
tetrabutylammonium fluoride (to remove the silyl protecting groups) gave the ADP-ribose dimer 
(2-1) in good yield after C18 ion-pairing purification. Extensive 2D NMR spectroscopic analysis 
was performed to verify the structure of dimer 2-1. Further structural confirmation was provided 
by the ability of the compound to be processed by PARG as well as its co-crystal structure with 
mutant PARG (discussed in chapter 3).  
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Figure 2.11. Fragment couplings and completion of the ADP-ribose dimer (2-1). i. NCS (4 eq), 
EtNiPr2 (4 eq), CH3CN, rt, 20 min, then: DBU (10 eq), CH3CN, rt, 20 min, 72%. ii. H2, Pd/C, 
Et3N (10 eq), tBuOH/H2O, rt, 16 h, 92%. iii. 2-2, carbonyldiimidazole (10 eq), Et3N (4 eq), 
pyridine, rt, 2 h, then: 2-43, ZnCl2 (8 eq), DMF, rt, 96 h, reverse phase purification, ion 
exchange, 79%. iv. NH3/MeOH. v. Bu4NF (33 eq), THF, rt, 3 h, ion pairing chromatography, ion 
exchange, 77%. 
 
2.2 Synthesis of the Propargyl ADP-ribose Dimer 
 
2.2.1 Motivation and Retrosynthesis  
The opportunity to synthesize derivatives of compound 2-1 presented by the convergent 
nature of the synthesis was immediately recognized as a method through which biochemical 
tools could be accessed. Towards this end, it was desired to synthesize an alkyne-containing 
ADP-ribose dimer (Figure 2.12, 2-45) that could be used with Huisgen 1,3-dipolar cycloaddition 
chemistry to append fluorophores and other useful molecules to the ADP-ribose dimer. It was 
envisioned that this ADP-ribose dimer derivative would originate from a pyrophosphate coupling 
between the previously described phosphate 2-43 and a new alkyne-containing ribose phosphate 
2-46 that could be synthesized via propargylation of lactol 2-38.  
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Figure 2.12. Retrosynthetic analysis of the propargyl ADP-ribose dimer (2-45). 
2.2.2 Synthesis of Propargyl Ribose Phosphate  
 Synthesis of propargyl ribose phosphate 2-46 (Figure 2.13) was relatively straightforward 
and involved lactol 2-38, an intermediate on the synthesis to ribose terminator 2-2. 
Propargylation of lactol 2-38 using propargyl bromide and sodium hydride gave compound 2-47 
as a single β-anomer, likely as a result of the steric bulk of the TBS groups. Deprotection of the 
trityl group of 2-47 was performed using trifluoroacetic acid to give alcohol 2-48. In contrast to 
the synthesis of protected phosphate 2-41 on route to the ADP-ribose dimer, alcohol 2-48 was 
coupled with fluorenylmethyl phosphoramidite 2-49 rather than the analogous dibenzyl reagent 
due to the susceptibility of the propargyl group to reduction via hydrogenation. Deprotection of 
2-50 with triethylamine gave the desired phosphate 2-46.  
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Figure 2.13. Synthesis of propargyl ribose phosphate 2-46. i. NaH (2 eq), propargyl bromide 
(1.2 eq), DMF, 0oC, 1 h, 81%. ii. CF3CO2H (2 eq), Et3SiH (4 eq), CH2Cl2, 0oC, 40 min, 69%. iii. 
2-49 (1.5 eq), dicyanoimidazole (1.5 eq), CH3CN/CH2Cl2, 1.5 h, rt, then: tBuOOH (5 eq), rt, 1 h, 
83%. iv. Et3N/CH3CN, rt, 14 h, 96%. 
 
2.2.3 Fragment Couplings and Completion of the Propargyl ADP-ribose Dimer (2-45) 
 Upon synthesis of propargyl ribose terminator 2-46, assembly of the fragments to 
produce the propargyl ADP-ribose dimer (2-45) was undertaken (Figure 2.14). A 
phosphorimidazolide coupling between phosphates 2-43 and 2-46 was performed to give fully 
protected propargyl ADP-ribose dimer 2-51. Global deprotection gave propargyl ADP-ribose 
dimer 2-45.  
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Figure 2.14. Fragment couplings to access propargyl ADP-ribose dimer 2-45. i. 2-46, 
carbonyldiimidaozle (5 eq), Et3N (14 eq), CH3CN, rt, 2 h, then: 2-46, ZnCl2 (8 eq), rt, 30 h. ii. 
NH3/MeOH, rt, 14 h. iii. Bu4NF, THF, rt, 3 h, ion pairing chromatography 18% from 2-43.  
  
2.2.4 Synthesis of ADP-ribose Dimer Tool Molecules 
 Upon successful synthesis of the propargyl ADP-ribose dimer (2-45), its use in the 
synthesis of tool molecules using copper-catalyzed Husigen 1,3-dipolar cycloaddition chemistry 
was demonstrated. Biotinylated (2-52) and Cy3-containing (2-53) ADP-ribose dimers were 
synthesized using this chemistry (Figure 2.15).  
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Figure 2.15. Synthesis of biotinylated (2-52) and Cy3-ADP-ribose (2-53) dimers. i. Biotin-Peg3-
N3 (2 eq), CuSO4.5H2O (2 eq), Cu wire, H2O, rt, 16 h. ii. SulfoCy3-N3, CuSO4.5H2O (0.6 eq), Cu 
wire, H2O, rt, 16 h. 
 
2.3 Summary 
  The synthesis of the ADP-ribose dimer (2-1) and the propargyl ADP-ribose dimer (2-38) 
were achieved. Key to the route to both compounds was the α-selective glycosylation to form the 
disaccharide repeating unit 2-5. Additionally, the fast and high yielding pyrophosphate coupling 
to form the first pyrophosphate en route to the ADP-ribose dimers substantially improved 
material throughput with respect to more traditional methods of pyrophosphate formation. While 
this synthetic route provides access to dimers 2-1 and 2-45, its major shortcoming is the low 
yields associated with the imidazolide coupling reactions used for the formation of the second 
pyrophosphate (synthesis of 2-44 from 2-43 or 2-51 from 2-43) and the inability of the H-
phosphonate coupling method (used successfully for the synthesis of 2-42 from 2-3) to proceed 
in the presence of another pyrophosphate in the molecule. Therefore, while this route is 
successful in providing dimers 2-1 and 2-45 and such molecules enable important biological 
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experiments (chapter 3), alternative approaches (such as those described in chapter 4) are 
necessary for the synthesis of longer oligomers.      
 
2.4 Experimental 
All reactions were run in flame or oven dried glassware under an atmosphere of dry 
nitrogen unless otherwise noted. Acetonitrile, tetrahydrofuran, methanol and methylene chloride 
used in reactions were obtained from a solvent dispensing system. Diethyl ether was distilled 
from sodium metal. 4 Å molecular sieves were dried at 200 oC on high vacuum overnight. 
Pyridine and Diazabicyclo[5.4.0]undec-7-ene were distilled from CaH2 and stored on 4 Å 
molecular sieves. 1,2-Dichloroethane and d3-acetonitrile were dried over 4 Å molecular sieves. 
All other reagents were of standard commercial purity and were used as received. 
Tetrakis(triphenylphosphine)palladium(0) was prepared using the procedure of Malpass, et al.28 
and was packaged in a glove-bag under nitrogen.  
 Analytical thin-layer chromatography was performed on EMD Merck silica gel plates 
with F254 indicator. Plates were visualized with UV light (254 nm) or staining with p-
anisaldehyde. Silica gel for column chromatography was purchased from Sorbent Technologies 
(40-75 mm particle size).   
 Unless otherwise indicated, 1H, 13C, 19F, and 31P NMR spectra were recorded at 500, 125, 
470 and 203 MHz, respectively. 1H and 13C NMR spectra were referenced to tetramethylsilane or 
the residual solvent peak as reported by Fulmer et al.29 13C Spectra taken in D2O contain 0.05% 
EtOH (17.47, 58.05 ppm) as an internal standard for referencing. 19F NMR spectra were 
referenced using C6F6 as an internal standard (-164.9 ppm). 31P NMR spectra were externally 
referenced to 85% H3PO4 (0.00 ppm) in water. Chemical shifts are reported in ppm and 
multiplicities are reported as s (singlet), d (doublet), t (triplet), q (quartet), p (pentet), h (hextet), 
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hep (heptet), m (multiplet), and br (broad). Mass spectrometry analysis was performed by the 
University of Illinois Mass Spectrometry Center or by direct injection on an Agilent 6230 
LC/MS TOF for samples run in negative ion mode. The LC/MS assay was performed on the 
Agilent 6230 LC/MS TOF system with a 1.8 mm, 2.1x50 mm Agilent ZORBAX Eclipse Plus 
C18 column and is described in more detail below. Analytical HPLC analysis was performed on 
a Waters e2695 separations module with a Waters 2489 UV detector using a 5 mm, 4.6x150 mm 
Waters XBridge BEH130 HPLC column and is described in more detail below. Other 
preparative C18 chromatography was performed using a Teledyne Isco CombiFlash Rf system 
with CombiFlash Gold columns using a gradient of H2O/CH3CN beginning with 95% H2O:5% 
CH3CN, ramping to 65% H2O:35% CH3CN over 6 min, ramping to 100% CH3CN for 3 min, and 
holding 100% CH3CN for 5 min. Optical rotations were measured using a Jasco DIP-360 digital 
polarimeter in either EtOH or CHCl3 with concentrations reported in g/dL. Infrared spectra were 
recorded on a Mattson Galaxy 5020 spectrophotometer with NaCl cells. Peaks are reported in 
cm-1.  
 
 
Unselective synthesis of compounds 2-8, 2-9 and 2-5: A modified version of the procedure of 
Cole et al.13 was followed. To a 250 mL round bottom flask was added N-Benzoyladenosine (2-
7) (10.0 g, 26.9 mmol, 1 eq). Compound 2-7 was evaporated three times with dry CH3CN on a 
nitrogen-filled rotary evaporator and dried on high vacuum over P2O5. The starting material was 
dissolved in DMF (25 mL) and cooled to 0oC. Imidazole (11.0 g, 161.4 mmol, 6 eq) was added, 
followed by a solution of TBSCl (11.4 g, 75.4 mmol, 2.8 eq) in DMF (25 mL) at 0 oC over 30 
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min. The reaction was allowed to warm to room temperature and stirred for 30 min. The reaction 
was poured into saturated aqueous NH4Cl, extracted three times EtOAc, filtered through Na2SO4 
and concentrated. The products were purified by silica column chromatography to isolate 
compounds 2-8 (2.47 g, 13%), 2-9 (6.60 g, 41%) and 2-5 (5.89 g, 36%).  
Compound 2-8 
1H NMR (500 MHz, CDCl3) δ 9.50 (s, 1H, NHBz), 8.82 (s, 1H, H-8), 8.35 (s, 1H, H-2), 8.05 (d, 
J = 7.5 Hz, 2H, Bz), 7.59 (t, J = 7.4 Hz, 1H, Bz), 7.51 (dd, J =7.6 Hz, 2H, Bz), 6.12 (d, J = 5.3 
Hz, 1H, H-1’), 4.68 (t, J = 4.8 Hz, 1H, H-2’), 4.30 (appt, J = 3.9 Hz, 1H, H-3’), 4.15 (q, J = 3.4 
Hz, 1H, H-4’), 4.03 (dd, J = 11.4, 3.9 Hz, 1H, H-5’a), 3.80 (dd, J = 11.4, 2.8 Hz, 1H, H-5’b), 
0.96 (s, 9H, -tBu), 0.93 (s, 9H, -tBu), 0.78 (s, 9H, -tBu), 0.15 (s, 3H, -CH3), 0.14 (s, 3H, -CH3), 
0.10 (s, 3H, -CH3), 0.05 (s, 3H, -CH3), -0.05 (s, 3H, -CH3), -0.27 (s, 3H, -CH3).  
13C NMR (125 MHz, CDCl3) δ 164.9, 152.9, 151.7, 149.8, 141.8, 134.1, 132.8, 128.9, 128.1, 
123.0, 88.5, 86.0, 76.1, 72.2, 62.7, 26.2, 26.0, 25.8, 18.7, 18.2, 18.0, -3.5, -4.3, -4.5, -4.6, -4.9, -
5.2. 
HRMS (ESI) m/z calcd for C35H60N5O5Si3 ([M+H]+) 714.3902, found 714.3909. 
IR (neat) ν  2929, 2857, 1698, 1611, 1580, 1454, 1254, 1072, 837, 776 cm-1. 
[a]D23 -35.9 (c = 1.23, CHCl3) 
Compound 2-9 (Rf 0.30 in 50:50 hexanes:ethyl acetate) 
1H NMR (500 MHz, CDCl3) δ 9.10 (s, 1H, NHBz), 8.80 (s, 1H, H-8), 8.41 (s, 1H, H-2), 8.01 (d, 
J = 7.7 Hz, 2H, Bz), 7.62 – 7.55 (m, 1H, Bz), 7.51 (t, J = 7.9 Hz, 2H, Bz), 6.18 (d, J = 5.0 Hz, 
1H, H-1’), 4.64 (appt, J = 5.0 Hz, 1H, H-2’), 4.28 (appq, J = 4.1 Hz, 1H, H-3’), 4.22 (appq, J = 
2.5 Hz, 1H, H-4’), 4.01 (dd, J = 11.5, 2.5 Hz, 1H, H-5’a), 3.86 (dd, J = 11.5, 2.4 Hz, 1H, H-5’b), 
	 42 
2.79 (d, J = 4.2 Hz, 1H, -OH), 0.94 (s, 9H, -tBu), 0.83 (s, 9H, -tBu), 0.14 (s, 3H, -CH3), 0.13 (s, 
3H, -CH3), -0.06 (s, 3H, -CH3), -0.15 (s, 3H, -CH3). 
13C NMR (125 MHz, CDCl3) δ 164.7, 153.0, 151.8, 149.6, 141.4, 133.9, 132.8, 129.0, 127.9, 
123.1, 88.3, 85.5, 77.2, 71.4, 63.2, 26.2, 25.7, 18.6, 18.0, -4.9, -5.1, -5.2, -5.3. 
HRMS (ESI) m/z calcd for C29H46N5O5Si2 ([M+H]+) 600.3038, found 600.3039 
IR (neat) ν  3365, 2947, 2926, 2850, 1701, 1611, 1580, 1455, 1247, 1136, 1063, 837, 782, 706 
cm-1. 
[a]D23  -35.0 (c = 0.88, CHCl3) 
Compound 2-5 (Rf 0.16 in 50:50 hexanes:ethyl acetate) 
1H NMR (500 MHz, CDCl3) δ 9.08 (s, 1H, NHBz), 8.78 (s, 1H, H-8), 8.27 (s, 1H, H-2), 8.01 (d, 
J = 7.3 Hz, 2H, Bz), 7.59 (t, J = 7.4 Hz, 1H, Bz), 7.50 (t, J = 7.7 Hz, 2H, Bz), 6.09 (d, J = 4.7 Hz, 
1H, H-1’), 4.63 – 4.54 (m, 2H, H-2’+H-3’), 4.13 (appq, J = 3.3 Hz, 1H, H-4’), 3.93 (dd, J = 11.4, 
3.5 Hz, 1H, H-5’a), 3.78 (dd, J = 11.4, 2.9 Hz, 1H, H-5’b), 3.21 (d, J = 6.6 Hz, 1H, -OH), 0.95 
(s, 9H, -tBu), 0.89 (s, 9H, -tBu), 0.17 (s, 6H, -CH3), 0.08 (s, 3H, -CH3), 0.05 (s, 3H, -CH3). 
13C NMR (125 MHz, CDCl3) δ 164.7, 152.8, 151.8, 149.6, 141.7, 133.9, 132.9, 129.0, 128.0, 
123.5, 89.1, 85.7, 75.3, 71.8, 62.5, 26.1, 25.9, 18.5, 18.2, -4.5, -4.7, -5.3, -5.4. 
HRMS (ESI) m/z calcd for C29H46N5O5Si2 ([M+H]+) 600.3038, found 600.3032 
IR (neat) ν  3310, 2928, 2864, 1704, 1613, 1580, 1461, 1253, 1073, 836, 775, 702 cm-1. 
[a]D23  -20.5 (c = 1.13, CHCl3) 
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Isomerization of compound 2-9 to 2-5 
To a 7 mL reaction vial was added compound 2-9 (100 mg, 0.17 mmol, 1 eq) and MeOH 
or EtOH (1 mL). The solution was stirred at 30 oC for 48 h, concentrated and purified by silica 
column chromatography to yield compound 2-5 (45 mg, 45% for MeOH treatment or 40 mg, 
40% for EtOH treatment).  
Alternatively, compound 2-9 (100 mg, 0.17 mmol, 1 eq) was added to a 7 mL 
scintillation vial, followed by imidazole (22.8 mg, 0.33 mmol, 2 eq) and DMF (2 mL). The 
reaction was stirred at 30 oC for 48 h, at which point a saturated aqueous NH4Cl solution was 
added. The reaction was extracted three times with EtOAc, dried through Na2SO4, concentrated, 
and purified by silica column chromatography to yield compound 2-5 (50.4 mg, 50%).   
Compound 2-9 could be recovered in nearly equal quantities as the desired compound (2-
5) in all of the above treatments.  
 
 
 
Compound 2-10: To a 0 oC solution of N-Benzoyladenosine (2-7) (10.0 g, 26.9 mmol, 1 eq) in 
DMF (150 mL) was added imidazole (5.5 g, 80.8 mmol, 3 eq). Next, TBSCl (6.09 g, 40.4 mmol, 
1.5 eq) was added in DMF (20 mL) and the reaction was stirred at 0oC for 1 h. The reaction was 
poured into saturated aqueous NH4Cl, extracted three times with EtOAc, washed twice with 
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saturated aqueous NH4Cl, dried through Na2SO4, and concentrated. Water was added to 
precipitate the product and the solid was washed twice with water. The solid was collected; 
EtOH was added and evaporated to remove residual water. The product was purified by silica 
column chromatography (Rf=0.31 in 25:75 Hexanes:EtOAc) to isolate compound 2-10 as a white 
foam (10.1 g, 77%). Compounds 2-5 (822 mg, 5%) and 2-9 (872 mg, 5%) were also isolated as 
minor products. Detailed characterization data for 2-5 and 2-9 is provided below. 
1H NMR (500 MHz, CD3OD) δ  8.72 (s, 1H, H-8), 8.67 (s, 1H, H-2), 8.09 (d, J = 7.4 Hz, 2H, 
Bz), 7.66 (t, J = 7.4 Hz, 1H, Bz), 7.57 (t, J = 7.7 Hz, 2H, Bz), 6.19 (d, J = 4.3 Hz, 1H, H-1’), 4.66 
(dd, J = 4.9, 4.2 Hz, 1H, H-2’), 4.41 (dd, J = 5.2, 4.9 Hz, 1H, H-3’), 4.16 (ddd, J = 5.2, 3.1, 3.1 
Hz, 1H, H-4’), 4.04 (dd, J = 11.6, 3.1 Hz, 1H, H-5’a), 3.91 (dd, J = 11.6, 3.1 Hz, 1H, H-5’b), 
0.94 (s, 9H, -tBu), 0.13 (s, 6H, -CH3). 
13C NMR (125 MHz, CD3OD) δ 167.9, 153.2, 153.0, 151.0, 143.8, 134.9, 133.8, 129.7, 129.4, 
124.9, 90.3, 86.4, 76.3, 71.2, 63.8, 26.5, 19.3, -5.3, -5.3. 
HRMS (ESI) m/z calcd for C23H32N5O5Si ([M+H]+) 486.2173, found 486.2173. 
 
 
 
Selective synthesis of compound 2-5: To a 250 mL round bottomed flask containing compound 
2-10 (1.70 g, 3.5 mmol, 1 eq) was added THF (35 mL), and the solution was cooled to -78oC. 
Next, TBSOTf (0.88 mL, 3.85 mmol, 1.1 eq) was added and the solution was stirred at -78oC for 
30 min. After 30 min, additional TBSOTf (0.44 mL, 1.92 mmol, 0.55 eq) was added and stirred 
for 30 min at -78oC. The reaction was quenched at -78oC with saturated aqueous NaHCO3 and 
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slowly warmed to room temperature. The aqueous layer was extracted once with ethyl acetate, 
once with methylene chloride and once with chloroform. The combined organic layers were 
dried though Na2SO4, concentrated and purified by silica column chromatography to give 
known13 compounds 2-5 (1.92 g, 91%) 2-9 as a minor byproduct (0.12 g, 6%) as white foams.  
 
 
 
Compound 2-16: A modified version of the procedure of Paquette et al.17 was followed. 
Specifically, to a 250 mL round bottom flask was added D-ribose (2-15) (10.0 g, 66.1 mmol, 1 
eq), methanol (40 mL), and acetone (40 mL). Next, concentrated HCl (1 mL) was added at room 
temperature, the flask was sealed, and the reaction was heated to 75 oC for 4 h. The solution was 
cooled to room temperature and quenched with pyridine (10 mL). The solution was concentrated, 
diluted with EtOAc, and poured into a saturated aqueous NaHCO3 solution. The aqueous layer 
was extracted ten times with EtOAc, the combined organic layers were dried over Na2SO4, 
concentrated, and purified by distillation under high vacuum (bp 110 oC at 1 torr, Rf 0.34, 50:50 
hexanes:ethyl acetate). Compound 2-16 was obtained as a colorless oil (11.3 g, 84%).  
1H NMR (499 MHz, CDCl3) δ 4.97 (s, 1H, H-1), 4.84 (d, J = 5.9 Hz, 1H, H-2), 4.59 (d, J = 5.9 
Hz, 1H, H-3), 4.43 (bs, 1H, H-4), 3.70 (ddd, J = 12.6, 2.4, 2.7 Hz, 1H, H-5a), 3.65-3.57 (m, 1H, 
H-5b), 3.44 (s, 3H, -OCH3), 3.21 (dd, J = 10.7, 2.7 Hz, 1H,-OH), 1.49 (s, 3H, -CH3), 1.32 (s, 3H, 
-CH3).  
13C NMR (126 MHz, CDCl3) δ 112.3, 110.3, 88.6, 86.0, 81.7, 64.2, 55.6, 26.6, 25.0. 
 HRMS (ESI) m/z calcd for C9H16O5Na ([M+Na]+) 227.0895, found 227.0896. 
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IR (neat) ν  3457, 2986, 2934, 2836, 1455, 1380, 1276, 1208, 1162, 1097, 1045, 1009, 963, 869 
cm-1.  
[a]D21 -73.5 (c = 2.71, CHCl3) 
 
 
 
Compound 2-17: To a 500 mL round bottom flask was added DMF (180 mL) and compound 2-
16 (10.0 g, 49.0 mmol, 1.1 eq). The reaction was cooled to 0 oC. Next, NaH (1.34 g, 55.6 mmol, 
1.25 eq) was added in one portion and stirred for 15 min at 0 oC. Lastly, 2-bromomethyl-
naphthalene (9.84 g, 44.5 mmol, 1 eq) was added portionwise and slowly warmed to room 
temperature. The reaction was stirred at room temperature for 36 h. The reaction was then cooled 
to 0 oC, quenched with saturated aqueous NH4Cl, extracted with EtOAc twice, the organic layer 
was dried over Na2SO4, concentrated and purified by silica gel chromatography. Compound 2-17 
was obtained as a white solid (13.54 g, 88%). 
1H NMR (500 MHz, CDCl3) δ 7.88 – 7.80 (m, 3H, Nap), 7.78 (s, 1H, Nap), 7.51 – 7.44 (m, 3H, 
Nap), 4.97 (s, 1H, H-1), 4.72 (s, 2H, -OCH2Nap), 4.70 (d, J = 6.1 Hz, 1H, H-2), 4.57 (d, J = 6.0 
Hz, 1H, H-3), 4.41 (ddd, J = 7.7, 6.5, 1.1 Hz, 1H, H-4), 3.56 (dd, J = 9.7, 6.4 Hz, 1H, H-5a), 3.50 
(dd, J = 9.7, 8.1 Hz, 1H, H-5b), 3.29 (s, 3H, -OCH3), 1.49 (s, 3H, -CH3), 1.32 (s, 3H, -CH3). 
13C NMR (126 MHz, CDCl3) δ 135.6, 133.3, 133.1, 128.3, 128.0, 127.8, 126.5, 126.2, 126.0, 
125.8, 112.5, 109.4, 85.3, 85.3, 82.3, 73.4, 71.2, 54.9, 26.6, 25.1. 
HRMS (ESI) m/z calcd for C20H25O5 ([M+H]+) 345.1702, found 345.1695. 
IR (neat) ν  3052, 2996, 2938, 1601, 1510, 1458, 1372, 1271, 1243, 1210, 1107, 1059, 1018, 
966, 870, 818, 753 cm-1. 
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[a]D22  -41.0 (c = 10.0, CHCl3) 
 
 
 
Compound 2-18: To a 1 L round bottom flask was added compound 2-17 (12.16 g, 35.3 mmol, 
1 eq) and MeOH (500 mL). The flask was placed in an oil bath at 114 oC and equipped with a 
distillation head. While the solution was warming to the bath temperature, concentrated H2SO4 
(4.6 mL) was added slowly over 5 minutes. The solution was heated to a vigorous boil and the 
distillate was collected. Fresh anhydrous methanol was slowly added to the solution to replenish 
the methanol that was lost. After 5 h the solution was cooled to room temperature. The reaction 
was quenched with solid NaHCO3 (20 g), the solution was decanted and concentrated. The 
organic slurry was diluted with CH2Cl2, filtered, and the filtrate was once again concentrated. 
The crude oil was purified by silica gel chromatography to furnish compound 2-18 as a white 
solid (10.68 g, 99%, α:β = ~1:3). 
α-anomer (Rf  0.23, 75:25 ethyl acetate:hexanes) 
1H NMR (500 MHz, CDCl3) δ 7.86 – 7.80 (m, 3H, Nap), 7.75 (s, 1H, Nap), 7.53 – 7.40 (m, 3H, 
Nap), 4.96 (d, J = 4.5 Hz, 1H, H-1), 4.74 (d, J = 12.1 Hz, 1H, CH2Nap), 4.69 (d, J = 12.2 Hz, 
1H, CH2Nap), 4.21 – 4.12 (m, 2H, H-2 + H-3), 3.98 (ddd, J = 7.7, 6.1, 3.1 Hz, 1H, H-4), 3.65 
(dd, J = 10.5, 3.4 Hz, 1H, H-5a), 3.62 (dd, J = 10.5, 4.3 Hz, 1H, H-5b), 3.49 (s, 3H, -OCH3), 2.92 
(d, J = 9.1 Hz, 1H, -OH), 2.66 (d, J = 8.1 Hz, 1H, -OH). 
13C NMR (126 MHz, CDCl3) δ 135.4, 133.3, 133.1, 128.4, 128.0, 127.8, 126.7, 126.3, 126.1, 
125.8, 103.0, 84.0, 73.8, 71.7, 71.5, 70.2, 55.8.  
HRMS (ESI) m/z calcd for C17H20O5Na ([M+Na]+) 327.1208, found 327.1210. 
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IR (neat) ν  3410, 3059, 2926, 2850, 1635, 1507, 1465, 1448, 1403, 1372, 1347, 1271, 1188, 
1125, 1094, 1039, 955, 896, 855, 817, 758 cm-1. 
[a]D22  + 72.5 (c = 1.9, CHCl3) 
β-anomer (Rf  0.34, 75:25 ethyl acetae:hexanes) 
1H NMR (500 MHz, CDCl3) δ 7.81 (td, J = 6.0, 5.5, 3.3 Hz, 3H, Nap), 7.77 (s, 1H, Nap), 7.51 – 
7.44 (m, 3H, Nap), 4.83 (s, 1H, H-1), 4.72 (d, J = 12.3 Hz, 1H, CH2Nap), 4.69 (d, J = 12.3 Hz, 
1H, CH2Nap), 4.23 – 4.09 (m, 3H, H-2 + H-3 + H-4), 3.99 (d, J = 4.6 Hz, 1H, -OH), 3.93 (s, 1H, 
-OH), 3.65 (dd, J = 10.3, 4.0 Hz, 1H, H-5a), 3.55 (dd, J = 10.3, 6.5 Hz, 1H, H-5b), 3.29 (s, 3H, -
OCH3). 
13C NMR (126 MHz, CDCl3) δ 135.3, 133.2, 133.0, 128.2, 127.9, 127.7, 126.6, 126.1, 125.9, 
125.8, 108.2, 81.9, 74.8, 73.5, 72.5, 72.1, 55.1. 
HRMS (ESI) m/z calcd for C17H20O5Na ([M+Na]+) 327.1208, found 327.1199. 
IR (neat) ν  3390, 3045, 1639, 1604, 1503, 1451, 1354, 1264, 1188, 1113, 1063, 1028, 976, 945, 
886, 858, 817, 752 cm-1. 
[a]D22  -32.5 (c = 4.55, CHCl3) 
 
 
Compound 2-19: To a flame dried 500 mL round bottom flask was added NaH (3.37 g, 140.0 
mmol, 4 eq) followed by DMF (80 mL) and the mixture was cooled to 0 oC. Then, compound 2-
18 (10.68 g, 35.1 mmol, 1 eq) was added dropwise as a solution in DMF (80 mL). After 30 min 
at 0 oC, allyl bromide (11.9 mL, 140.0 mmol, 4 eq) was added, the reaction was slowly warmed 
to room temperature and was stirred for 12 h. The reaction was cooled to 0 oC, quenched with a 
saturated aqueous NH4Cl solution, diluted with H2O and extracted with EtOAc three times. The 
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organic layer was dried over Na2SO4, concentrated, and purified by silica gel chromatography. 
Compound 2-19 was obtained as a slightly yellow oil (11.985 g, 89%, α:β = ~1:3). 
α-anomer (Rf 0.21, 30:70 ethyl acetate:hexanes) 
1H NMR (500 MHz, CDCl3) δ 7.87 – 7.78 (m, 3H, Nap), 7.76 (s, 1H, Nap), 7.51 – 7.43 (m, 3H, 
Nap), 5.97 (ddt, J = 17.2, 10.3, 5.9 Hz, 1H, -CH2CH=CH2), 5.87 (ddt, J = 17.3, 10.3, 5.9 Hz, 1H, 
-CH2CH=CH2), 5.28 (dd, J = 17.2, 1.6 Hz, 1H, -CH2CH=CH2), 5.22 – 5.13 (m, 2H, -
CH2CH=CH2), 5.09 (dd, J = 10.3, 1.7 Hz, 1H, -CH2CH=CH2), 4.97 (d, J = 4.3 Hz, 1H, H-1), 
4.77 (d, J = 12.3 Hz, 1H, -CH2Nap), 4.69 (d, J = 12.3 Hz, 1H, -CH2Nap), 4.26 (appq, J = 4.0 Hz, 
1H, H-4), 4.17 – 4.10 (m, 3H, -CH2CH=CH2), 4.06 (dd, J = 13.2, 5.9 Hz, 1H, -CH2CH=CH2), 
3.89 (dd, J = 6.7, 2.9 Hz, 1H, H-3), 3.84 (dd, J = 6.8, 4.3 Hz, 1H, H-2), 3.60 (d, J = 4.0 Hz, 2H, 
H-5a + H-5b), 3.46 (s, 3H, -OCH3). 
13C NMR (126 MHz, CDCl3) δ 135.5, 135.0, 134.7, 133.3, 133.1, 128.3, 127.9, 127.8, 126.6, 
126.3, 126.0, 125.7, 117.9, 117.6, 102.5, 82.2, 78.2, 75.5, 73.7, 72.0, 71.9, 70.3, 55.5. 
HRMS (ESI) m/z calcd for C23H28O5Na ([M+Na]+) 407.1834, found 407.1830 
IR (neat) ν  2912, 1642, 1594, 1509, 1346, 1275, 1108, 1040, 910, 856, 818, 753 cm-1. 
[a]D22 + 60.1 (c = 5.8, CHCl3) 
β-anomer (Rf 0.58, 30:70 ethyl acetate:hexanes) 
1H NMR (500 MHz, CDCl3) d 7.87 – 7.75 (m, 4H, Nap), 7.52 – 7.41 (m, 3H, Nap), 5.99 – 5.83 
(m, 2H, -CH2CH=CH2), 5.31 (dd, J = 17.2, 1.6 Hz, 1H, -CH2CH=CH2), 5.25 (dd, J = 17.2, 1.6 
Hz, 1H, -CH2CH=CH2), 5.20 (dd, J = 10.4, 1.5 Hz, 1H, -CH2CH=CH2), 5.16 (dd, J = 10.4, 1.5 
Hz, 1H, -CH2CH=CH2), 4.92 (s, 1H, H-1), 4.78 (d, J = 12.6 Hz, 1H, -CH2Nap), 4.74 (d, J = 12.2 
Hz, 1H, -CH2Nap), 4.32 (ddd, 7.07, 5.85, 3.59 Hz, 1H, H-4), 4.19 – 4.04 (m, 3H, -CH2CH=CH2), 
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4.03 – 3.97 (m, 2H, -CH2CH=CH2 + H-3), 3.83 (d, J = 4.6 Hz, 1H, H-2), 3.69 (dd, J = 10.6, 3.6 
Hz, 1H, H-5a), 3.59 (dd, J = 10.6, 5.9 Hz, 1H, H-5b), 3.35 (s, 3H, -OCH3). 
13C NMR (126 MHz, CDCl3) d 135.9, 134.5, 134.4, 133.3, 133.0, 128.1, 127.9, 127.8, 126.3, 
126.1, 125.9, 125.7, 117.7, 117.6, 106.5, 80.5, 79.7, 78.4, 73.3, 71.6, 71.5, 71.5, 55.2. 
HRMS (ESI) m/z calcd for C23H28O5Na ([M+Na]+) 407.1834, found 407.1839. 
IR (neat) ν  3059, 2916, 2850, 1639, 1507, 1458, 1354, 1254, 1106, 1066, 1039, 983, 935, 818, 
754 cm-1. 
[a]D21 + 7.3 (c = 4.97, CHCl3) 
 
 
 
Compound 2-20: To a 1 L round bottom flask was added compound 2-19 (11.95 g, 31.1 mmol, 
1 eq) and 1,4-dioxane (150 mL). The flask was fitted with an air condenser and a rubber septum 
without positive pressure of nitrogen and heated in an oil bath. While the solution was warming, 
1 M HCl (150 mL) was added in portions over 5 min. The solution was heated at 140 oC for 2 h. 
The reaction was quenched with saturated aqueous NaHCO3 and extracted with EtOAc three 
times. The organic layer was dried over NaSO4, concentrated, and purified by silica gel 
chromatography (Rf=0.6 in 50:50 hexanes:ethyl acetate) to provide compound 2-20 as a yellow 
oil (9.91 g, 86%, 1.6:1 anomeric mixture). 
1H NMR (500 MHz, CDCl3) δ 7.84 –7.71 (m, 4H major, 4H minor, Nap), 7.51 – 7.39 (m, 3H 
major, 3H minor, Nap), 5.99 – 5.80 (m, 2H major, 2H minor, -CH2CH=CH2), 5.34 – 5.12 (m, 5H 
major, 5H minor, H-1 + -CH2CH=CH2), 4.83 – 4.62 (m, 2H major, 2H minor, -CH2Nap), 4.33 
(ddd, J = 4.0, 3.9, 2.4 Hz, 1H major, H-4), 4.26 (ddd, J = 6.6, 3.2, 3.2 Hz, 1H minor, H-4), 4.21 – 
3.90 (m, 6H major, 5H minor, H-3 (major + minor), H-2 (major), -CH2CH=CH2), 3.83 (d, J = 4.7 
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Hz, 1H minor, H-2), 3.72 (dd, J = 10.4, 2.9 Hz, 1H minor, H-5a), 3.61 (dd, J = 10.4, 3.5 Hz, 1H 
minor, H-5b), 3.57 (dd, J = 10.5, 3.7 Hz, 1H major, H-5a), 3.53 (dd, J = 10.5, 4.4 Hz, 1H major, 
H-5b). 
13C NMR (100 MHz, CDCl3) δ 135.4 (major), 135.0 (minor), 134.4 (minor), 134.4 (minor), 
134.2 (major), 134.1 (major), 133.3 (minor), 133.3 (major), 133.1 (minor), 133.1 (major), 128.4 
(minor), 128.3 (major), 127.9 (minor), 127.9 (major), 127.8 (major), 127.8 (minor), 126.8 
(minor), 126.5 (major), 126.3 (major), 126.3 (minor), 126.1 (minor), 126.0 (major), 125.8 
(minor), 125.6 (major), 117.8 (major), 117.7 (minor), 117.7 (minor), 117.6 (major), 100.5 
(minor, C-1), 96.2 (major, C-1), 80.9 (minor, C-4), 80.7 (major, C-4), 77.9 (minor, C-2), 77.7 
(major), 77.5 (minor), 77.4 (minor, C-3), 73.7 (major), 73.6 (minor), 71.9 (major), 71.7 (major), 
71.6 (minor), 71.5 (minor), 70.1 (major), 70.0 (minor). 
HRMS (ESI) m/z calcd for C22H26O5Na ([M+Na]+) 393.1678, found 393.1674 
IR (neat) ν  3421, 3045, 2912, 2863, 1646, 1509, 1455, 1427, 1344, 1271, 1089, 1032, 924, 856, 
817, 753 cm-1. 
[a]D21 +37.5 (c = 8.5, CHCl3) 
 
Compound 2-6: To a 25 mL round-bottomed flask was added compound 2-20 (5.0 g, 13.5 
mmol, 1 eq) and THF (65 mL). The solution was cooled to -50 oC and diethylaminosulfur 
trifluoride (2.1 mL, 16.2 mmol, 1.2 eq) was added slowly over 2 min. The solution was 
immediately warmed to room temperature and stirred for 1 h. The solution was cooled to -50 oC 
and quenched with saturated aqueous NaHCO3 (20 mL). The solution was warmed to room 
temperature, the organic layer was extracted with EtOAc three times, dried over Na2SO4, 
ONap
O
AllO OAll
HO Et2NSF3 (1.2 eq)
THF, -50oC to rt, 1 h
89%
ONap
O
AllO OAll
F 1
2 3
4 5
2-20 2-6
	 52 
concentrated, and purified by silica gel chromatography to give compound 2-6 as a pale yellow 
oil (4.48 g, 89%). 
1H NMR (500 MHz, CDCl3) δ 7.87 – 7.77 (m, 4H, Nap), 7.51 – 7.44 (m, 3H, Nap), 5.99 – 5.81 
(m, 2H, -CH2CH=CH2), 5.73 (d, J = 63.4 Hz, 1H, H-1), 5.37 – 5.15 (m, 4H, -CH2CH=CH2), 4.81 
(d, J = 12.3 Hz, 1H, CH2Nap), 4.75 (d, J = 12.3 Hz, 1H, CH2Nap), 4.39 (dddd, J = 8.2, 8.2, 5.3, 
3.2 Hz, 1H, H-4), 4.18 (appdt, J = 5.7, 1.4 Hz, 1H, H-3), 4.14 – 3.97 (m, 5H, -CH2CH=CH2, + 
H-2), 3.77 (dd, J = 11.1, 3.2 Hz, 1H, H-5a), 3.67 (dd, J = 11.0, 5.4 Hz, 1H, H-5b). 
13C NMR (125 MHz, CDCl3) δ 135.7, 134.2, 134.1, 133.4, 133.1, 128.3, 128.0, 127.8, 126.5, 
126.2, 126.0, 125.8, 118.3, 118.0, 112.8 (d, J = 224.4 Hz), 82.5 (d, J = 2.6 Hz), 79.1 (d, J = 29.9 
Hz), 77.1, 73.6, 72.1, 72.0, 70.4. 
19F NMR (470 MHz, CDCl3) δ -118.4 (d, J = 63.6 Hz). 
HRMS (ESI) m/z calcd for C22H25O4NaF ([M+Na]+) 395.1635, found 395.1638 
IR (neat) ν  3052, 2919, 2862, 1646, 1601, 1510, 1469, 1420, 1347, 1271, 1101, 994, 948, 855, 
818, 747 cm-1. 
[a]D21 +46.6 ( c = 4.8, CHCl3) 
 
 
Compound 2-21: To a 250 mL schlenk flask was added SnCl2 (3.39 g, 17.9 mmol, 2.0 eq) and 
freshly dried powdered 4 Å molecular sieves (6.0 g). Dried AgPF6 (4.53 g, 17.90 mmol, 2.0 eq), 
contained in a 7 mL vial, was added to the flask keeping the AgPF6 and SnCl2 segregated. The 
flask was dried overnight under high vacuum.  To the flask was added CH2Cl2 (60 mL) and the 
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reaction was cooled to -78 oC. Lastly, compound 2-6 (4.0 g, 10.7 mmol, 1.2 eq) and compound 
2-5 (5.37 g, 8.95 mmol, 1 eq) were added in CH2Cl2 (40 mL). Compounds 2-6 and 2-5 had been 
previously dried by azeotropic removal of water with dry CH3CN three times on a rotary 
evaporator filled with dry nitrogen and dried over P2O5 under high vacuum for 5 h. The solution 
was stirred for 30 min at -78 oC and then stirred at 4 oC for 15 h. The solution was quenched with 
a 0oC saturated aqueous NaHCO3 solution and stirred for 3 h, after which point the biphasic 
mixture was filtered through celite washing with CH2Cl2. The organic layer was dried over 
Na2SO4, concentrated, and purified by silica gel chromatography (Rf 0.5 in 50:50 hexanes:ethyl 
acetate) to give compound 2-21 as a pale yellow foam (6.04 g, 72%). 
1H NMR (500 MHz, CDCl3) δ 8.93 (s, 1H, NHBz), 8.81 (s, 1H, H-8), 8.39 (s, 1H, H-2), 8.00 (d, 
J = 7.0 Hz, 2H, Bz), 7.86 – 7.75 (m, 3H, Nap), 7.71 (s, 1H, Nap), 7.61 (t, J = 7.5 Hz, 1H, Bz), 
7.52 (t, J = 7.5 Hz, 2H, Bz), 7.48 – 7.42 (m, 2H, Nap), 7.39 (dd, J = 8.5, 1.7 Hz, 1H, Nap), 6.33 
(d, J = 5.0 Hz, 1H, H-1’), 5.89-5.78 (m, 2H, -CH2CH=CH2), 5.23 – 5.10 (m, 5H, -CH2CH=CH2 
+ H-1’’), 4.84 (appt, J = 4.8 Hz, 1H, H-2’), 4.69 (d, J = 12.3 Hz, 1H, -CH2Nap), 4.61 (d, J = 12.3 
Hz, 1H, -CH2Nap), 4.53 (appt, J = 4.4 Hz, 1H, H-3’), 4.23-4.17 (m, 2H, H-4’ + H-4’’), 4.13 – 
4.02 (m, 2H, - CH2CH=CH2), 4.02 – 3.91 (m, 3H, -CH2CH=CH2 + H-5’a), 3.85 (dd, J = 6.4, 4.4 
Hz, 1H, H-3’’), 3.81 – 3.72 (m, 2H, H-2’’+ H-5’b), 3.52 (d, J = 3.7 Hz, 2H, H-5’’a + H-5’’b) 
0.93 (s, 9H, -tBu), 0.91 (s, 9H, -tBu), 0.16 (s, 3H, -CH3), 0.14 (s, 3H, -CH3), 0.10 (s, 3H, -CH3), 
0.10 (s, 3H, -CH3). 
13C NMR (125 MHz, CDCl3) δ 164.7, 152.8, 151.6, 149.5, 142.3, 135.6, 134.9, 134.6, 133.9, 
133.3, 133.1, 132.8, 129.0, 128.3, 127.9, 127.9, 127.8, 126.5, 126.3, 126.0, 125.7, 123.3, 117.6, 
117.5, 101.5, 87.0, 85.6, 81.9, 79.6, 77.8, 75.6, 73.7, 72.0, 71.6, 71.2, 69.9, 62.3, 26.2, 26.0, 18.6, 
18.3, -4.4, -5.0, -5.3, -5.3. 
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HRMS (ESI) m/z calcd for C51H70N5O9Si2 ([M+H]+) 952.4712, found 952.4711. 
IR (neat) ν  2933, 2857, 1698, 1611, 1580, 1455, 1250, 1084, 1039, 834, 782 cm-1. 
[a]D21 +2.7 (c = 2.41, CHCl3)  
 
 
Compound 2-23: To a 125 mL round bottomed flask containing compound 2-21 (1.0 g, 1.05 
mmol, 1 eq) was added Pd(PPh3)4 (240 mg, 0.21 mmol, 0.2 eq) and 1,3-Dimethylbarbituric acid 
(1.62 g, 10.3 mmol, 10 eq). Methanol (30 mL) was added and the reaction was stirred at room 
temperature for 16 h. The reaction was quenched at 0oC with an aqueous Na2CO3 solution and 
stirred for 2 h at room temperature. The reaction mixture was extracted three times with ethyl 
acetate and three times with chloroform, filtered through Na2SO4, and concentrated. The product 
was purified by silica gel chromatography (Rf 0.53 in 40:60 hexanes:ethyl acetate) to yield 
compound 2-23 as a bright yellow foam (917 mg, 99%).   
1H NMR (500 MHz, CDCl3) δ 8.92 (s, 1H, NHBz), 8.62 (s, 1H, H-8), 8.40 (s, 1H, H-2), 8.02 
(dd, J=7.0 Hz, 1.5 Hz, 2 H, -Bz), 7.83-7.80 (m, 3H, -Nap), 7.69-7.44 (m, 7H, -Nap+Bz), 6.25 (d, 
J = 2.7 Hz, 1H, H-1’), 5.37 (d, J = 4.2 Hz, 1H, H-1’’), 4.73-4.63 (m, 4H, CH2Nap + H-2’ + H-
3;), 4.26-4.25 (m, 1H, H-4’’), 4.21 (ddd, J = 9.8, 5.7, 4.1 Hz, 1H, H-2’’), 4.13 (dd, J = 6.0, 2.8 
Hz, 1H, H-4’), 4.09-3.98 (m, 2H, H-5’a, H-3’’), 3.81 (dd, J = 11.7, 2.4 Hz, 1H, H-5’b), 3.62 (dd, 
J = 10.6, 3.8 Hz, 1H, H-5’’a), 3.58 (dd, J = 10.6, 3.6 Hz, 1H, H-5’’b), 3.06 (d, J = 9.8 Hz, 1H, -
OH), 2.94 (d, J = 10.7 Hz, 1H, -OH), 0.94 (s, 9H, -tBu), 0.92 (s, 9H, -tBu), 0.151 (s, 6H, -CH3), 
0.11 (s, 3H, -CH3), 0.10 (s, 3H, -CH3).  
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13C NMR (125 MHz, CDCl3) δ 164.7, 152.9, 151.2, 149.6, 141.4, 135.3, 133.8, 133.3, 133.1, 
132.9, 129.0, 128.4, 128.0, 127.9, 127.8, 126.6, 126.3, 126.1, 125.7, 123.4, 101.5, 87.3, 85.1, 
84.6, 79.5, 73.8, 72.0, 72.0, 67.0, 69.8, 61.3, 26.2, 26.0, 18.6, 18.3, -4.1, -4.7, -5.2, -5.3. 
HRMS m/z calcd for C45H62N5O9Si2 ([M+H]+) 872.4086, found 872.4077 
IR (neat) ν  3344, 2926, 2850, 1698, 1608, 1576, 1458, 1438, 1254, 1119, 830 cm-1. 
[aD]21 +15.3 (c = 15.3, CHCl3) 
 
 
 
Compound 2-24: A 7 mL reaction vial containing compound 2-23 (910 mg, 1.043 mmol, 1 eq) 
and 4-dimethylaminopyridine (127 mg, 1.043 mmol, 1 eq) was evacuated and backfilled three 
times with dry nitrogen. Methylene chloride (10 mL) was added and the vial was cooled to 0 oC. 
Next, EtNiPr2 (1.09 mL, 6.26 mmol, 6 eq) and TBSOTf (0.72 mL, 3.13 mmol, 3 eq) were added 
and the reaction was allowed to warm to room temperature. A saturated aqueous NH4Cl solution 
was added after 2 h, and the reaction was stirred vigorously for 1 h. The product was purified by 
silica gel chromatography (Rf 0.68 in 60:40 hexanes:ethyl acetate) to yield compound 2-24 (862 
mg, 75%) as a white foam.  
1H NMR (500 MHz, CDCl3) d 8.93 (s, 1H, NHBz), 8.78 (s, 1H, H-8), 8.39 (s, 1H, H-2), 8.01 (d, 
J=7.1 Hz, 2H, -Bz),  7.85 – 7.76 (m, 3H, -Nap), 7.74 (s, 1H, -Nap),  7.61 (t, J=7.6 Hz, 1H, -Bz), 
7.53 (t, J = 7.6 Hz, 2H, -Bz), 7.49 – 7.45 (m, 2H, Nap), 7.42 (dd, J = 8.4, 1.7 Hz, 1H, -Nap), 6.23 
(d, J = 3.2 Hz, 1H, H-1’), 5.28 (d, J = 3.7 Hz, 1H, H-1’’), 4.76 – 4.62 (m, 3H, -CH2Nap + H-2’), 
4.55 (dd, J = 6.1, 4.5 Hz, 1H, H-3’),  4.24-4.18 (m, 2H, H-4’ + H-4’’), 4.05-3.99 (m, 3H, H-2’’ + 
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H-3’’ + H-5’a),  3.78 (dd, J = 11.5, 2.5 Hz, 1H, H-5’b), 3.62 (dd, J = 10.7, 3.0 Hz, 1H, H-5’’a), 
3.57 (dd, J = 10.8, 3.8 Hz, 1H, H-5’’b), 0.91 (s, 18H, -tBu), 0.86 (s, 9H, -tBu), 0.85 (s, 9H, -tBu), 
0.13 (s, 3H, -CH3), 0.10 (s, 6H, -CH3), 0.09 (s, 3H, -CH3), 0.03 (s, 6H, -CH3), 0.00 (s, 3H, -CH3), 
-0.01 (s, 3H, -CH3). 
13C NMR (125 MHz, CDCl3) d 164.7, 152.8, 151.3, 149.4, 142.1, 135.8, 134.0, 133.4, 133.1, 
132.8, 129.0, 128.2, 127.9, 127.9, 127.8, 126.4, 126.2, 126.0, 125.7, 123.4, 103.2, 87.9, 84.6, 
83.6, 81.0, 73.7, 73.6, 71.5, 70.0, 69.7, 61.7, 26.2, 26.2, 26.1, 26.0, 18.6, 18.5, 18.3, 18.3, -4.2, -
4.3, -4.4, -4.5, -4.6, -4.8, -5.2, -5.2. 
HRMS m/z calcd for C57H90N5O9Si4 ([M+H]+) 1100.5816, found 1100.5829 
IR (neat) n 2928, 2857, 1701, 1610, 1576, 1455, 1252, 1070, 836, 778 cm-1 
[aD]23 + 10.1 (c = 1.04, CHCl3)  
 
 
 
Compound 2-25: To a 100 mL round bottomed flask was added compound 2-24 (530 mg, 0.48 
mmol, 1 eq) and THF (12 mL). The solution was cooled to 0 oC. A cold solution of 
trichloroacetic acid (3.5 g, 21.7 mmol, 45 eq) in water (12 mL) was added dropwise at 0 oC over 
30 min. The reaction was stirred at 0 oC for 5 h, at which point it was quenched by pouring into a 
0 oC solution of saturated aqueous NaHCO3. The quenched reaction was extracted three times 
with EtOAc, dried through Na2SO4 and concentrated. Silica gel chromatography (Rf=0.46 in 
60:40 hexanes:ethyl acetate) yielded compound 2-25 as a white foam (403 mg, 85%).  
O
TBSO O
N
N
N
N
NHBz
TBSO
O
TBSO OTBS
ONap
Cl3CCO2H (46 eq)
THF/H2O (1/1), 0oC, 5 h
85%
O
TBSO O
N
N
N
N
NHBz
HO
O
TBSO OTBS
ONap
5
8
4 2
6
1'
2'3'
4'5'
1''
2'' 3''
4''
5''
2-24 2-25
	 57 
1H NMR (500 MHz, CDCl3) δ 9.19 (s, 1H, -NHBz), 8.78 (s, 1H, H-8), 8.07 (s, 1H, H-2), 8.00 
(d, J=7.6 Hz, 2H, -Bz), 7.84 – 7.78 (m, 3H, -Nap), 7.75 (s, 1H, -Nap), 7.59 (t, J = 7.6 Hz, 1H, -
Bz), 7.51-7.41 (m, 5H, -Nap + -Bz), 6.07 (d, J = 7.5 Hz, 1H, H-1’), 5.84 (bd, J=10.6 Hz, 1H, -
OH), 4.99 (dd, J = 7.5, 4.4 Hz, 1H, H-2’), 4.89 (d, J = 3.6 Hz, 1H, H-1’’), 4.67 (d, J = 3.5 Hz, 
2H, -CH2Nap), 4.62 (dd, J = 4.5, 1.3 Hz, 1H, H-3’), 4.24 – 4.16 (m, 2H, H-4’ + H-4’’), 4.02 – 
3.92 (m, 2H, H-5’a + H-3’’), 3.85 (dd, J = 4.9, 3.6 Hz, 1H, H-2’’), 3.76 (ddd, J = 12.9, 11.1, 1.9 
Hz, 1H, H-5’b), 3.59 (dd, J = 10.8, 3.0 Hz, 1H, H-5’’a), 3.53 (dd, J = 10.8, 3.6 Hz, 1H, H-5’’b), 
0.93 (s, 9H, -tBu), 0.86 (s, 9H, -tBu), 0.75 (s, 9H, -tBu), 0.14 (s, 3H, -CH3), 0.10 (s, 3H, -CH3), -
0.01 (s, 3H, -CH3), -0.02 (s, 3H, -CH3), -0.09 (s, 3H, -CH3), -0.12 (s, 3H, -CH3).  
13C NMR (125 MHz, CDCl3) δ 164.5, 152.2, 150.6, 150.3, 143.7, 135.7, 133.6, 133.3, 133.0, 
132.9, 129.0, 128.2, 127.9, 127.9, 127.7, 126.4, 126.1, 125.9, 125.8, 124.5, 104.1, 89.3, 89.2, 
83.0, 81.4, 73.6, 73.6, 73.0, 71.4, 69.4, 62.7, 26.1, 26.1, 26.1, 18.5, 18.2, 18.2, -4.2, -4.3, -4.4, -
4.5, -4.6, -4.7. 
HRMS (ESI) m/z calcd for C51H76N5O9Si3 ([M+H]+) 986.4951, found 986.4959 
IR (neat) ν  3254, 2919, 2857, 1705, 1611, 1580, 1458, 1251, 1153, 1108, 834, 775 cm-1 
[aD]23 +3.0 (c = 1.08, CHCl3) 
 
 
 
Compound 2-26: To a dry 20 mL reaction vial was added compound 2-25 (520 mg, 0.47 mmol, 
1 eq) and dibenzyl N,N-diisopropylphosphoramidite (195 mg, 0.56 mmol, 1.2 eq). The 
compounds were co-evaporated three times on a N2-filled rotary evaporator with dry CH3CN and 
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then dried over P2O5 overnight. Separately, 4,5-dicyanoimidazole (66.6 mg, 0.56 mmol, 1.2 eq) 
was evaporated and dried in a similar manner. To compound 2-21 and the phosphoramidite was 
added dry CH2Cl2 (4.7 mL), followed by a solution of the 4,5-dicyanoimidazole in CH3CN (1.5 
mL) at room temperature. After 2 h, the reaction was cooled to 0 oC and a solution of t-butyl 
peroxide (0.39 mL of a 5.5 M solution in decane, 2.35 mmol, 5 eq) was added. The reaction was 
warmed to room temperature and stirred for 3 h. Next, the reaction was poured into a saturated 
aqueous NaHCO3 solution, extracted three times with ethyl acetate, dried through Na2SO4, and 
concentrated. The product was purified by silica gel chromatography (Rf 0.29 in 50:50 
hexanes:ethyl acetate) to give compound 2-26 as a colorless oil (533 mg, 91%). 
1H NMR (500 MHz, CDCl3) δ 9.07 (s, 1H, -NHBz), 8.74 (s, 1H, H-8), 8.27 (s, 1H, H-2), 8.01 
(d, J = 7.0 Hz, 2H, -Bz), 7.86 – 7.77 (m, 3H, -Nap), 7.75 (s, 1H, -Nap), 7.60 (t, J = 7.4 Hz, 1H, -
Bz), 7.55 – 7.39 (m, 5H, -Nap + -Bz), 7.33 – 7.27 (m, 10H), 6.18 (d, J = 3.1 Hz, 1H, H-1’), 5.26 
(d, J = 3.8 Hz, 1H, H-1’’), 5.00 (appt, J = 8.1 Hz, 4H, -CH2Bn), 4.83 (dd, J = 4.4, 3.5 Hz, 1H, H-
2’), 4.72 (d, J = 12.0 Hz, 1H, -CH2Nap), 4.66 (d, J = 12.2 Hz, 1H, -CH2Nap), 4.55 (dd, J = 6.2, 
4.5 Hz, 1H, H-3’), 4.40 (ddd, J = 11.2, 5.6, 3.6 Hz, 1H, H-5’a), 4.35 – 4.28 (m, 1H, H-4’), 4.25 
(appq, J = 3.6 Hz, 1H, H-4’’), 4.19 (ddd, J = 11.2, 5.2, 3.7 Hz, 1H, H-5’b), 4.03 (dd, J = 5.3, 4.3 
Hz, 1H, H-3’’), 4.00 (dd, J = 5.3, 3.9 Hz, 1H, H-2’’), 3.63 (dd, J = 10.8, 3.1 Hz, 1H, H-5’’a), 
3.58 (dd, J = 10.8, 3.7 Hz, 1H, H-5’’b), 0.91 (s, 9H, -tBu), 0.88 (s, 9H, -tBu), 0.83 (s, 9H, -tBu), 
0.13 (s, 3H, -CH3), 0.09 (s, 3H, -CH3), 0.04 (s, 3H, -CH3), -0.00 (s, 6H, -CH3), -0.02 (s, 3H, -
CH3). 
13C NMR (125 MHz, CDCl3) δ 164.5, 152.7, 151.2, 149.6, 142.2, 135.7, 135.6, 133.8, 133.3, 
133.1, 132.8, 128.9, 128.6, 128.6, 128.2, 128.0, 128.0, 128.0, 127.8, 127.8, 126.4, 126.2, 125.9, 
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125.7, 123.7, 103.5, 88.5, 83.9, 82.3 (d, J = 8.7 Hz), 80.3, 73.6, 71.5, 70.4, 69.7, 69.5 (appt, J = 
4.9 Hz), 65.5 (d, J = 3.9 Hz), 26.1, 26.1, 25.9, 18.4, 18.2, 18.2, -4.3, -4.4, -4.5, -4.6, -4.6, -4.9. 
31P NMR (202 MHz, CDCl3) δ 0.030 
HRMS (ESI) m/z calcd for C65H89N5O12Si3P ([M+H]+) 1246.5553, found 1246.5544 
 
 
 
Compound 2-27: To a 20 mL reaction vial was added compound 2-26 (308 mg, 0.247 mmol, 1 
eq), methylene chloride (5.3 mL) and deionized water (1.2 mL). The solution was cooled to 0 oC 
and 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (84.1 mg, 0.371 mmol, 1.5 eq) was added. The 
reaction was stirred at 0 oC for 2 h. After 2 h, the reaction was poured into a saturated aqueous 
Na2S2O3 solution, extracted three times with ethyl acetate, dried through Na2SO4, and 
concentrated. The product was purified by silica column chromatography (Rf 0.69 in 30:70 
hexanes:ethyl acetate) to yield compound 2-27 as a colorless oil (251 mg, 92%). 
1H NMR (500 MHz, CDCl3) δ  8.97 (s, 1H, -NHBz), 8.77 (s, 1H, H-8), 8.25 (s, 1H, H-2), 8.01 
(d, J = 7.4, 2H, -Bz), 7.62 (t, J = 7.4 Hz, 1H, -Bz), 7.54 (t, J = 7.7 Hz, 2H, -Bz), 7.31-7.29 (m, 
10H, -Bn), 6.16 (d, J = 4.1 Hz, 1H, H-1’), 5.19 (d, J = 3.5 Hz, 1H, H-1’’), 5.03 - 4.99 (m, 4H, -
CH2Bn), 4.90 (appt, J = 4.4 Hz, 1H, H-2’), 4.52 (appt, J = 4.8 Hz, 1H, H-3’), 4.39 (ddd, J = 10.7, 
6.0, 4.2 Hz, 1H, H-5’a), 4.31 – 4.23 (m, 1H, H-4’), 4.21 – 4.08 (m, 2H, H-5’b + H-4’’), 4.00 
(appt, J = 6.0 Hz, 1H, H-3’’), 3.92 (dd, J = 5.0, 3.5 Hz, 1H, H-2’’), 3.78 (d, J = 12.1 Hz, 1H, H-
5’’a), 3.60-3.54 (m, 1H, H-5’’b), 0.90 (s, 9H, -tBu), 0.90 (s, 9H, -tBu), 0.85 (s, 9H, -tBu), 0.11 
O N
N
N
N
NHBz
TBSO O
O
PBnO
O
BnO
O
ONap
TBSO OTBS
O N
N
N
N
NHBz
TBSO O
O
PBnO
O
BnO
O
OH
TBSO OTBS
O
O
CN
CNCl
Cl
(1.5 eq)
CH2Cl2:H2O (4:1), 0oC, 6 h
92%
5
8
4 2
6
1'
2'3'
4'5'
1''
2'' 3''
4''
5''
2-26 2-27
	 60 
(s, 3H, -CH3), 0.08 (s, 3H, -CH3), 0.07 (s, 3H, -CH3), 0.06 (s, 3H, -CH3), -0.00 (d, 3H, -CH3), -
0.02 (s, 3H, -CH3). 
13C NMR (125 MHz, CDCl3) δ 165.0, 152.8, 151.5, 149.6, 142.6, 135.7, 135.6, 133.2, 129.1, 
128.9, 128.8, 128.2, 128.1, 123.7, 103.5, 88.1, 83.5, 82.9, 80.2, 77.5, 73.8, 70.8, 69.8, 65.9, 61.4, 
26.2, 26.2, 26.0, 18.6, 18.3, 18.3, -4.0, -4.2, -4.3, -4.5, -4.5, -4.8. 
31P NMR (202 MHz, CDCl3) δ 0.06 
HRMS (ESI) m/z calcd for C54H81N5O12Si3P ([M+H]+) 1106.4927, found 1106.4918. 
 
 
Compound 2-29: To a -78oC solution of compound 2-27 (250 mg, 0.23 mmol, 1 eq) in THF (2 
mL) was added diisopropylethylamine (0.047 mL, 0.27 mmol, 1.2 eq) followed by 2-Cyanoethyl 
N,N-diisopropylchlorophosphoramidite (2-28) (64 mg, 0.27 mmol, 1.2 eq). The -78oC bath was 
removed and the reaction was allowed to warm to room temperature and stirred for 3 h. The 
reaction mixture was filtered through celite, concentrated. The product was purified by silica 
column chromatography (0.67 in 50:50 hexanes:ethyl acetate with 1% triethylamine) to give 
compound 2-29 (310 mg, 99%) as a mixture of 2 diastereomers at the phosphoramidite. 
1H NMR (500 MHz, CDCl3) δ 8.91 (s, 2H, -NHBz), 8.75 (s, 1H, H-8), 8.75 (s, 1H, H-8), 8.27 
(s, 1H, H-2), 8.24 (s, 1H, H-2), 8.03 – 7.98 (m, 4H, -Bz), 7.66 – 7.58 (m, 2H, -Bz), 7.57 – 7.50 
(m, 4H, -Bz), 7.31-7.28 (m, 20H, -Bn), 6.16 (d, J = 3.0 Hz, 1H, H-1’), 6.15 (d, J = 3.1 Hz, 1H, 
H-1’), 5.22 (d, J = 3.9 Hz, 1H, H-1’’), 5.21 (d, J = 3.8 Hz, 1H, H-1’’), 5.02 – 4.94 (m, 8H, -
CH2Bn), 4.81 – 4.74 (m, 2H, H-2’), 4.55 – 4.48 (m, 2H, H-3’), 4.43 – 4.34 (m, 2H, H-5’a), 4.32 
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– 4.25 (m, 2H, H-4’), 4.22 – 4.14 (m, 4H, H-5’b + H-4’’), 4.07 – 3.99 (m, 2H, H-3’’), 3.99 – 
3.91 (m, 2H, H-2’’), 3.87 - 3.52 (m, 12H, H-5’’a+b + -CH2CH2CN + -CH(CH3)2),  2.59 (appq, J 
= 6.1 Hz, 4H, -CH2CH2CN), 1.20 – 1.12 (m, 24H, -CH(CH3)2), 0.90 (s, 9H, -tBu), 0.90 (s, 9H, -
tBu), 0.89 (s, 9H, -tBu), 0.89 (s, 9H, -tBu), 0.83 (s, 9H, -tBu), 0.83 (s, 9H, -tBu), 0.12 (s, 3H, -
CH3), 0.12 (s, 3H, -CH3), 0.08 (s, 3H, -CH3), 0.08 (s, 3H, -CH3), 0.06 (s, 3H, -CH3), 0.06 (s, 3H, 
-CH3), 0.06 (s, 3H, -CH3), 0.06 (s, 3H, -CH3) 0.01 (s, 3H, -CH3), 0.00 (s, 3H, -CH3), -0.01 (s, 3H, 
-CH3), -0.01 (s, 3H, -CH3). 
13C NMR (125 MHz, CDCl3) δ 164.5, 152.8, 151.3, 151.2, 149.6, 149.6, 142.4, 142.3, 135.8, 
135.8, 133.9, 133.0, 133.0, 129.1, 128.8, 128.2, 128.2, 128.0, 123.8, 123.7, 117.8, 117.7, 103.6, 
103.5, 88.7, 88.7, 84.6, 84.5, 84.2, 84.1, 80.5, 80.4, 73.8, 71.3, 71.1, 70.5, 70.4, 69.7, 69.6, 69.6, 
69.6, 65.6, 65.6, 63.2, 63.2, 63.1, 63.0, 58.7, 58.6, 58.5, 58.4, 43.4, 43.3, 43.3, 43.2, 26.2, 26.2, 
26.2, 26.0, 26.0, 25.0, 24.9, 24.9, 24.8, 24.8, 20.6, 20.6, 20.6, 20.6, 18.6, 18.5, 18.3, -4.1, -4.2, -
4.2, -4.2, -4.3, -4.3, -4.4, -4.4, -4.5, -4.8, -4.8. 
31P NMR (202 MHz, CDCl3) δ 149.67, 0.15, 0.12 
Compound 2-29 hydrolyzed when subjected to ESI-MS. 
 
 
 
Compound 2-3: To a 7 mL reaction vial was added compound 2-29 (170 mg, 0.13 mmol, 1 eq) 
and CH3CN (1 mL). Next, 4,5-dicyanoimidazole (18.4 mg, 0.16 mmol, 1.2 eq) and deionized 
water (7.0 mg, 0.39 mmol, 3 eq) were added and the reaction was stirred at room temperature for 
2 h. The reaction mixture was poured into saturated aqueous NaHCO3, extracted three times with 
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EtOAc, dried through Na2SO4, and concentrated to give compound 2-3 (158 mg, 99%) as a 
brown oil and a mixture of diastereomers at the H-phosphonate. The compound was of sufficient 
purity to be used in the next step without further purification.  
1H NMR (500 MHz, CDCl3) δ  8.91 (s, 1H, -NHBz), 8.90 (s, 1H, NHBz), 8.78 (s, 1H, H-8), 
8.77 (s, 1H, H-8), 8.29 (s, 1H, H-2), 8.26 (s, 1H, H-2), 8.01 (d, J = 6.7 Hz, 4H, -Bz), 7.67-7.60 
(m, 2H, -Bz) 7.57 – 7.50 (m, 4H, -Bz), 7.33-7.29 (m, 20H, -Bn), 6.93 (d, J = 729 Hz, 1H, -PH), 
6.93 (d, J = 707 Hz, 1H, -PH), 6.16 (d, J = 3.8 Hz, 2H, H-1’), 5.28 (d, J = 3.2 Hz, 1H, H-1’’), 
5.25 (d, J = 3.3 Hz, 1H, H-1’’), 5.04-4.97 (m, 8H, -Bn), 4.88 (appt, J = 4.2 Hz, 1H, H-2’), 4.84 
(appt, J = 4.2 Hz, 1H, H-2’), 4.56 – 4.45 (m, 2H, H-3’), 4.42 - 3.93 (m, 20H), 2.77 – 2.67 (m, 
4H), 0.90 (s, 9H), 0.90 (s, 9H), 0.90 (s, 9H), 0.90 (s, 9H), 0.86 (s, 9H), 0.86 (s, 9H), 0.12 (s, 3H), 
0.11 (s, 3H), 0.08 (s, 3H), 0.08 (s, 3H), 0.08 (s, 3H), 0.08 (s, 3H), 0.08 (s, 3H), 0.07 (s, 3H), 0.02 
(s, 3H), 0.02 (s, 3H), -0.01 (s, 3H), -0.01 (s, 3H). 
13C NMR (125 MHz, CDCl3) δ 164.6, 164.6, 152.7, 152.6, 151.3, 151.3, 149.7, 149.6, 142.2, 
142.1, 135.7, 135.6, 133.8, 132.9, 129.0, 128.7, 128.7, 128.1, 128.1, 128.0, 127.9, 123.8, 103.4, 
103.2, 88.0, 87.9, 82.8, 82.7, 80.5, 80.3, 73.3, 70.8, 70.6, 70.5, 69.6, 65.6, 64.9, 64.8, 60.1, 59.9, 
47.0, 46.2, 22.7, 22.5, 20.1, 20.0, 19.2, 18.5, 18.5, 18.2, 18.2, 18.2, -4.0, -4.1, -4.3, -4.3, -4.4, -
4.4, -4.5, -4.6, -4.6, -4.7, -4.9, -4.9. 
31P NMR (202 MHz, CDCl3) δ 9.40, 9.28, -0.17, -0.18 
HRMS (ESI) m/z calcd for C57H85N6O14Si3P2 ([M+H]+) 1223.4907, found 1223.4899. 
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Compound 2-8: A modified version of the procedure of Aritomo et al.23 was followed. To a 20 
mL scintillation vial was added N-Benzoyladenosine (2-7) (500 mg, 1.35 mmol, 1 eq) and 
imidazole (458 mg, 6.73 mmol, 5 eq). Next, DMF (5 mL) was added followed by TBSCl (1.01 g, 
6.73 mmol, 5 eq) and the reaction was stirred at room temperature for 14 h. The reaction was 
concentrated and purified by silica column chromatography (Rf 0.32 in 70:30 hexanes:ethyl 
acetate) to yield compound 2-8 as a yellow oil (866 mg, 90%).  
 
 
 
Compound 2-30: A modified version of the procedure of Zhu et al.24 was followed. To a 250 
mL round bottom flask was added compound 2-8 (3.0 g, 4.2 mmol, 1 eq) and THF (60 mL). The 
solution was cooled to 0 oC. Next, a 0 oC solution of trichloroacetic acid (32 g, 193 mmol, 46 eq) 
in water (15 mL) was added slowly dropwise by cannula. The reaction was stirred at 0 oC for 3 h 
and then quenched by dropwise addition of a 0 oC solution of saturated sodium bicarbonate. The 
reaction was extracted three times with CH2Cl2, dried through Na2SO4, concentrated and purified 
by silica column chromatography (Rf 0.10 in 50:50 hexanes:ethyl acetate) to yield compound 2-
30 as a white solid (2.02 g, 93%).  
1H NMR (500 MHz, CDCl3) δ 9.04 (s, 1H, -NHBz), 8.83 (s, 1H, H-8), 8.06 – 8.01 (m, 3H, H-2 
+   -Bz), 7.63 (t, J = 7.4 Hz, 1H, -Bz), 7.54 (t, J = 7.6 Hz, 2H, -Bz), 6.13 (dd, J = 12.0, 2.0 Hz, 
1H, -OH), 5.86 (d, J = 7.9 Hz, 1H, H-1’), 5.06 (dd, J = 7.9, 4.5 Hz, 1H, H-2’), 4.35 (d, J = 4.5 
Hz, 1H, H-3’), 4.21-4.18 (m, 1H, H-4’), 3.98 (appdt, J = 13.1, 2.0 Hz, 1H, H-5’a), 3.74 (ddd, J = 
13.3, 12.1, 1.6 Hz, 1H, H-5’b), 0.96 (s, 9H, -tBu), 0.75 (s, 9H, -tBu), 0.14 (s, 3H, -CH3), 0.13 (s, 
3H, -CH3), -0.13 (s, 3H, -CH3), -0.64 (s, 3H, -CH3). 
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13C NMR (125 MHz, CDCl3) δ 164.4, 152.4, 150.6, 150.5, 143.4, 133.7, 133.1, 129.1, 128.0, 
124.5, 91.4, 89.8, 74.2, 74.0, 63.1, 25.9, 25.8, 18.2, 17.9, -4.4, -4.4, -4.5, -5.7. 
HRMS (ESI) m/z calcd for C29H46N5O5Si2 ([M+H]+) 600.3038, found 600.3030. 
IR (neat) ν  3268, 2929, 2850, 1702, 1611, 1510, 1459, 1252, 1157, 1098, 1063, 836, 777 cm-1. 
[a]D23 -46.1 (c = 1.1, CHCl3) 
 
 
 
Compound 2-32: To a 25 mL round-bottomed flask was added compound 2-30 (500 mg, 0.83 
mmol, 1 eq) and phosphoramidite 2-31 (301 mg, 1.0 mmol, 1.2 eq). The compounds were co-
evaporated three times on a N2-filled rotary evaporator with dry CH3CN and then dried over 
P2O5 overnight. Separately, 4,5-dicyanoimidazole (118 mg, 1.0 mmol, 1.2 eq) was evaporated 
and dried in a similar manner. To compounds 2-30 and 2-31 was added dry CH2Cl2 (7 mL), 
followed by a solution of the 4,5-dicyanoimidazole in CH3CN (1 mL). After 1.5 h, the reaction 
was cooled to 0 oC and a solution of t-butyl peroxide (1.0 mL of a 5.5 M solution in decane, 5.5 
mmol, 5.5 eq) was added. The reaction was warmed to room temperature and stirred for 3 h. 
Next, the reaction was poured into a saturated aqueous NaHCO3 solution, extracted three times 
with EtOAc, dried through Na2SO4 and concentrated. The product was purified by silica gel 
chromatography (Rf=0.11 in 100% EtOAc) to give compound 2-32 as a white foam (640 mg, 
98%). 
1H NMR (500 MHz, CDCl3) δ  8.90 (s, 1H, -NHBz), 8.82 (s, 1H, H-8), 8.25 (s, 1H, H-2), 8.02 
(d, J = 8.2 Hz, 2H, -Bz), 7.63 (t, J = 7.4 Hz, 1H, -Bz), 7.54 (t, J = 7.6 Hz, 2H, -Bz), 6.00 (d, J = 
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4.0 Hz, 1H, H-1’), 4.92 (appt, J = 4.1 Hz, 1H, H-2’), 4.51 (dd, J = 10.6, 4.3 Hz, 1H, H-5’a), 4.43 
– 4.35 (m, 2H, H-3’ + H-5’), 4.35 – 4.21 (m, 5H, H-4’ + -CH2CH2CN), 2.81 – 2.73 (m, 4H, -
CH2CH2CN), 0.94 (s, 9H, -tBu), 0.85 (s, 9H, -tBu), 0.14 (s, 3H, -CH3), 0.12 (s, 3H, -CH3), 0.03 
(s, 3H, -CH3), -0.12 (s, 3H, -CH3). 
13C NMR (125 MHz, CDCl3) δ 164.8, 152.9, 151.7, 149.9, 142.5, 133.8, 133.1, 129.1, 128.1, 
116.5, 90.1, 82.6 (d, J = 8.5 Hz), 74.8, 71.6, 67.0 (d, J = 5.0 Hz), 62.7 (t, J = 4.8 Hz), 26.0, 26.0, 
19.9 (d, J = 7.3 Hz), 18.3, 18.1, -4.1, -4.4, -4.6, -4.6. 
31P NMR (202 MHz, CDCl3) δ -0.97 
HRMS (ESI) m/z calcd for C35H53N7O8PSi2 ([M+H]+) 786.3232, found 786.3225  
IR (neat) ν  2954, 2919, 2857, 1701, 1611, 1576, 1458, 1250, 1036, 997, 884, 782 cm-1 
[a]D23 -6.7 (c = 1.05, CHCl3) 
 
 
Compound 2-4: To a 25 mL round-bottomed flask was added compound 2-32 (500 mg, 0.64 
mmol, 1 eq), followed by CH3CN (7 mL). The solution was cooled to 0 oC, and 1,8-
Diazabicyclo[5.4.0]undec-7-ene (974 mg, 6.4 mmol, 10 eq) was added dropwise. Finally, 
TMSCl (413 mg, 3.8 mmol, 6 eq) was added. After 5 min, the reaction was removed from the 0 
oC bath, allowed to warm to room temperature, and stirred for 12 h. The reaction was 
concentrated and applied to a Dowex 50W-X8 cation exchange resin (Me2EtNH+ form) and 
eluted with MeOH. The product was purified by C-18 chromatography to yield compound 2-4 as 
the dimethyl ethyl ammonium salt (316 mg, 66%) as a white foam. 
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1H NMR (500 MHz, CD3OD) δ 8.90 (s, 1H, H-8), 8.75 (s, 1H, H-2), 8.11 (d, J=7.0, 2H, -Bz), 
7.67 (t, J=7.5 Hz, 1H, -Bz), 7.58 (t, J=7.5 Hz, 2H, -Bz), 6.26 (d, J = 6.8 Hz, 1H, H-1’), 4.99 – 
4.85 (m, 1H, H-2’), 4.49 (dd, J = 4.4, 1.8 Hz, 1H, H-3’), 4.32 – 4.24 (m, 1H, H-4’), 4.24 – 4.18 
(m, 1H, H-5’a), 4.13 (ddd, J = 11.3, 5.0, 3.2 Hz, 1H, H-5’b), 3.16 (q, J = 7.3 Hz, 2H, 
CH3CH2N(CH3)2),  2.85 (s, 6H, CH3CH2N(CH3)2), 1.33 (t, J = 7.3 Hz, 3H, CH3CH2N(CH3)2), 
1.01 (s, 9H, -tBu), 0.77 (s, 9H, -tBu), 0.22 (s, 3H, -CH3), 0.19 (s, 3H, -CH3), 0.03 (s, 3H, -CH3), -
0.31 (s, 3H, -CH3). 
13C NMR (125 MHz, CD3OD) δ 168.1, 153.8, 153.3, 151.2, 144.7, 135.1, 133.8, 129.8, 129.4, 
124.8, 88.8, 87.5 (d, J=9.0 Hz), 77.6, 74.7, 65.7 (d, J=5.8 Hz), 53.9, 42.8, 26.4, 26.2, 18.9, 18.7, 
10.0, -4.2, -4.3, -4.3, -5.1. 
31P NMR (202 MHz, CD3OD) δ 1.93 
HRMS (ESI) m/z calcd for C29H47N5O8PSi2 ([M+H]+) 680.2701, found 680.2706 
 [a]D22 -46.1 (c = 1.2, EtOH) 
 
 
 
Compound 2-54: A modified version of the procedure of Ireland et al.25 was followed. To a 20 
mL reaction vial was added compound D-ribonolactone (2-36) (500 mg, 3.38 mmol, 1 eq) and 
pyridine (10 mL). Next, triphenylmethyl chloride (1.13 g, 4.05 mmol, 1.2 eq) was added 
followed by and 4-dimethylaminopyridine (82 mg, 0.675 mmol, 0.2 eq). The reaction was stirred 
at 70oC for 16 h at which point it was concentrated and purified by silica column 
chromatography to yield compound 2-54 (800 mg, 61%) as a white solid. 
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1H NMR (500 MHz, Acetone-d6) δ  7.46 -7.26 (m, 15H, -CPh3), 4.76 (d, J = 5.4 Hz, 1H, H-2), 
4.47 (apptd, J = 3.4, 1.0 Hz, 1H, H-4), 4.27 (d, J = 5.3 Hz, 1H, H-3), 3.55 (dd, J = 10.9, 3.4 Hz, 
1H, H-5a), 3.28 (dd, J = 10.9, 3.3 Hz, 1H, H-5b). 
13C NMR (125 MHz, Acetone-d6) δ 176.2, 144.4, 129.4, 128.8, 128.2, 88.2, 84.3, 70.9, 69.8, 
64.1. 
HRMS (ESI) m/z calcd for C24H22O5Na ([M+Na]+) 413.1365, found 413.1361 
 
 
 
Compound 2-37: To a 20 mL reaction vial was added compound 2-54 (370 mg, 0.95 mmol, 1 
eq) and CH2Cl2 (10 mL). The vial was cooled to 0oC and 2,6-Lutidine (0.66 mL, 5.7 mmol, 6 eq) 
was added. Finally, TBSOTf (0.65 mL, 2.9 mmol, 3 eq) was added over 30 min. The reaction 
was stirred for 1 h at 0oC at which point a saturated aqueous NaHCO3 solution. The mixture was 
extracted three times with CHCl3, dried through Na2SO4, concentrated and purified by silica 
column chromatography to yield known26,29 compound 2-37 (527 mg, 90%) as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.47 – 7.40 (m, 6H, -CPh3), 7.38 – 7.31 (m, 6H, -CPh3), 7.31 – 
7.25 (m, 3H, -CPh3), 4.72 (d, J = 5.2 Hz, 1H, H-2), 4.33 (ddd, J = 3.6, 2.7, 1.1 Hz, 1H, H-4), 
3.99 (dd, J = 5.1 Hz, 1.1 Hz, 1H, H-3), 3.66 (dd, J = 11.0, 3.6 Hz, 1H, H-5a), 3.25 (dd, J = 11.0, 
2.8 Hz, 1H, H-5b), 0.97 (s, 9H, -tBu), 0.84 (s, 9H, -tBu), 0.23 (s, 3H, -CH3), 0.15 (s, 3H, -CH3), 
0.05 (s, 3H, -CH3), -0.02 (s, 3H, -CH3). 
13C NMR (125 MHz, CDCl3) δ 175.2, 143.2, 128.6, 128.2, 127.5, 87.7, 84.7, 72.2, 70.4, 62.4, 
26.0, 25.8, 18.5, 18.2, -4.5, -4.5, -4.7, -5.0. 
HRMS (ESI) m/z calcd for C36H50NaO5Si2 ([M+Na]+) 641.3089, found 641.3064. 
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Compound 2-38: To a -78oC solution of compound 2-37 (200 mg, 0.32 mmol, 1 eq) in CH2Cl2 
(3.5 mL) was added diisobutylaluminum hydride (0.42 mL of 1 M solution in hexanes, 0.42 
mmol, 1.3 eq). The reaction was stirred at -78oC for 1 h, at which point the reaction was slowly 
quenched with MeOH. The reaction mixture was poured into a saturated aqueous solution of 
potassium sodium tartrate, extracted three times with EtOAc and CH2Cl2, dried through Na2SO4, 
concentrated and purified by silica column chromatography to give compound 2-38 as a white 
solid (187 mg, 94%). 
1H NMR (500 MHz, CDCl3) δ 7.52 – 7.41 (m, 6H major and minor, -CPh3), 7.38 – 7.29 (m, 6H, 
major and minor, -CPh3), 7.29 – 7.21 (m, 3H major and minor, -CPh3), 5.22 (dd, J = 4.4, 1.1 Hz, 
1H minor, H-1b), 5.16 (dd, J = 11.3, 4.2 Hz, 1H major, H-1a), 4.42 (dd, J = 7.3, 4.0 Hz, 1H, H-
3b minor), 4.26 (d, J = 11.3 Hz, 1H major, -OHa), 4.23 (appt, J= 4.0 Hz, 1H major, H-4a), 4.19 
(appt, J = 4.5 Hz, 1H major, H-2a), 4.10 (ddd, J = 6.9, 3.8, 2.8 Hz, 1H minor, H-4b), 3.99 (d, J = 
4.0 Hz, 1H minor, H-2b), 3.95 (d, J = 4.6 Hz, 1H major, H-3a), 3.51 (dd, J = 10.3, 2.7 Hz, 1H 
minor, H-5b), 3.30 (dd, J = 10.3, 5.0 Hz, 1H major, H-5a), 3.14 (dd, J = 10.3, 3.3 Hz, 1H major, 
H-5a’), 3.14-3.11 (m, 1H, minor, H-5b') 2.79 (d, J = 4.6 Hz, 1H minor, -OHb), 0.96 (s, 9H 
major, -tBu), 0.94 (s, 9H minor, -tBu), 0.88 (s, 9H major, -tBu), 0.78 (s, 9H minor, -tBu), 0.16 (s, 
3H major, -CH3), 0.14 (s, 3H minor, -CH3), 0.13 (s, 3H major, -CH3), 0.12 (s, 3H minor, -CH3), 
0.07 (s, 3H major, -CH3), 0.01 (s, 3H major, -CH3), 0.00 (s, 3H minor, -CH3), -0.16 (s, 3H minor, 
-CH3). 
13C NMR (125 MHz, CDCl3) δ 143.8 (major), 143.8 (minor), 129.0 (minor), 128.8 (major), 
128.0 (major), 127.9 (minor), 127.3 (major), 127.2 (minor), 102.2 (minor), 97.9 (major), 87.1 
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(major), 87.0 (minor), 84.4 (major), 81.8 (minor), 74.6 (major and minor), 72.6 (major), 71.8 
(major), 63.8 (major), 63.4 (minor), 26.0 (major), 26.0 (minor), 25.9 (minor), 25.9 (major), 18.4 
(major), 18.3 (minor), 18.1 (major and minor), -4.1 (minor), -4.3 (minor), -4.4 (minor), -4.5 
(major), -4.6 (major), -4.7 (major), -4.9 (major), -4.9 (minor). 
HRMS (ESI) m/z calcd for C36H52O5Si2Na ([M+Na]+) 643.3251, found 643.3259. 
 
 
 
Compound 2-39: To a 7 mL reaction vial was added compound 2-38 (100 mg, 0.16 mmol, 1 eq) 
and DMF (1 mL). Imidazole (27 mg, 0.4 mmol, 2.5 eq) was added, followed by tert-
Butyl(chloro)diphenylsilane (0.083 mL, 0.32 mmol, 2 eq) and the reaction was heated to 70oC 
for 18 h. The reaction was quenched with a saturated aqueous NH4Cl solution, extracted three 
times with CH2Cl2, dried through Na2SO4, concentrated and purified by silica column 
chromatography to yield compound 2-39 as a white foam (110 mg, 80%).  
1H NMR (500 MHz, CDCl3) δ 7.86 – 7.78 (m, 2H, -TBDPS), 7.73 – 7.66 (m, 2H, -TBDPS), 
7.63 – 7.53 (m, 6H, -CPh3), 7.49 – 7.36 (m, 6H, -TBDPS), 7.30 – 7.24 (m, 6H, -CPh3), 7.24 – 
7.17 (m, 3H, -CPh3), 5.17 (s, 1H, H-1), 4.40 (dd, J = 8.5, 3.6 Hz, 1H, H-3), 4.18 (ddd, J = 8.4, 
6.2, 2.0 Hz, 1H, H-4), 3.79 (d, J = 3.6 Hz, 1H, H-2), 3.44 (dd, J = 10.1, 2.0 Hz, 1H, H-5a), 3.15 
(dd, J = 10.2, 6.2 Hz, 1H, H-5b), 1.03 (s, 9H, -tBu), 0.77 (s, 9H, -tBu), 0.76 (s, 9H, -tBu), -0.02 
(s, 3H, -CH3), -0.12 (s, 3H, -CH3), -0.14 (s, 3H, -CH3), -0.39 (s, 3H, -CH3). 
13C NMR (125 MHz, CDCl3) δ 144.3, 135.9, 135.7, 134.1, 132.9, 130.0, 130.0, 129.1, 128.0, 
128.0, 127.8, 126.9, 102.1, 86.6, 80.6, 77.8, 72.1, 65.3, 27.0, 26.0, 25.9, 19.3, 18.3, 18.1, -4.0, -
4.7, -4.9, -5.0. 
HRMS (ESI) m/z calcd for C52H70O5Si3Na ([M+Na]+) 881.4429, found 881.4441. 
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Compound 2-40: To a 7 mL reaction vial was added compound 2-39 (90 mg, 0.105 mmol, 1 eq) 
and CH2Cl2 (1 mL). The solution was cooled to 0oC and Et3SiH (0.067 mL, 0.419 mmol, 4 eq) 
was added. Finally, CF3CO2H (0.016 mL, 0.209 mmol, 2 eq) was added in a solution of CH2Cl2 
(0.1 mL) and the reaction was stirred at 0oC for 1 h. The reaction was quenched with a solution 
of saturated aqueous NaHCO3, extracted three times with CH2Cl2, dried through Na2SO4, 
concentrated, and purified by silica column chromatography to give compound 2-40 (44 mg, 
75%).  
1H NMR (500 MHz, CDCl3) δ  7.72 – 7.69 (m, 2H, -TBDPS), 7.66 – 7.62 (m, 2H, -TBDPS), 
7.48 – 7.36 (m, 6H, -TBDPS), 5.05 (s, 1H, H-1), 4.60 (dd, J = 8.3, 3.6 Hz, 1H, H-3), 4.04 (ddd, J 
= 8.3, 2.6, 2.5 Hz, 1H, H-4), 3.86 (dd, J = 12.0, 2.5 Hz, 1H, H-5a), 3.78 (d, J = 3.6 Hz, 1H, H-2), 
3.60 (dd, J = 12.2, 2.6 Hz, 1H, H-5b), 2.01 (bs, 1H, -OH), 1.07 (s, 9H, -tBu), 0.92 (s, 9H, -tBu), 
0.76 (s, 9H, -tBu), 0.15 (s, 3H, -CH3), 0.11 (s, 3H, -CH3), -0.10 (s, 3H, -CH3), -0.34 (s, 3H, -
CH3). 
13C NMR (125 MHz, CDCl3) δ 135.8, 133.3, 132.7, 130.3, 130.2, 128.1, 101.8, 82.0, 78.2, 70.3, 
60.8, 26.9, 26.1, 25.8, 19.2, 18.3, 18.1, -4.1, -4.7, -4.8, -4.8. 
HRMS (ESI) m/z calcd for C33H56O5NaSi3 ([M+Na]+) 639.3333, found 639.3342. 
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Compound 2-41: A 7 mL vial containing compound 2-40 (35 mg, 0.057 mmol, 1 eq) was 
azeotroped twice in a nitrogen filled rotary evaporator with dry CH3CN and dried on a high 
vacuum for 20 min. To compound 2-40 was added dibenzyl N,N-diisopropylphosphoramidite 
(28 mg, 0.080 mmol, 1.4 eq) in a solution of CH3CN (0.4 mL). Next, dicyanoimidazole (9.4 mg, 
0.080 mmol, 1.4 eq) was added in a solution of CH3CN (0.1 mL), the reaction was stirred at 
room temperature for 1.5 h at which point tBuOOH (0.052 mL of a 5.5 M solution in decane, 
0.285 mmol, 5 eq) was added. The reaction stirred an additional 1 h at room temperature at 
which point it was quenched with saturated aqueous NaHCO3, extracted three times with 
CH2Cl2, dried through Na2SO4, and concentrated. The reaction was purified by silica column 
chromatography to give compound 2-41 (49 mg, 98%). 
1H NMR (500 MHz, CDCl3) d  7.76 – 7.69 (m, 2H, -TBDPS), 7.66 – 7.60 (m, 2H, -TBDPS), 
7.47 – 7.28 (m, 16H, -TBDPS + -Bn), 5.10 – 4.96 (m, 5H, H-1 + CH2Ph), 4.40 (dd, J = 8.0, 3.6 
Hz, 1H, H-3), 4.35 – 4.29 (m, 1H, H-5a), 4.20 – 4.09 (m, 2H, H-4 + H-5b), 3.83 (d, J = 3.6 Hz, 
1H, H-2), 1.05 (s, 9H, -tBu), 0.91 (s, 9H, -tBu), 0.77 (s, 9H, -tBu), 0.12 (s, 3H, -CH3), 0.10 (s, 
3H, -CH3), -0.08 (s, 3H, -CH3), -0.32 (s, 3H, -CH3). 
13C NMR (125 MHz, CDCl3) d 135.8, 135.7, 133.6, 132.9, 130.1, 129.9, 128.6, 128.5, 128.0, 
128.0, 128.0, 127.9, 101.9, 79.6 (d, J = 8.5 Hz), 77.8, 72.0, 69.3 (d, J = 5.6 Hz), 69.2 (d, J = 5.6 
Hz), 68.6 (d, J = 5.6 Hz), 26.9, 26.0, 25.8, 19.2, 18.2, 18.0, -4.1, -4.6, -4.8. 
31P NMR (202 MHz, CDCl3) d -0.29  
HRMS (ESI) m/z calcd for C47H69O8PSi3Na ([M+Na]+) 899.3936, found 899.3935.  
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Compound 2-2: To a 20 mL vial containing compound 2-41 (48 mg, 0.055 mmol, 1 eq) was 
added 10% Palladium on activated charcoal (50 mg). Next, tBuOH (4 mL) and deionized water 
(0.5 mL) were added, followed by Et3N (0.075 mL, 0.55 mmol, 10 eq). The reaction was fitted 
with a ballon of hydrogen gas, purged for 1 min and stirred at room temperature for 16 h. After 
16 h, the reaction was filtered through celite, concentrated, and purified by reverse phase 
chromatography to give compound 2-2 as a pale yellow oil (32 mg, 75%).  
 1H NMR (500 MHz, CD3OD) δ  7.79 – 7.71 (m, 2H, -TBDPS), 7.68 – 7.61 (m, 2H, -TBDPS), 
7.52 – 7.35 (m, 6H, -TBDPS), 5.03 (s, 1H, H-1), 4.34 (dd, J = 7.9, 3.6 Hz, 1H, H-3), 4.24 (ddd, J 
= 10.5, 6.1, 2.7 Hz, 1H, H-5a), 4.12 (apptd, J = 8.1, 2.7 Hz, 1H, H-4), 3.99 (ddd, J = 10.5, 8.3, 
5.0 Hz, 1H, H-5b), 3.89 (d, J = 3.6 Hz, 1H, H-2), 3.15 (q, J = 7.3 Hz, 6H, -(CH3CH2)3N), 1.28 (t, 
J = 7.3 Hz, 9H, -(CH3CH2)3N), 1.06 (s, 9H, -tBu), 0.94 (s, 9H, -tBu), 0.78 (s, 9H, -tBu), 0.18 (s, 
3H, -CH3), 0.15 (s, 3H, -CH3), -0.06 (s, 3H, -CH3), -0.28 (s, 3H, -CH3). 
13C NMR (125 MHz, CD3OD) δ  137.0, 136.8, 134.5, 133.9, 131.2, 131.0, 129.0, 128.9, 103.0, 
82.4 (d, J = 8.8 Hz), 79.08, 74.34, 69.2 (d, J = 5.4 Hz), 47.4, 27.3, 26.6, 26.2, 19.9, 19.0, 18.8, 
9.1, -4.0, -4.3, -4.4, -4.5. 
31P NMR (202 MHz, CD3OD) δ 2.11 
HRMS (ESI) m/z calcd for C33H58O8Si3P ([M+H]+) 697.3177, found 697.3192. 
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Compound 2-42: To a 7 mL reaction vial was added compound 2-3 (68 mg, 0.056 mmol, 1 eq) 
and compound 2-4 (50 mg, 0.067 mmol, 1.2 eq). The mixture was co-evaporated three times 
with dry CH3CN and dried over P2O5 overnight. Compounds 2-3 and 2-4 were dissolved in dry 
CH3CN (0.5 mL) containing N,N-diisopropylethylamine (29 mg, 0.22 mmol, 4 eq) and N-
chlorosuccinimide (30 mg, 0.22 mmol, 4 eq) was added and the reaction was stirred for 20 min at 
room temperature. Diazabicyclo[5.4.0]undec-7-ene (84 mg, 0.556 mmol, 10 eq) was added and 
the reaction was stirred for 20 min at room temperature. The solution was concentrated and 
purified by reverse phase chromatography. The purified compound was passed through a short 
column of Dowex 50W-X8 (Et3NH+ form) to yield compound 2-42 as the triethylammonium salt 
as a pale yellow foam (82 mg, 72%). 
1H NMR (500 MHz, CD3OD) δ  8.96 (s, 1H), 8.71 (s, 1H), 8.66 (s, 1H), 8.45 (s, 1H), 8.12 – 
8.00 (m, 4H), 7.71 – 7.60 (m, 2H), 7.59 – 7.48 (m, 4H), 7.37 – 7.19 (m, 10H), 6.27 (d, J = 2.7 
Hz, 1H), 6.25 (d, J = 6.9 Hz, 1H), 5.20 (d, J = 4.3 Hz, 1H), 4.99 – 4.88 (m, 6H), 4.78 – 4.71 (m, 
1H), 4.46 (dd, J = 4.3, 1.5 Hz, 1H), 4.40 – 4.29 (m, 3H), 4.28 – 4.13 (m, 6H), 4.12 – 4.03 (m, 
2H), 3.16 (q, J = 7.3 Hz, 12H), 1.28 (t, J = 7.3 Hz, 18H), 0.98 (s, 9H), 0.92 (s, 9H), 0.91 (s, 9H), 
0.81 (s, 9H), 0.73 (s, 9H), 0.19 (s, 3H), 0.17 (s, 3H), 0.16 (s, 3H), 0.12 (s, 3H), 0.10 (s, 3H), 0.09 
(s, 3H), 0.04 (s, 3H), 0.02 (s, 3H), 0.01 (s, 3H), -0.36 (s, 3H). 
13C NMR (125 MHz, CD3OD) δ 168.0, 168.0, 153.9, 153.4, 153.3, 152.9, 151.4, 151.3, 144.9, 
144.5, 137.0, 137.0, 135.3, 135.1, 134.0, 134.0, 129.9, 129.8, 129.8, 129.6, 129.6, 129.2, 125.4, 
124.8, 104.8, 90.1, 88.7, 87.4 (d, J = 8.9 Hz), 86.4 (d, J = 9.7 Hz), 83.5 (d, J = 8.0 Hz), 81.5, 
77.6, 75.0, 74.7, 72.5, 71.8, 71.0, 71.0, 67.3 (d, J = 5.7 Hz), 66.7 (d, JP = 5.8 Hz), 66.6 (d, JP = 
5.4 Hz), 47.4, 27.0, 26.8, 26.7, 26.7, 26.4, 19.3, 19.2, 19.2, 19.1, 18.8, 9.3, -3.6, -3.7, -3.9, -3.9, -
4.0, -4.0, -4.1, -4.1, -4.5, -4.9. 
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 31P NMR (202 MHz, CD3OD) δ  -0.09, -10.01 (d, J = 19.9 Hz), -10.34 (d, J = 19.8 Hz). 
HRMS (ESI) m/z calcd for C83H124N10O22P3Si5 ([M-H]-) 1845.6956, found 1845.6959 
 
 1H 13C 31P 
1H-1H 
COSY 
1H-13C 
HMBC 
I-Ado 1’ 6.25 (d, J = 6.9 Hz) 88.69 
 
4.89 
74.73, 77.60, 
87.43, 144.92, 
153.89 
I-Ado 2’ 4.90 (dd, 6.9, 4.4 Hz) 77.60  4.47, 6.25 74.73, 88.69 
I-Ado 3’ 4.47 (d, J = 3.6 Hz) 74.73  4.25, 4.90 66.63, 77.60, 87.43, 88.69 
I-Ado 4’ 4.25 87.43 (d, JP = 8.9 Hz)    
I-Ado 5’a 4.24 66.63  
(d, JP = 5.4 Hz) 
-10.34 
(d, J = 19.8 Hz) 
4.35  
I-Ado 5’b 4.35 4.24  
      
I-Ade 2 8.71 153.39 
 
- 
124.81, 
151.27, 
153.89 
I-Ade 4 - 153.89  - - 
I-Ade 5 - 124.81  - - 
I-Ade 6 - 151.27  - - 
I-Ade 8 8.95 144.92  - 124, 81, 153.89 
      
a- Rib 1’’ 5.20 (d, J = 4.2 Hz). 104.78  4.09 72.52, 75.03, 81.47, 86.40 
a- Rib 2’’ 4.09 (dd, J = 5.8, 4.2 Hz) 75.03 
 4.18, 5.20 104.78 
a- Rib 3’’ 4.18 (dd, J = 5.8, 3.1 Hz) 72.52 
 4.09 66.67, 75.03, 86.40 
a- Rib 4’’ 4.25 86.40 (d, JP = 9.7 Hz).  4.07 75.03 
a- Rib 5’’a 4.07 66.67  
(d, JP = 5.8 Hz). 
-10.01  
(d, J = 19.8 Hz) 
4.25 72.52, 86.40 
a- Rib 5’’b 4.07 4.25 72.52, 86.40 
      
D-Ado 1’ 6.27 (d, J = 2.6 Hz), 90.11 
 
4.89 
71.83, 81.47, 
83.46, 144.53, 
152.87 
D-Ado 2’ 4.90 81.47  4.74, 6.27 71.83, 83.46, 104.78 
D-Ado 3’ 4.74 (dd, J = 6.7, 4.5 Hz) 71.83 
 4.33, 4.90 67.25, 81.47, 83.46, 90.11 
D-Ado 4’ 4.33 83.46 (d, JP = 8.0 Hz)    
D-Ado 5’a 4.20 67.25  
(d, JP = 5.7 Hz) 
-0.09 4.37  
D-Ado 5’b 4.37 4.20  
      
D-Ade 2 8.66 153.32 
 
- 
125.37, 
151.39, 
152.87 
D-Ade 4 - 152.87  - - 
D-Ade 5 - 125.37  - - 
D-Ade 6 - 151.39  - - 
D-Ade 8 8.44 144.53  - 125.37, 152.87 
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Compound 2-43: To a 20 mL vial was added compound 2-42 (51 mg, 0.025 mmol, 1 eq) and 
10% palladium on activated charcoal (50 mg). Next, t-butanol (2.4 mL) and deionized water (0.4 
mL) were added followed by Et3N (0.070 mL, 0.498 mmol, 20 eq). Lastly, the vial was fitted 
with a balloon of hydrogen gas and purged for 1 min. The reaction was stirred under an 
atmosphere of hydrogen gas at room temperature for 16 h. The reaction was filtered through 
celite and the product was purified by reverse phase chromatography to yield compound 2-43 as 
a white foam (45 mg, 92%).  
1H NMR (600 MHz, CD3OD) δ  9.00 (s, 1H), 8.84 (s, 1H), 8.71 (s, 1H), 8.70 (s, 1H), 8.12 – 
8.03 (m, 4H), 7.67 – 7.62 (m, 2H), 7.60 – 7.52 (m, 4H), 6.34 (d, J = 3.6 Hz, 1H), 6.25 (d, J = 6.7 
Hz, 1H), 5.26 (d, J = 4.1 Hz, 1H), 4.88 (dd, J = 6.8, 4.4 Hz, 1H), 4.67 (appt, J = 4.1 Hz, 1H), 
4.61 (appt, J = 5.0 Hz, 1H), 4.46 (dd, J = 4.4, 1.7 Hz, 1H), 4.36-4.30 (m, 2H), 4.29 – 4.22 (m, 
4H), 4.17 (dd, J = 5.7, 3.1 Hz, 1H), 4.11 – 4.02 (m, 4H), 3.18 (q, J = 7.3 Hz, 18H), 1.29 (t, J = 
7.3 Hz, 27H), 0.98 (s, 9H), 0.93 (s, 9H), 0.91 (s, 9H), 0.82 (s, 9H), 0.74 (s, 9H), 0.19 (s, 3H), 
0.17 (s, 3H), 0.16 (s, 3H), 0.15 (s, 3H), 0.08 (s, 3H), 0.08 (s, 3H), 0.03 (s, 3H), 0.03 (s, 3H), 0.02 
(s, 3H), -0.33 (s, 3H). 
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13C NMR (125 MHz, CD3OD) δ 168.1, 168.1, 153.8, 153.8, 153.2, 153.2, 153.1, 153.1, 151.1, 
151.0, 144.9, 144.3, 135.1, 133.8, 133.8, 129.7, 129.7, 129.4, 129.4, 125.0, 124.7, 104.9, 89.0, 
88.7, 87.2 (d, J = 9.2 Hz), 85.9 (d, J = 9.8 Hz) 85.2 (d, J = 9.3 Hz) 82.8, 77.6, 74.7, 74.5, 72.3, 
72.1, 66.5 (d, J = 5.5 Hz), 66.4 (d, J = 5.0 Hz), 64.6 (d, J = 4.6 Hz), 47.4, 26.9, 26.7, 26.7, 26.5, 
26.3, 19.1, 19.1, 19.1, 18.9, 18.7, 9.2, -3.7, -3.8, -4.1, -4.1, -4.2, -4.2, -4.3, -4.3 -4.4, -5.0. 
31P NMR (202 MHz, CD3OD) δ 1.86, -9.66 (d, J = 19.3 Hz), -10.06 (d, J = 19.1 Hz). 
HRMS (ESI) m/z calcd for C69H112N10O22P3Si5 ([M-H]-) 1665.6017, found 1665.6018 
 
 1H 13C 31P 
1H-1H 
COSY  
I-Ado 1’ 6.25 (d, J = 6.7 Hz) 88.7  4.88  
I-Ado 2’ 4.88 (dd, J = 6.8, 4.4 Hz) 77.6  6.25, 4.46  
I-Ado 3’ 4.46 (dd, J =4.4, 1.7 Hz) 74.5  4.88, 4.25  
I-Ado 4’ 4.25 87.2 (d, JP = 9.2 Hz) 
 4.46, 4.43, 
4.25  
I-Ado 5’a 4.25 66.4 (d, JP = 5.0 Hz) 
-10.06  
(d, J = 19.1 Hz) 
4.33, 4.25  
I-Ado 5’b 4.33 4.25, 4.25  
      
a- Rib 1’’ 5.26 (d, J = 4.1 Hz) 104.9  4.04  
a- Rib 2’’ 4.04 74.7  5.26, 4.17  
a- Rib 3’’ 4.17 72.3  4.23,4.04  
a- Rib 4’’ 4.23 85.9 (d, JP = 9.8 Hz) 
 4.23, 4.06, 
4.06  
a- Rib 5’’a 4.06  66.5 (d, JP = 5.5 Hz) 
 
-9.66  
(d, J = 19.3 Hz) 
4.23, 4.06  
a- Rib 5’’b 4.06   4.23, 4.06  
      
D-Ado 1’ 6.34 (d, J = 3.6 Hz) 89.0  4.67  
D-Ado 2’ 4.67 (appt, J = 4.1 Hz) 82.8  6.34, 4.61  
D-Ado 3’ 4.61 (appt, J = 5.0 Hz) 72.1  4.67, 4.32  
D-Ado 4’ 4.32  85.2 (d, JP = 9.3 Hz)  
64.6 (d, JP = 4.6 Hz) 
 
 
1.86 
4.61, 4.26, 
4.05  
D-Ado 5’a 4.26 4.32, 4.05  
D-Ado 5’b 4.05   4.32, 4.26  
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Compound 2-44: To a 7 mL vial was added compound 2-2 (10 mg, 5.7 mmol, 1 eq). This 
material was azeotropically dried three times with anhydrous CH3CN. To a separate 7 mL vial 
was added compound 3 (8.1 mg, 10.1 mmol, 2 eq) and carbonyldiimidazole (8.3 mg, 51.1 mmol, 
10 eq). A solution of triethylamine (2.1 mg, 20.7 mmol, 4 eq) in pyridine (0.2 mL) was added 
and the reaction was stirred at room temperature for 2 h. The reaction was quenched with MeOH 
containing 10% Et3N (v/v). After 30 min, the solution was concentrated to dryness and 
azeotropically dried with anhydrous CH3CN (three times). Compound 2-43 was added in 
methanol to the crude imidazolide, the solution was concentrated to dryness and azeotropically 
dried with anhydrous CH3CN (three times). The solid residue was dried under high vacuum over 
P2O5 for 16 h. A solution of freshly dried ZnCl2 (5.5 mg, 40.4 mmol, 8 eq) in DMF (0.3 mL) was 
added and the reaction was stirred at room temperature for 96 h. The reaction was quenched by 
addition of a methanol solution containing the triethylammonium salt of EDTA (1 mL of 
methanol, 100 mg of EDTA (0.342 mmol, 67 eq, tetraacid), and 0.2 mL of triethylamine) and 
stirred for 30 min. The reaction was concentrated and purified by C18 chromatography to give 
compound 2-44 as the triethylammonium salt (11.0 mg, 79%). 
1H NMR (600 MHz, CD3OD) δ 9.01 (s, 1H), 8.97 (s, 1H), 8.71 (s, 1H), 8.70 (s, 1H), 8.10-8.05 
(m, 4H), 7.76 – 7.69 (m, 2H), 7.68 – 7.61 (m, 4H), 7.56 – 7.52 (m, 4H), 7.47 – 7.35 (m, 6H), 
6.33 (d, J = 3.7 Hz, 1H), 6.25 (d, J = 6.8 Hz, 1H), 5.23 (bs, 1H), 5.01 (s, 1H), 4.87 (m, 1H) 4.64 
ZnCl2 (8 eq)
DMF, rt, 96 h
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(bs, 1H), 4.59 (appt, J = 4.9 Hz, 1H), 4.46 (dd, J = 4.4, 1.6 Hz, 1H), 4.43-4.38 (m, 1H), 4.34-4.27 
(m, 4H), 4.26 – 4.03 (m, 10H), 3.89 – 3.86 (m, 1H), 3.17 (q, J = 7.3 Hz, 24H), 1.28 (t, J = 7.3 
Hz, 36H), 1.01 (s, 9H), 0.97 (s, 9H), 0.91 (s, 9H), 0.90 (s, 9H), 0.90 (s, 9H) 0.79 (s, 9H), 0.76 (s, 
9H), 0.74 (s, 9H), 0.18 (s, 3H), 0.18 (s, 3H), 0.16 (s, 3H), 0.15 (s, 3H), 0.14 (s, 3H), 0.13 (s, 3H), 
0.13 (s, 3H), 0.11 (s, 3H), 0.07 (s, 3H), 0.07 (s, 3H), 0.01 (s, 3H), -0.08 (s, 3H), -0.29 (s, 3H), -
0.34 (s, 3H). 
13C NMR (125 MHz, CD3OD) δ 168.1, 168.0, 153.8, 153.2, 153.2, 153.1, 151.1, 151.0, 144.9, 
144.4, 137.0, 136.8, 135.7, 135.2, 135.1, 134.6, 133.9, 133.8, 131.2, 131.0, 129.8, 129.4, 129.0, 
129.0, 128.9, 128.9, 124.9, 124.6, 105.0, 102.9, 88.8, 88.6, 87.3, 87.2, 86.2, 85.2, 83.1, 82.2, 
79.2, 77.7, 74.8, 74.6, 74.5, 72.3, 69.8, 66.6, 66.4, 65.3, 47.3, 27.4, 27.0, 26.8, 26.7, 26.7, 26.5, 
26.3, 26.3, 19.9, 19.1, 19.1, 19.1, 18.9, 18.8, 18.8, 18.7, 9.2, -3.7, -3.8, -3.9, -4.0, -4.1, -4.2, -4.2, 
-4.2, -4.2, -4.2, -4.3, -4.3, -4.4, -5.0. 
31P NMR (243 MHz, CD3OD) δ -10.84 (d, J = 18.5 Hz), -11.01 (d, J = 19.5 Hz), -11.39 (d, J = 
19.3 Hz), -11.44 (d, J = 18.3 Hz). 
HRMS (ESI) m/z calcd for C102H167O29Si8P4 ([M-H]-) 2343.9011, found 2343.9024. 
 
 
Compound 2-1: To a 4 mL reaction vial was added compound 2-44 (9.0 mg, 3.27 mmol, 1 eq) 
and 7M ammonia in methanol (1.5 mL). The reaction was at room temperature for 20 h at which 
point the solution was concentrated to dryness. The residue was dissolved in methanol containing 
10% triethylamine (v/v) and concentrated to dryness (twice). The solution was then 
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azeotropically dried with CH3CN (three times), and dried over P2O5 under high vacuum for 2 h. 
Next, THF (0.22 mL) was added followed by tetrabutylammonium fluoride (0.1 mL of a 1 M 
solution in THF, 0.11 mmol, 33 eq). The reaction was stirred for 3 h at room temperature. The 
reaction was concentrated to a total volume of ~0.1 mL, 0.1 mL of a 3M aqueous NaOAc 
solution was added, and the solution was stirred for 0.5 h. The solution was transferred in 0.1 mL 
aliquots to 1.7 mL centrifuge tubes and 0.95 mL of ethanol was added to each tube. The tubes 
were cooled to -78oC for 0.5 h and were centrifuged at 4oC for 20 min at 14,000 rcf. The 
supernatant was discarded and the pellet was resuspended in 1 mL of fresh ethanol. The tubes 
were again cooled at -78oC and centrifuged as described above. The pellet was dissolved in 1 mL 
of water and purified by reverse phase chromatography (99% 8 mM Et3NHOAc/1% CH3CN to 
90% 8 mM Et3NHOAc/10% CH3CN over 12 min). The fractions containing the product were 
concentrated to dryness followed by repeated lyophillization with H2O and exchange for the 
sodium salt (Dowex 50W-X8 Na+ form) to produce compound 2-1 (3.0 mg, 77%) as the sodium 
salt. Note: NMR Data for compound 2-1 was obtained before exchange for the Na+ ion and 
contains ~10 eq of Et3NHOAc. It was observed that removal of the buffer beyond this point 
caused dramatic suppression of the NMR signal, which we believe is due to a compound 
aggregation phenomenon. Addition of a solution containing ~10 eq Et3NHOAc in D2O to buffer-
free samples of 2-1 restored its NMR signal.  
1H NMR (600 MHz, D2O) δ 8.47 (bs, 2H), 8.24 (bs, 2H), 6.22 (d, J = 3.1 Hz, 1H), 6.03 (d, J = 
5.6 Hz, 1H), 5.35 (d, J = 4.1 Hz, 1H), 5.33 (d, J = 4.3 Hz, 1H), 5.23 (d, J = 2.2 Hz, 1H), 4.71 
(appt, J = 5.7 Hz, 1H), 4.65-4.61 (m, 1H), 4.60 – 4.56 (m, 1H), 4.52 – 4.49 (m, 1H), 4.43 – 4.38 
(m, 1H), 4.38 – 4.33 (m, 3H), 4.33 – 4.30 (m, 1H), 4.29 – 4.17 (m, 7H), 4.13 – 4.01 (m, 9H). 
13C NMR (125 MHz, D2O) δ See table; assignments and shifts from HSQC/HMBC. 
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31P NMR (243 MHz, D2O) δ -9.65 - -11.98 (m, 4P) 
HRMS (ESI) m/z calcd for C30H43N10O27P4 ([M-H]-) 1099.1255 found 1099.1221. 
LCMS: tR = 5.3 min,  98% 5 mM pentylamine:HOAc (pH=6.5) with 2% CH3CN to 75% 6 mM 
pentylamine:HOAc (pH=6.5) with 25% CH3CN over 5 min, then hold 75% 6 mM 
pentylamine:HOAc (pH=6.5) with 25% CH3CN for 3 min 
  
 
 
 
Table of NMR Data: 
 
 1H 13C 1H-1H COSY 1H-13C HMBC 
I-Ado 1’ 6.03 (d, J = 5.9 Hz) 87.23 4.71 74.63, 140.45, 148.3 
I-Ado 2’ 4.71 (at, 5.4 Hz) 74.63 6.03, 4.51 84.02, 87.23 
I-Ado 3’ 4.51 (dd, J = 4.9, 3.3 Hz) 70.63 4.71, 4.37 65.01, 87.25 
I-Ado 4’ 4.36 84.02 4.51 65.01 
I-Ado 5’a 4.22 65.01   I-Ado 5’b 4.22   
     
I-Ade 2 8.25 150.45 - 118.24, 148.33, 153.81 
I-Ade 4 - 148.33 - - 
I-Ade 5 - 118.24 - - 
I-Ade 6 - 153.81 - - 
I-Ade 8 8.47 140.45 - 118.49, 148.36 
     
D-Rib 1’’ 5.33 (d, J = 4.3 Hz) 101.42  69.88, 71.67, 78.92, 84.31,  
D-Rib 2’’ 4.27 71.48  84.52 
D-Rib 3’’ 4.23 69.94  84.31, 65.67 
D-Rib 4’’ 4.36 84.31   
D-Rib 5’’a 4.07 65.8   D-Rib 5’’b 4.07   
     
D-Ado 1’ 6.22 (d, J = 3.1 Hz) 87.04 4.63 140.45 
D-Ado 2’ 4.63 (m) 78.94 6.22, 4.58 101.34, 83.21 
D-Ado 3’ 4.58 (m) 68.94 4.63, 4.40 64.52, 86.94 
D-Ado 4’ 4.40 83.15 4.58  
D-Ado 5’a 4.35 64.49  68.94 D-Ado 5’b 4.25*   
     
D-Ade 2 8.25 150.45 - 118.24, 148.33, 153.81 
D-Ade 4 - 148.33 - - 
D-Ade 5 - 118.24 - - 
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D-Ade 6 - 153.81 - - 
D-Ade 8 8.47 140.45 - 118.49, 148.36 
     
a Rib 1’’ 5.35 (d, J = 4.1 Hz) 96.40 4.13 70.09, 81.87 
a Rib 2’’ 4.14 70.81   
a Rib 3’’ 4.19 70.11  96.36, 65.67 
a Rib 4’’ 4.24 81.92   
a Rib 5’’a 4.07 65.8   a Rib 5’’b 4.04   
     
b Rib 1’’ 5.23 (d, J = 2.2 Hz) 101.23 4.03 70.72, 81.26 
b Rib 2’’ 4.03 75.22 4.32, 5.23 81.16 
b Rib 3’’ 4.32 70.55 4.03 66.38, 101.28 
b Rib 4’’ 4.10 81.19   
b Rib 5’’a 4.13 66.41   b Rib 5’’b 4.07   
 
 
 
 
Compound 2-47: To a 0oC solution of compound 2-38 (90 mg, 0.145 mmol, 1 eq) in DMF (1 
mL) was added sodium hydride (60% dispersion in mineral oil, 12.8 mg, 0.322 mmol, 2.2 eq) 
followed by propargyl bromide (0.027 mL, 0.242 mmol, 1.7 eq). The solution was stirred at 0oC 
for 1 h at which time it was poured into saturated aqueous NH4Cl and extracted three times with 
diethyl ether. The combined ether extracts were washed three times with water, dried through 
Na2SO4, concentrated and purified by silica column chromatography to afford compound 2-47 
(80 mg, 81%). 
1H NMR (500 MHz, CDCl3) δ 7.55 – 7.49 (m, 6H, -CPh3), 7.33 – 7.27 (m, 6H, -CPh3), 7.26 – 
7.20 (m, 3H), 5.12 (s, 1H, H-1), 4.33 (dd, J = 2.4, 1.6 Hz, 2H, -CH2CCH), 4.24 – 4.17 (m, 2H, 
H-3, H-4), 3.98 (d, J = 2.8 Hz, 1H, H-2), 3.37 (dd, J = 10.2, 1.7 Hz, 1H, H-5a), 3.09 – 3.00 (m, 
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1H, H-5b), 2.44 (t, J = 2.4 Hz, 1H, -CH2CCH), 0.93 (s, 9H, -tBu), 0.72 (s, 9H, -tBu), 0.13 (s, 3H, 
-CH3), 0.09 (s, 3H-CH3), -0.05 (s, 3H-CH3), -0.25 (s, 3H-CH3). 
13C NMR (126 MHz, CDCl3) δ 144.1, 128.9, 127.9, 127.0, 105.3, 86.4, 81.5, 79.4, 76.3, 74.6, 
71.9, 64.0, 54.5, 25.9, 25.9, 18.2, 18.0, -4.1, -4.3, -4.6, -5.1. 
HRMS (ESI) m/z calcd for C39H54O5Si2Na ([M+Na]+) 681.3408, found 681.3408. 
 
 
Compound 2-48: To a 0oC solution of compound 2-47 (80 mg, 0.121 mmol, 1 eq) in CH2Cl2 (1 
mL) was added triethylsilane (0.077 mL, 0.486 mmol, 1 eq) followed by a solution of 
trifluoroacetic acid (28 mg, 0.243 mmol, 2 eq) in CH2Cl2 (0.1 mL) and the reaction was stirred at 
0oC for 40 min. The reaction was quenched with saturated aqueous NaHCO3 (1 mL), extracted 
three times with chloroform, dried through Na2SO4, concentrated and purified by silica column 
chromatography to afford compound 2-48 (35 mg, 69%) as a white foam. 
1H NMR (500 MHz, CDCl3) δ 4.95 (s, 1H, H-1), 4.33 – 4.18 (m, 3H, -CH2CCH, H-3), 4.10 – 
4.03 (m, 1H, H-4), 3.95 (d, J = 4.0 Hz, 1H, H-2), 3.85 (dd, J = 12.2, 2.5 Hz, 1H, H-5a), 3.57 (dd, 
J = 12.2, 3.5 Hz, 1H, H-5b), 2.46 (t, J = 2.4 Hz, 1H, -CH2CCH), 1.88 (bs, 1H, -OH), 0.91 (s, 9H, 
-tBu), 0.89 (s, 9H, -tBu), 0.10 (s, 6H, -CH3), 0.09 (s, 3H, -CH3), 0.08 (s, 3H, -CH3). 
13C NMR (126 MHz, CDCl3) δ 106.6, 82.8, 79.7, 76.7, 74.7, 70.6, 61.5, 55.4, 26.0, 25.9, 18.2, 
18.2, -4.1, -4.4, -4.5, -4.9. 
HRMS (ESI) m/z calcd for C20H41O5Si2 ([M+H]+) 417.2493, found 417.2489. 
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Compound 2-50: To a room temperature solution of compound 2-48 (10 mg, 0.024 mmol, 1 eq) 
in CH2Cl2 (0.3 mL) was added phosphoramidite 2-49 (18.8 mg, 0.036 mmol, 1.5 eq) in CH2Cl2 
(0.1 mL) followed by 4,5-dicyanoimidazole (4.2 mg, 0.036 mmol, 1.5 eq) in CH3CN (0.4 mL). 
The reaction was stirred at room temperature for 1.5 h, at which point tBuOOH (0.021 mL of 5.5 
M solution, 0.12 mmol, 5 eq) was added and the reaction was stirred for an additional 1 h. The 
reaction was poured into saturated aqueous NaHCO3, extracted three times with chloroform, 
dried through Na2SO4, concentrated and purified by silica column chromatography to give 
compound 2-50 (17 mg, 83%). 
1H NMR (500 MHz, CDCl3) δ 7.79 – 7.67 (m, 4H, -FM), 7.60 – 7.48 (m, 4H, -FM), 7.43 – 7.31 
(m, 4H, -FM), 7.30 – 7.20 (m, 4H, -FM), 4.95 (s, 1H, H-1), 4.32-4.24 (m, 4H, -CH2CHAryl), 
4.22 – 4.03 (m, 7H, -CH2CHAryl + H-4 + H-5a + H-3, -CH2CCH), 3.96 (appdt, J = 10.6, 5.1 Hz, 
1H, H-5b), 3.92 (d, J = 3.8 Hz, 1H, H-2), 2.28 (t, J = 2.4 Hz, 1H, -CH2CCH), 0.89 (s, 9H, -tBu), 
0.86 (s, 9H, -tBu), 0.09 (s, 3H, -CH3), 0.08 (s, 3H, -CH3), 0.03 (s, 3H, -CH3), 0.00 (s, 3H, -CH3). 
13C NMR (126 MHz, CDCl3) δ 143.3, 141.5, 128.0, 127.2, 125.3, 120.1, 104.9, 80.4 (d, J = 7.8 
Hz), 79.2, 76.3, 74.7, 71.4, 69.5 (appt, J = 6.3 Hz), 67.2 (d, J = 5.2 Hz), 54.1, 48.1 (d, J = 8.1 
Hz), 25.9, 25.9, 18.2, 18.1, -4.1, -4.4, -4.5, -5.0. 
31P NMR (202 MHz, CD3OD) δ -0.80 
HRMS (ESI) m/z calcd for C48H62O8PSi2 ([M+H]+) 853.3721, found 853.3718. 
 
O O
TBSO OTBS
OH
O O
TBSO OTBS
O
P
OFM
O
OFM
NiPr2
P
FMO OFM
(1.5 eq)
4,5-dicyanoimidazole (1.5 eq)
CH3CN/CH2Cl2 (1/1), rt, 1.5 h
then: tBuOOH, rt, 1 h
83%
1
2 3
4 5
2-48 2-50
2-49
O O
TBSO OTBS
O
P OFM
O
OFM
Et3N/CH3CN (1/1)
rt, 14 h, 96%
O O
TBSO OTBS
O
P
O
O
OH
Et3NH+
1
2 3
4 5
2-50 2-46
	 84 
Compound 2-46: To a room temperature solution of compound 2-50 (17 mg, 0.020 mmol, 1 eq) 
in CH3CN (0.4 mL) was added Et3N (0.2 mL). The solution was stirred for 14 h at which point it 
was evaporated and purified by C-18 chromatography to give compound 2-46 (11.5 mg, 96%).  
1H NMR (500 MHz, CD3OD) δ 5.05 (d, J = 1.3 Hz, 1H, H-1), 4.34 (dd, J = 16.1, 2.4 Hz, 1H, -
CH2CCH), 4.28 – 4.20 (m, 2H, -CH2CCH + H-3), 4.10 – 4.02 (m, 2H, H-4 + H-5a), 3.98 (dd, J = 
4.1, 1.3 Hz, 1H, H-2), 3.81 (ddd, J = 11.3, 6.7, 4.2 Hz, 1H, H-5b), 3.19 (q, J = 7.3 Hz, 6H, 
(CH3CH2)3N), 2.81 (appt, J = 2.4 Hz, 1H, -CH2CCH), 1.31 (t, J = 7.3 Hz, 9H(CH3CH2)3N), 0.93 
(s, 9H, -tBu), 0.92 (s, 9H, -tBu), 0.14 (s, 3H, -CH3), 0.13 (s, 3H, -CH3), 0.12 (s, 3H, -CH3), 0.11 
(s, 3H, -CH3). 
13C NMR (126 MHz, CD3OD) δ 105.5, 83.5 (d, J = 9.0 Hz), 80.2, 77.8, 75.7, 73.5, 66.5 (d, J = 
5.6 Hz) 54.7, 47.8, 26.5, 26.4, 19.0, 18.9, 9.2, -4.1, -4.3, -4.3, -4.6. 
31P NMR (202 MHz, CD3OD) δ 2.11 
HRMS (ESI) m/z calcd for C20H40O8PSi2 ([M-H]-) 495.2005, found 495.1999. 
 
 
 
 
Compound 2-51: To a 4 mL reaction vial was added compound 2-46 (4.3 mg, 7.2 mmol, 2 eq) 
and the compound was azeotroped three times with CH3CN and dried under high vacuum. 
Compound 2-46 was dissolved in CH3CN (0.2 mL) and Et3N (1.5 mg, 14.4 mmol, 4 eq). N,N-
carbonyldiimidazole (5.8 mg, 36 mmol, 10 eq) was added and the reaction stirred for 2 h at room 
temperature. Excess carbonydiimidazole was quenched using 10% Et3N in methanol (0.2 mL) 
and the crude reaction was concentrated to dryness. Compound 2-43 (7.0 mg, 3.6 mmol, 1 eq) 
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was added and the solution was azeotroped three times with CH3CN and dried under high 
vacuum. The coupling reaction was initiated by addition of of 4,5-dicyanoimidazole (3.4 mg, 29 
mmol, 8 eq) in DMF (0.2 mL) and was stirred for 16 h at room temperature. The crude reaction 
was applied to a column of silica and eluted using a gradient of 90:0:10 iPrOH:H2O:NH4OH to 
70:20:10 iPrOH:H2O:NH4OH to give compound 2-451 as the ammonium salt (2.0 mg, 25%) and 
an inseparable by-product resulting from dimerization of compound 2-46. 
HRMS (ESI) m/z calcd for C89H152N10O29P4Si7 ([M-H]-) 2144.8012, found 2144.7959. 
 
 
Compound 2-45: To a 4 mL reaction vial was added compound 2-51 (2.0 mg, 0.903 mmol, 1 
eq) and NH3/MeOH (0.2 mL of a 7M solution). The solution was stirred for 14 h, the solvent was 
evaporated and 0.5 mL of 40% Et3N in MeOH was added and subsequently evaporated. A 
solution of Bu4NF (0.2 mL of 1M solution in THF) was added and the reaction was stirred for 5 
h at room temperature. To the solution was added 0.2 mL of a 3M aqueous NaOAc solution and 
the solution stirred for 20 min. Ethanol (0.5 mL) was added, the solution was aliquoted into 
centrifuge tubes and put into a -80oC freezer. The tubes were centrifuged for 5 min at 14,000 rcf, 
the supernatant was discarded, ethanol was again added and the tubes were again centrifuged. 
The pellet was dissolved in water and purified by preparative HPLC (99% 8 mM Et3NHOAc/1% 
CH3CN to 90% 8 mM Et3NHOAc/10% CH3CN over 12 min). The fractions containing the 
product were concentrated to dryness followed by repeated lyophillization with H2O and 
exchange for the ammonium salt (Dowex 50W-X8 NH4+ form) to produce compound 2-45 (0.4 
mg, 36%) as the ammonium salt.  
O N
N
N
N
NHBz
O
TBSO O O
TBSO OTBS
O
P
O
O
O
P
O
O
O N
N
N
N
NHBz
O
TBSO OTBS
O O
TBSO OTBS
O
P
O
O
P
O
O
O
4 NH4+
2-51
1. NH3/MeOH
2. Bu4NF (33 eq)
THF, rt, 5 h
36%
O N
N
N
N
NH2
O
HO O O
HO OH
O
P
O
O
O
P
O
O
O N
N
N
N
NH2
O
HO OH
O O
HO OH
O
P
O
O
P
O
O
O
2-45 (Propargyl ADP-Ribose Dimer)
4 NH4+
	 86 
1H NMR (600 MHz, D2O) δ 8.41 (s, 1H), 8.39 (s, 1H), 8.17 (s, 1H), 8.16 (s, 1H), 6.19 (d, J = 
3.3 Hz, 1H), 6.02 (d, J = 6.0 Hz, 1H), 5.31 (d, J = 4.2 Hz, 1H), 5.10 (s, 1H), 4.68 (appt, J = 5.6 
Hz, 1H), 4.65 (q, J = 2.5 Hz, 1H), 4.61 (appt, J = 5.7 Hz, 1H), 4.52 – 4.48 (m, 1H), 4.42 – 4.17 
(m, 13H), 4.17-4.06 (m, 3H), 4.03 (d, J = 4.6 Hz, 1H), 4.00-3.94 (m, 1H), 2.82 (s, 1H). 
31P NMR (243 MHz, D2O) δ  -10.55 – -11.90 (m, 4P). 
HRMS (ESI) m/z calcd for C33H46N10O27P4 ([M-H]-) 1137.1412, found 1137.1423. 
LCMS: tR = 6.0 min,  98% 5 mM pentylamine:HOAc (pH=6.5) with 2% CH3CN to 75% 6 mM 
pentylamine:HOAc (pH=6.5) with 25% CH3CN over 5 min, then hold 75% 6 mM 
pentylamine:HOAc (pH=6.5) with 25% CH3CN for 3 min 
 
  
 
Note: m/z = 1033.9 corresponds to a component of the reference mixture 
 
 
Compound 2-52: To a well of a 384 well plate was added a solution of compound 2-45 (10 mL 
of a 2 mM aqueous solution, 0.002 mmol, 1 eq), a solution of Peg3-biotin-N3 (10 mL of a 4 mM 
aqueous solution, 0.004 mmol, 2 eq), a solution of CuSO4.5H2O (10 mL of a 20 mM aqueous 
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solution) and copper wire (3.2 mg). The solution was diluted to a final volume of 50 mL and 
incubated at room temperature overnight. The solution was purified by reverse phase HPLC 
(99% 8 mM Et3NHOAc/1% CH3CN to 70% 8 mM Et3NHOAc/30% CH3CN over 12 min) to 
give compound 2-52. Compound 2-52 was >95% pure by LC/MS analysis. 
HRMS (ESI) m/z calcd for C51H78N16O32P4S ([M-H]-) 1581.3566, found 1581.3615. 
LCMS: tR = 5.80 min,  98% 5 mM pentylamine:HOAc (pH=6.5) with 2% CH3CN to 65% 6 
mM pentylamine:HOAc (pH=6.5) with 35% CH3CN over 5 min, then hold 65% 6 mM 
pentylamine:HOAc (pH=6.5) with 35% CH3CN for 3 min 
 
  
 
 
 
 
Compound 2-53:  To a 500 mL eppendorf tube was added copper wire (2 mg). A solution of 
compound 2-45 (50 mL of a 3.1 mM solution, 0.16 mmol, 1 eq), a solution of sulfoCy3-N3 (20 
mL of a 10 mg/mL solution, 0.27 mmol, 1.7 eq) and a solution of CuSO4.5H2O (50 mL of a 0.5 
mg/mL solution, 0.1 mmol, 0.6 eq). The reaction was incubated at room temperature for 15 h and 
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purified by HPLC (99% 8 mM Et3NHOAc/1% CH3CN to 70% 8 mM Et3NHOAc/30% CH3CN 
over 12 min) to give compound 2-53. Compound 2-53 was >95% pure by LC/MS analysis. 
HRMS (ESI) m/z calcd for C66H89N16O34P4S2 ([M-H]-) 1836.4046, found 1836.4058. 
          m/z calcd for C66H89N16O34P4S2 ([M-2H]2) 917.6987, found 917.6983. 
LCMS: tR = 5.97 min,  98% 5 mM pentylamine:HOAc (pH=6.5) with 2% CH3CN to 65% 6 
mM pentylamine:HOAc (pH=6.5) with 35% CH3CN over 5 min, then hold 65% 6 mM 
pentylamine:HOAc (pH=6.5) with 35% CH3CN for 3 min 
   
 
 
 
Compound 2-22: To a 4 mL reaction vial was added compound 2-23 (50 mg, 0.057 mmol, 1 
eq), CH2Cl2 (1.3 mL), and H2O (0.26 mL). The solution was cooled to 0 oC, and 2,3-Dichloro-
5,6-dicyano-1,4-benzoquinone (14.3 mg, 0.063 mmol, 1.1 eq) was added. The reaction was 
stirred at 0 oC for 3 h, at which point an additional 1.1 eq of 2,3-Dichloro-5,6-dicyano-1,4-
benzoquinone was added and the reaction stirred for 1 h. The reaction was quenched with a 
saturated aqueous Na2S2O3 solution, extracted three times with EtOAc, filtered through Na2SO4 
and concentrated. The crude reaction mixture was dissolved in CH2Cl2 (0.2 mL), Et3N.3HF (46 
mL, 0.285 mmol, 5 eq) was added, and the reaction stirred at room temperature for 5 h. Next, 
NH4OH (0.16 mL of a 25% solution) was added and the reaction stirred for 12 h. The crude 
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reaction was poured into CH2Cl2, extracted three times with water and concentrated. Silica 
column chromatography was performed revealing two compounds (Rf = 0.38 and 0.15 in 80:20 
CH2Cl2:MeOH). The mixture was treated with NH3/MeOH (0.3 mL of a 7 M solution) for 12 h. 
Next, Dowex 50W-X8 (Na+ form) was added and stirred for 15 min. The mixture was filtered 
through a cotton plug, concentrated and purified by silica column chromatography (Rf 0.15 in 
80:20 CH2Cl2:MeOH) to furnish compound 2-22 as a yellow oil (9.5 mg, 42%).  
1H NMR (500 MHz, D2O) δ 8.33 (s, 1H, H-2), 8.20 (s, 1H, H-8), 6.19 (d, J = 6.2 Hz, 1H, H-1’), 
5.07 (d, J = 4.1 Hz, 1H, H-1’’), 4.88 (dd, J = 6.3, 5.2 Hz, 1H, H-2’), 4.54 (dd, J = 5.2, 3.0 Hz, 
1H, H-3’), 4.32 (appq, J = 3.1 Hz, 1H, H-4’), 4.20 (appdt, J = 4.9, 3.4 Hz, 1H, H-4’’), 4.10 – 
4.02 (m, 2H, H-2’’ + H-3’’), 3.92 (dd, J = 12.9, 2.7 Hz, 1H, H-5’a), 3.84 (dd, J = 12.9, 3.5 Hz, 
1H, H-5’b), 3.68 (dd, J = 12.5, 3.6 Hz, 1H, H-5’’a), 3.61 (dd, J = 12.5, 4.8 Hz, 1H, H-5’’b). 
13C NMR (125 MHz, D2O) δ 156.3, 153.2, 149.0, 141.4, 119.8, 102.6, 87.7, 86.9, 86.1, 79.8, 
72.2, 71.6, 70.4, 62.2, 62.1. 
HRMS (ESI) m/z calcd for C15H22N5O8 ([M+H]+) 400.1477, found 400.1468.  
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Chapter 3. Biological Studies Using the ADP-ribose Dimer and Fragments 
 
Portions of this chapter are reprinted with permission from: Lambrecht, M. J.; Brichacek, M.; 
Barkauskaite, E.; Ariza, A.; Ahel, I.; and Hergenrother, P. J. J. Am. Chem. Soc. 2015, 137, 3558-
3564. This work was performed in close collaboration with Dr. Matthew Brichacek. X-ray 
crystallography was performed by Dr. Eva Barkuskaite, Dr. Antonio Ariza and Prof. Ivan Ahel at 
the University of Oxford. ADP-HPD and ADP-HPM were synthesized by Dr. Bryan Yestrepsky.  
 
3.1 Introduction 
With the synthesis of the ADP-ribose dimer (2-1) complete, we sought to demonstrate its 
ability to enable biological experiments that were otherwise challenging or impossible to 
perform.  For example, at the time of the work herein only one x-ray co-crystal structure of a 
PAR oligomer in complex with a protein had been published1. The lack of such examples was 
mostly due to the challenges associated with accessing homogeneous PAR oligomers and 
polymers as detailed in chapter 1. Additionally, analysis of PAR-protein binding in a quantitative 
manner remained difficult due to the heterogeneity of PAR. Prior to this work, most methods to 
characterize PAR-protein binding interactions were inconvenient and not amenable to high-
throughput screening. Finally, while the ADP-ribose dimer (2-1) had been fully characterized by 
multidimensional NMR upon its synthesis, the lack of a literature spectrum with which to 
compare to complicated its analysis. Therefore, the work herein served to further prove its 
structure by demonstrating its competence in biological experiments.  
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3.2 The Processing of the ADP-ribose Dimer (2-1) by PARG and ARH3 
 Having accessed the ADP-ribose dimer (2-1), it was first important to assess the ability of 
PARG to hydrolyze it to two units of ADP-ribose. This experiment would both serve as further 
conformation of the structure of the ADP-ribose dimer (2-1) and would also show that it is a 
biochemically competent substrate for PARG. Interestingly, the ADP-ribose dimer (2-1) had 
never been explicitly shown to be a substrate for PARG, but previous work by the Ahel lab 
suggested that it would be1,2. When comparing PAR polymers treated with F398G Tetrahymena 
thermophilia PARG or F902G human PARG (inactive mutants) to the appropriate wild type 
enzymes, it was found that the amount of ADP-ribose dimer (2-1) detected by LCMS/MS 
analysis for the wild type enzymes was substantially decreased relative to treatment with the 
mutants1. However, substantial amounts of the ADP-ribose dimer (2-1) did still remain upon 
completion of wild type treatment in this assay (and to a lesser extent the trimer and tetramer), 
especially for human PARG1. It was therefore not clear when these studies commenced how 
good of a substrate this dimer was for PARG, especially for the human enzyme. 
 To address this question, the ADP-ribose dimer (2-1) was treated with PARG from 
various sources and conversion was monitored by HPLC (Figure 3.1). PARG from Bos taurus 
(bovine), Tetrahymena thermophilia (protozoan), and Thermomonospora curvata3 (bacterial) 
was found to catalyze the hydrolysis of the ADP-ribose dimer (2-1) to two molecules of ADP-
ribose. ARH3, another enzyme with PAR processing activity4 was also found to possess activity 
against the dimer. The necessity of high enzyme concentrations and long reaction times are 
consistent with previous reports of the reduced in vitro activity of ARH3 when compared to 
PARG5. Treatment of the ADP-ribose dimer (2-1) with human PARG was evaluated by an 
LCMS assay (Figure 3.2), and it was confirmed that the product of the reaction was ADP-ribose 
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by MS analysis (the appearance of ADP-ribose in the HPLC assay was confirmed by retention 
time comparison to standards but not by MS). Importantly, catalytically inactive T. thermophilia 
(E256Q, Figure 3.1a) and human (E755N and E756N, Figure 3.2a) PARGs showed no 
processing of the ADP-ribose dimer (2-1) even at long times and high concentrations of enzyme.   
 
Figure 3.1. Processing of ADP-ribose dimer (2-1) by PARG from various sources as analyzed 
by HPLC. a) 25 nM T. thermophilia PARG without enzyme, with enzyme after 1 min, 30 min, 1 
h, 2 h and with 250 nM E256Q (mutant) at 12 h. b) 5 nM B. taurus PARG at 1 min, 1 h, and 2 h. 
c) 250 nM T. curvata PARG at 1 min, 1 h, 2 h, and 4 h and d) 250 nM human ARH3 at 1 min, 1 
h, 2 h, and 4 h. The peak near 4 min in panels a, b, and c is found in all traces containing the 
PARG assay buffer.  
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Figure 3.2. Processing of ADP-ribose dimer (2-1) by Human PARG as analyzed by LCMS. a) 
Treatment of ADP-ribose dimer (2-1) with 7.5 nM PARG at 1 min, 2 h and treatment with 75 
nM E755N and E756N mutant PARGs at 4 h. b) Mass spectra at 4.15 min, 5.36 min for traces in 
a. ADP-Ribose ([M-H]- = 558.1) is shown on top, while the ADP-ribose dimer (2-1) ([M-H]- = 
1099.2 and [M-2H]2- = 549.1) is shown on bottom.  
 
3.3 ADP-ribose Dimer (2-1)/Human PARG X-Ray Structure 
 The inability of mutant PARGs to processes the ADP-ribose dimer (2-1) offered the 
opportunity to solve a co-crystal structure of the ADP-ribose dimer (2-1) in complex with human 
PARG. Though X-ray structures of human PARG existed6, including those bound to the 
inhibitors ADP-HPD and ADP-ribose, such structures did not exist with human PARG bound to 
its natural substrate. Through a collaboration with Prof. Ivan Ahel’s lab, a co-crystal structure of 
the ADP-ribose dimer (2-1) was solved in complex with human E756N PARG to 1.9 Å (Figure 
3.3). Such a structure could not be solved with E755N human PARG, as only monomeric ADP-
ribose was seen upon crystallization. This result suggests that the E755N mutant retains small 
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amounts of activity, especially at the high ratios of enzyme to substrate in crystallography 
experiments.  
 
Figure 3.3. Human PARG-ADP-ribose dimer co-crystal structure. a) Surface representation of  
human PARG (E756N) bound to the ADP-ribose dimer (2-1). The gray mesh shows the 2FO-FC 
electron density corresponding to the ordered region of the ADP-ribose dimer (2-1) at a counter 
level of 1σ. b) Overlay of protozoan (PDB:4L2H) and human PARG (this work) structures 
bound to a PAR fragment (pink) and the ADP-ribose dimer (2-1) (yellow), respectively. Figures 
by Dr. Eva Barkuskaite, Dr. Antonio Ariza, and Prof. Ivan Ahel (University of Oxford).    
 
Examination of the human PARG/ADP-ribose dimer co-crystal structure reveals many 
similarities to the previously solved T. thermophilia PARG structure with short oligomers 
obtained through enzymatic synthesis and fractionation,1 but also some differences. As with the 
T. thermophilia structure, binding appears to be tightest to the N ADP-ribose unit (Figure 3.3a). 
Most interactions with the N ADP-ribose unit are maintained in both structures, and the polymer 
is in a nearly identical conformation in both (Figure 3.3b). The human PARG structure offers the 
first view of the glycosidic linkage and N-1 ADP-ribose unit for the human protein and some 
differences with respect to T. thermophilia exist. Specifically, human PARG lacks a residue 
homologous to Arg164, and therefore the N-1 adenine in the human system is more exposed. 
The analogous residue to T. thermophilia Ser297 in the human protein is Ala796, and this 
replacement lacks contacts with the N-1 adenine again leaving it further solvent exposed. The N-
1 β phosphate in the human protein forms hydrogen bonds with Arg663 which are not present in 
N-1	ADP-Ribose	
N	ADP-ribose	
W2	
a	 b	
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the protozoan structure. The N-1 ribose residue is not seen in either structure due to disorder in 
this region.        
3.4 Interrogation of the Minimal PARG Substrate 
 In an attempt to understand what portions of the PAR polymer are recognized and 
processed by PARG, the synthesis of a series of analogs and fragments of PAR was undertaken. 
This work was done with the goal of finding simplified analogs that PARG might bind to and 
process from which inhibitors and substrates could be designed. Specifically, if the presence of 
the pyrophosphate motif was not required for PARG substrate recognition and processing, 
inhibitors that lack this motif could be synthesized and would likely have better cell permeability 
properties than ADP-HPD (the best current in vitro inhibitor of PARG). Discovery of simplified 
substrates could also enable design of molecules that could be used in activity assays for PARG 
for applications such as screening.   
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Figure 3.4. Synthesis of PAR fragments. i. DDQ (1.1 eq), CH2Cl2/H2O, 0oC, 5 h. ii. Et3N.3HF, 
CH2Cl2, rt, 5 h, iii. NH3/MeOH, rt, 12 h, 42% (for 3 steps). iv. DDQ (1.5 eq), CH2Cl2/H2O, 0oC, 
2 h, 79%. v. (BnO)2PN(iPr)2 (2.5 eq), dicyanoimidazole (2.5 eq), CH3CN, rt, 1 h, then: tBuOOH 
(10 eq), rt, 1 h, 70%. vi. NH3/MeOH, rt, 15 h. vii. Bu4NF, THF, rt, 3 h. viii. H2, Pd/C, Et3N (6 
eq), tBuOH/H2O, 16 h, ion pairing chromatography, cation exchange, 19% (3 steps). ix. 
NH3/MeOH, rt, 15 h. x. Bu4NF, THF, rt, 3.5 h, 44% (2 steps). 
 
 Using intermediates of the synthetic route described in chapter 2, PAR fragments were 
synthesized (Figure 3.4). The central disaccharide of PAR (2-22) had been previously 
synthesized to confirm the structure of the glycosylated product (section 2.1.4). Alcohol 2-25 
was used as a starting material to synthesize iso-ADP-ribose (3-1). Treatment of alcohol 2-25  
with DDQ afforded a diol that after a bis phosphoramidite coupling, oxidation and global 
deprotection afforded iso-ADP-ribose (3-1). While iso-ADP-ribose has been synthesized 
enzymatically by digestion of PAR with snake venom phosphodiesterase, this represented the 
first chemical synthesis of this widely used molecule7-9. Global deprotection of phosphate 2-43 
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afforded compound 3-2, an analog very similar to the portion of the ADP-ribose dimer (2-1) that 
is visible in the PARG x-ray structure (Figure 3.3), lacking only the N-1 β phosphate.  
 
Figure 3.5. Processing of ADP-ribose dimer derivatives 2-22, 2-45, 3-1, and 3-2 by T. 
thermophilia PARG as analyzed by LCMS. In addition to dimer 2-1, compounds 2-45 and 3-2 
retain the ability to be processed by PARG in this assay. Compounds 2-22 and 3-1 are not 
processed under the assay conditions. 
 
 The ability of these compounds to be processed by PARG was next examined (Figure 
3.5). Neither disaccharide 2-22 nor iso-ADP-ribose (3-1) was found to be a substrate for PARG, 
even at high concentrations of enzyme. Phosphate 3-2 and the propargyl ADP-ribose dimer (2-
45) were both found to be good substrates for the enzyme, as the glycosidic linkage was 
hydrolyzed with similar efficiency to the natural ADP-ribose dimer (2-1) under the conditions 
tested. This result was important in that it suggests that at least for PARG, the alkyne substitution 
to the N-1 ADP-ribose is not deleterious to the properties of the molecule. Therefore, the biotin 
and fluorophore containing probe molecules (synthesized in chapter 2) are likely to retain 
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biological activity. Also, because the propargyl ADP-ribose dimer (2-45) contains the unnatural 
β-stereochemical linkage at the N-1 ribose, the enzyme does not process this molecule to two 
molecules of ADP-ribose, but rather one molecule of ADP-ribose and one molecule of propargyl 
ADP-ribose.  
3.5 Development of a PAR-protein Binding Assay  
The ability of ADP-ribose oligomers and polymers to bind proteins is known, however 
quantifying such interactions is often challenging. Additionally few methods exist for high 
throughput screening for compounds that inhibit or disrupt PAR-protein binding. It was 
imagined that the Cy3 ADP-ribose dimer (2-45) may present a potential solution to these 
problems could its binding to proteins be detected by fluorescence polarization. A fluorescence 
polarization-based binding assay was therefore developed (Figure 3.6) using this molecule. 
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Figure 3.6. PAR-protein binding assay by fluorescence polarization. a) The Cy3 ADP-ribose 
dimer (2-53) binds to E755N (red circles) and E756N (black squares) PARG, but not to bovine 
serum albumin (BSA, blue diamonds). b) The Cy3 ADP-ribose dimer (2-53) does not bind to 
BSA even at high concentrations of protein. c) Fragments and inhibitors compete for binding 
with the Cy3 ADP-ribose dimer (2-53) to E755N PARG. d) Fragments and inhibitors compete 
for binding with the Cy3 ADP-ribose dimer (2-53) to E756N PARG.    
 
 The Cy3 ADP-ribose dimer (2-53) exhibited good binding to both E755N and E756N 
human PARG (Figure 3.6a), with Kd values of 208 ±14 and 83 ± 7 nM, respectively. Interaction 
between the Cy3 ADP-ribose dimer (2-53) and bovine serum albumin (BSA), a protein that does 
not bind PAR, was not seen (Figure 3.6a) even at high concentrations of the protein (Figure 
3.6b). Binding of the Cy3 ADP-ribose dimer (2-53) to the PARG mutants could be competed 
away with unlabeled ADP-ribose dimer (2-1) as well as with various compounds that inhibit 
c d 
a b 
3-2 
3-1 
3-2 
3-1 
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PARG (Figure 3.6 c and d), suggesting that this may be a viable assay for high-throughput 
screening of PAR-protein binding inhibitors. Interestingly, the ability of ADP-HPD, ADP-HPM 
and ADP-ribose to compete for binding with the Cy3 ADP-ribose dimer (2-53) is much reduced 
for E755N relative to E756N PARG (Figure 3.6c vs. 3.6d). The exact origins of this discrepancy 
are not yet well understood. The traditional role of E755 is believed to be a hydrogen bonding 
interaction with the 2’’-OH of the N ADP-ribose unit and in most cases, mutation of this residue 
leads to abolishment of glycohydrolase activity. Therefore, it could be that mutation of E755 
leads to reduced binding of the PAR polymer (and by extension inhibitors) to PARG. However, 
the Cy3 ADP-ribose dimer (2-53) does still bind well to this protein (only a 2 fold reduction in 
Kd) and the ADP-ribose dimer (2-1) and compound 3-2 do still compete away binding. Attempts 
by Dr. Bryan Yestrepsky and Tomohiro Shiari to strengthen the interaction of ADP-HPD to this 
residue in the wild type protein by installation of an amine in the 2’’ position of APD-HPD have 
been unsuccessful.   
3.6 Conclusions 
The results presented here show the ability of the chemical synthesis of dimeric ADP-
ribose and the synthetic route designed in chapter 2 to impact understanding of PAR biology. 
The chemical synthesis of dimeric ADP-ribose (2-1) enabled the first x-ray co-crystal structure 
of human PARG in complex with a natural substrate. Additionally, a brief SAR of PARG 
binding and processing of fragments was undertaken using molecules that could be easily 
synthesized from intermediates on the route to dimeric ADP-ribose (2-1). While these studies in 
many ways show why PARG inhibitors such as ADP-HPD and ADP-HPM are good inhibitors 
(strong binding of PARG to ADP-ribose motifs), they fail to inform design of better inhibitors of 
PARG that do not contain the pyrophosphate motif that limits cell permeability.  
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3.7 Experimental 
Crystallographic Data and Model Refinement Parameters 
 
Data collection  
Space group P212121 
Cell dimensions  
a, b, c (Å) 67.5, 91.3, 96.12 
α, β, γ (°) 90, 90, 90 
Resolution 55.22-1.95 (2.00-1.95) 
Rmerge (%) 10.5 (58.1) 
I/sigma 21.4 (4.9) 
Completeness 99.9 (99.8) 
Multiplicity 13.2 (12.1) 
Refinement  
Resolution  55.22-1.95 
No. unique reflections 44991 
R work/R free 13.7 / 17.9 
No of atoms  
Protein 4202 
Ligand/ion 205 
Water 421 
r.m.s. deviations  
Bond lengths (Å) 0.019 
Bond angles (°) 1.55 
B factors (Å2)  
Protein 23.025 
Ligand/ion 43.813 
Water 35.080 
 
 
Methods 
 
Plasmids and proteins 
T. thermophila PARG (TTHERM_00294690) and human PARG (a.a. 448–976 [K616A, Q617A, 
K618A, E688A, K689A, K690A]) proteins were expressed and purified as described 
previously1,6 with the following changes. 6His-TEV-tagged catalytic mutant human PARG was 
obtained by introducing the E756N mutation using the QuickChange II site-directed mutagenesis 
kit (Stratagene). The human PARG proteins were purified from the clarified lysate by 
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immobilised metal affinity chromatography (IMAC) using a 5 mL His-TRAP HP column (GE 
Healthcare).  Pooled fractions enriched for 6His-TEV-PARG were incubated with 6-His-tagged 
TEV protease whilst being dialysed for 24 hours at 4ºC. Cleaved protein was separated from 
uncleaved material, free 6-His tags and TEV protease by subtractive IMAC.  The cleaved protein 
was concentrated before loading on a Superdex 200 pg (16/600) column (GE Healthcare) for size 
exclusion chromatography.  Pooled fractions containing human PARG were concentrated to 7.5 
mg/mL for crystallisation studies. IMAC and size exclusion chromatography were performed on 
an ÄKTA PURE FPLC system (GE Healthcare). 
Crystallization and structure solution 
Crystals were grown at 293K by sitting-drop vapour diffusion by mixing 350 nL purified protein 
(at 7.5 mg/mL in 50mM HEPES, pH 7.0, 150 mM NaCl, 2mM DTT) briefly pre-incubated with 
1mM of 1 dimer with 150 nL of seed stock and 500 nL of mother liquor consisting of 18-23% 
PEG-3350, 0.2 M ammonium sulphate, 0.1 M PCTP pH 7.5.  Seed stock was prepared using a 
Seed BeadTM (Hampton Research) from a co-crystal of mutant human PARG with ADP-ribose. 
The co-crystal mother liquor (19% PEG-3350, 0.2 M ammonium sulphate, 0.1 M PCTP pH 7.5) 
was used as the stabilising solution for the seed stock. Crystals appeared over 48 hours and 
continued to grow for a further week and were then cryoprotected in a solution of 20% glycerol 
in mother liquor prior to being flash-cooled in liquid nitrogen. The diffraction data were 
collected at the Diamond Light Source (UK), with the automatic processing carried out by Xia2. 
The structure was solved by molecular replacement using using Phaser and the previously 
reported human PARG structure, by iterative rounds of manual building in Coot and 
crystallographic refinement in REFMAC5. Crystallographic figures were generated using 
PyMOL (http://www.pymol.org). 
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PARG Catalyzed Degradation LC/MS Assay (Figure 3.2) 
Concentrated PARG stock solutions were diluted to the appropriate concentration in 
PARG activity buffer (50 mM K2HPO4, 50 mM KCl, 9 mM β-mercaptoethanol, pH = 7.5). Next, 
to a 0.5 mL tube was added 80 mL of PARG/ARH3 activity buffer, 10 mL of a 1 mM solution of 
synthetic ADP-Ribose Dimer, and 10 mL of the diluted PARG/ARH3. The tube was vortexed 
and transferred to a 384-well plate. The sample was analyzed by LC/MS (10 mL injections) at 
the appropriate time points. The HPLC method (98% 5 mM pentylamine:HOAc (pH=6.5) with 
2% CH3CN to 75% 6 mM pentylamine:HOAc (pH=6.5) with 25% CH3CN over 5 min, then hold 
75% 6 mM pentylamine:HOAc (pH=6.5) with 25% CH3CN for 3 min) results in elution of ADP-
Ribose at 4 min and PAR dimer at 5.2 min. 
 
PARG or ARH3 Catalyzed Degradation HPLC Assay (Figure 3.1) 
Concentrated PARG/ARH3 stock solutions were diluted to the appropriate concentration 
in PARG activity buffer (50 mM K2HPO4, 50 mM KCl, 9 mM β-mercaptoethanol, pH = 7.5) or 
ARH3 activity buffer (50 mM PBS, 10 mM MgCl2, 5 mM TCEP, pH = 7.1). Next, to a 0.5 mL 
tube was added 42.5 mL of PARG/ARH3 activity buffer, 5 mL of a 1 mM solution of synthetic 
ADP-Ribose Dimer, and 2.5 mL of the diluted PARG/ARH3. The tube was vortexed and 
transferred to an HPLC vial with a small volume insert. The sample was analyzed by HPLC (10 
mL injections) at the appropriate time points. The HPLC method (99% 8 mM Et3NHOAc/1% 
CH3CN to 90% 8 mM Et3NHOAc/10% CH3CN) results in elution of ADP-Ribose at 5.1 min and 
PAR dimer at 6.9 min.  
Fluorescence Polarization Assays 
 E755N and E756N PARG dilutions (final concentrations of 5 µM to 0 µM) were made in 
PARG binding buffer (50 mM KCl, 50 mM K2HPO4, 0.05% Trition X-100, pH = 7.5) and 
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compound 22 was added to a final concentration of 7.5 nM. The solutions were transferred to a 
black 384 well plate incubated at room temperature for 30 min and read using an Analyst HT 
(excitation at 530 ± 25 nm and emission at 570 ± 10 nm). Polarization data was converted to 
anisotropy, plotted and fit to the following equation10,11 using Origin Lab: 
 !!"# = !! + !! − !! !! + !!" + !! − !! + !!" + !! ! + 4!!"!!2!!"  
 
where AOBS is the observed anisotropy, AF is the anisotropy of the free probe, AB is the 
anisotropy of the bound probe KD is the dissociation constant of the protein-ligand (fluorescently 
labeled compound) interaction, LST is the total concentration of the labeled ligand in the assay, 
and RT is the total receptor (protein) concentration. The error of the reported KD values 
corresponds to the error in the curve fitting.  
 For competition binding experiments, unlabeled compound 1 or ADP-HPD was diluted to 
the appropriate concentrations and protein in binding buffer was added to final concentrations for 
E755N and E756N of 500 nM and 250 nM, respectively. The solutions were incubated for 30 
min at room temperature at which point compound 22 was added at a final concentration of 7.5 
nM. The solutions were transferred to a 384 well black plate incubated an additional 30 min and 
read using the conditions described above. Polarization data was converted to anisotropy, plotted 
and fit to the following equation using Origin Lab: 
 ! =  !! + !! − !!1 + 10!"# !!!!"!"  
 
where LT is the concentration of unlabeled competitor and IC50 is the concentration of unlabeled 
competitor necessary to produce 50% decrease in binding of the labeled probe. 
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Compound 3-3: To a 0oC solution of compound 2-25 (50 mg, 0.051 mmol, 1 eq) in CH2Cl2 (0.9 
mL) and H2O (0.2 mL) was added 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (17.3 mg, 0.076 
mmol, 1.5 eq). The solution was stirred at 0oC for 2 h, poured into saturated aqueous Na2S2O3, 
extracted three times with ethyl acetate, dried through Na2SO4, concentrated and purified by 
silica column chromatography to afford compound 3-3 (34 mg, 79%). 
1H NMR (500 MHz, CDCl3) δ 9.19 (s, 1H, -NHBz), 8.79 (s, 1H, H-8), 8.09 (s, 1H, H-2), 8.02 
(d, J = 7.7 Hz, 2H, -Bz), 7.62 (t, J = 7.5 Hz, 1H, -Bz), 7.53 (t, J = 7.7 Hz, 2H, -Bz), 6.07 (d, J = 
7.6 Hz, 1H, H-1’), 5.02 (dd, J = 7.7, 4.3 Hz, 1H, H-2’), 4.82 (d, J = 3.1 Hz, 1H, H-1’’), 4.59 (d, J 
= 4.3 Hz, 1H, H-3’), 4.21 (s, 1H, H-4’), 4.10 (d, J = 6.7 Hz, 1H, H-3’’), 4.02 – 3.91 (m, 2H, H-
4’’ + 5’a), 3.87 – 3.69 (m, 3H, 2’’ + 5’b + 5’’a), 3.53 (d, J = 12.1 Hz, 1H, H-5’’b), 0.94 (s, 9H, -
tBu), 0.88 (s, 9H, -tBu), 0.85 (s, 9H, -tBu), 0.16 (s, 3H, -CH3), 0.13 (s, 3H, -CH3), 0.03 (s, 3H, -
CH3), 0.01 (s, 3H, -CH3), -0.00 (s, 3H, -CH3), -0.05 (s, 3H, -CH3). 
13C NMR (125 MHz, CDCl3) δ 164.7, 152.4, 150.8, 150.5, 143.9, 133.7, 133.2, 129.2, 128.1, 
124.7, 104.9, 89.7, 89.1, 82.8, 81.9, 73.9, 73.5, 70.6, 63.0, 60.9, 26.3, 26.2, 26.2, 18.8, 18.4, 18.4, 
-3.9, -4.0, -4.1, -4.4, -4.7. 
HRMS (ESI) m/z calcd for C40H68N5O9Si3 ([M+H]+) 846.4325, found 846.4318. 
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Compound 3-4: To a dry 4 mL reaction vial was added compound 3-3 (19.0 mg, 0.0225 mmol, 
1 eq) and dibenzyl N,N-diisopropylphosphoramidite (19.4 mg, 0.562 mmol, 2.5 eq). The 
compounds were co-evaporated three times on a N2-filled rotary evaporator with dry CH3CN and 
then dried over P2O5 overnight. Separately, 4,5-dicyanoimidazole (6.6 mg, 0.0562 mmol, 2.5 eq) 
was evaporated and dried in a similar manner. To compound 3-3 and the phosphoramidite was 
added dry CH3CN (0.1 mL), followed by a solution of the 4,5-dicyanoimidazole in CH3CN (0.1 
mL) at room temperature. The reaction was stirred for 1 h at which point tBuOOH (0.041 mL of 
a 5.5 M solution, 0.225 mmol, 10 eq) was added and the reaction stirred an additional hour. The 
reaction was quenched with saturated aqueous NaHCO3, extracted three times with ethyl acetate, 
dried through Na2SO4, and purified by silica column chromatography to give compound 3-4 
(21.5 mg, 70%).  
1H NMR (500 MHz, CDCl3) δ 8.96 (bs, 1H, -NHBz) 8.69 (s, 1H, H-8), 8.24 (s, 1H, H-2), 7.98 
(d, J = 7.5 Hz, 2H, -Bz), 7.63 – 7.56 (m, 1H, -Bz), 7.51 (t, J = 7.7 Hz, 2H, -Bz), 7.37 – 7.25 (m, 
20H, -Bn), 6.11 (d, J = 2.8 Hz, 1H, H-1’), 5.19 (d, J = 3.7 Hz, 1H, H-1’’), 5.03 – 4.88 (m, 8H, -
CH2Ph), 4.71 (dd, J = 4.5, 2.9 Hz, 1H, H-2’), 4.46 (dd, J = 6.6, 4.5 Hz, 1H, H-3’), 4.35 (ddd, J = 
11.4, 5.7, 3.4 Hz, 1H, H-5’a), 4.28 – 4.23 (m, 1H, H-4’’), 4.18 (dd, J = 4.5, 2.7 Hz, 1H, H-4’), 
4.15 – 4.05 (m, 2H, H-5’b, H-5’’a), 3.97 (ddd, J = 11.2, 5.8, 3.6 Hz, 1H, H-5’’b), 3.93 (appt, J = 
4.9 Hz, 1H, H-3’’), 3.89 (dd, J = 5.3, 3.7 Hz, 1H, H-2’’), 0.84 (s, 18H, -tBu), 0.79 (s, 9H, -tBu), 
O N
N
N
N
NHBz
HO
TBSO O O
TBSO OTBS
OH
NiPr2
P
BnO OBn
(2.5 eq)
4,5-dicyanoimidazole (2.5 eq)
CH3CN, rt, 1 h
then: tBuOOH, rt, 1 h
70%
O N
N
N
N
NHBz
O
TBSO O O
TBSO OTBS
O
P
O
OBn
OBn
P
BnO
O
OBn
5
8
4 2
6
1'
2'3'
4'5'
1''
2'' 3''
4'' 5''
3-3 3-4
	 109 
0.05 (s, 3H, -CH3), 0.03 (s, 3H, -CH3), 0.00 (s, 3H, -CH3), -0.02 (s, 3H, -CH3), -0.04 (s, 3H, -
CH3), -0.06 (s, 3H, -CH3). 
13C NMR (125 MHz, CDCl3) δ 164.7, 152.8, 151.2, 149.6, 142.2, 136.01 – 135.87 (m), 135.80 
(d, J = 6.7 Hz), 133.0, 129.1, 128.8, 128.1, 120.2, 103.5, 88.7, 82.87 (d, J = 8.0 Hz), 82.26 (d, J 
= 8.3 Hz), 80.7, 73.6, 71.0, 70.3, 69.79 – 69.55 (m), 69.7 – 69.4 (m), 66.8 (d, J = 5.4 Hz), 65.5 
(d, J = 5.3 Hz), 26.2, 26.0, 18.5, 18.3, 18.3, -4.1, -4.3, -4.4, -4.4, -4.5, -4.8. 
31P NMR (202 MHz, CDCl3) δ 0.17, 0.05 
HRMS (ESI) m/z calcd for C66H95N5O15Si3P2Na ([M+Na]+) 1366.5506, found 1366.5494. 
 
 
 
iso-ADP-ribose (3-1): To a 7 mL reaction vial containing compound 3-4 (24 mg, 0.0176 mmol, 
1 eq) was added ammonia solution (0.5 mL of a 7M solution in MeOH) and the reaction was 
stirred at room temperature for 15 h. The reaction was evaporated and THF (0.2 mL) and 
tetrabutylammonium fluoride (0.11 mL of a 1M solution in THF, 0.11 mmol, 6 eq) was added 
and the reaction was stirred at room temperature for 3 h at which time the solution was 
concentrated and run through a short column of silica. The eluent was collected, concentrated 
and transferred to a 7 mL reaction vial. Palladium on carbon (10 mg) was added followed by 
tBuOH (0.2 mL), water (0.03 mL) and triethylamine (11 mg, 0.109 mmol, 6 eq). A balloon filled 
with hydrogen was fitted to the flask and stirred at room temperature for 16 h. The solution was 
filtered through celite, concentrated and purified by preparative HPLC (gradient of 99% 8 mM 
Et3NHOAc/1% CH3CN to 90% 8 mM Et3NHOAc/10% CH3CN). The fractions containing 
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product were combined, concentrated and exchanged for the NH4+ cation using a Dowex 50W-
X8 cation exchange column to give compound 3-1 (2.0 mg, 19%). 
1H NMR (500 MHz, D2O) δ 8.57 (s, 1H, H-8), 8.27 (s, 1H, H-2), 6.29 (d, J = 5.6 Hz, 1H, H-1’), 
5.22 (d, J = 4.1 Hz, 1H, H-1’’), 4.86 (dd, J = 5.5, 5.2 Hz, 1H, H-2’), 4.62 (dd, J = 5.2, 3.6 Hz, 
1H, H-3’), 4.45 – 4.39 (m, 1H, H-4’), 4.34 (appdt, J = 4.1, 2.2 Hz, 1H, H-4’’), 4.18-4.16 (m, 2H, 
H-2’’ + H-3’’), 4.13 – 4.02 (m, 2H, H-5’a + H-5’b), 3.90 (ddd, J = 11.5, 5.9, 4.0 Hz, 1H, H-
5’’a), 3.84 (dt, J = 11.4, 4.3 Hz, 1H, H-5’’b). 
13C NMR (125 MHz, D2O) δ 13C shifts determined from HSQC/HMBC, see table. 
31P NMR (242 MHz, D2O) δ 2.12-1.92 (m, 2P) 
HRMS (ESI) m/z calcd for C15H22N5O14P2 ([M-H]-) 558.0644, found 558.0637. 
 
 1H 13C 31P 
Ado 1’ 6.29 (d, J = 5.6 Hz) 86.1  
Ado 2’ 4.86 (dd, J = 5.6, 5.2 Hz) 80.2  
Ado 3’ 4.62 (dd, J = 4.9, 3.3 Hz) 70.8  
Ado 4’ 4.42 84.9  
Ado 5’a 4.18 64.3 2.05 Ado 5’b 4.16  
    
Ade 2 8.27 152.6  
Ade 4 - 148.8  
Ade 5 - 118.5  
Ade 6 - 155.6  
Ade 8 8.57 140.3  
    
Rib 1’’ 5.22 (d, J = 4.1 Hz) 102.1  
Rib 2’’ 4.17 70.2  
Rib 3’’ 4.17 71.5  
Rib 4’’ 4.34 84.7  
Rib 5’’a 3.90 64.5 2.05 Rib 5’’b 3.84  
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Compound 3-2: To a 7 mL vial containing compound 2-43 (5.7 mg, 2.9 mmol, 1 eq), was added 
NH3/MeOH (0.5 mL of a 7M solution) and the reaction was stirred for 15 h. The solution was 
evaporated and Bu4NF solution was added (0.2 mL of a 1 M solution in THF) and the reaction 
was stirred for 3.5 h. The reaction was quenched by addition of 3M aqueous NaOAc (0.2 mL) 
and stirred for 30 min. The solution was transferred to four 1.5 mL centrifuge tubes, EtOH (0.5 
mL) was added to each tube, and the tubes were centrifuged for 5 min at 4oC and 14,000 rcf. The 
supernatant was discarded and the pellet was washed with EtOH (0.5 mL) and again centrifuged. 
The pellet was suspended in H2O (1 mL) and purified by preparative HPLC (gradient of 99% 8 
mM Et3NHOAc/1% CH3CN to 90% 8 mM Et3NHOAc/10% CH3CN). Compound 3-2 was 
obtained as the ammonium salt (1.1 mg, 44%) of the product was obtained after concentration 
and cation exchange (Dowex 50W-X8, NH4+ form).   
1H NMR (500 MHz, D2O) δ 8.51 (s, 1H), 8.35 (s, 1H), 8.14 (s, 1H), 8.11 (s, 1H), 6.17 (d, J = 
4.0 Hz, 1H), 6.00 (d, J = 5.9 Hz, 1H), 5.24 (d, J = 4.2 Hz, 1H), 4.69-4.64 (m, 2H), 4.58 (appt, J = 
5.3 Hz, 1H), 4.47 (dd, J = 5.2, 3.5 Hz, 1H), 4.39 – 4.31 (m, 3H), 4.27 – 4.15 (m, 4H), 4.12 – 3.95 
(m, 4H). 
13C NMR (125 MHz, D2O) δ 155.6, 155.4, 153.0, 152.8, 148.9, 148.9, 140.1, 139.9, 118.6, 
118.5, 101.7, 87.3, 86.6, 84.5, 84.5, 84.5, 79.7, 74.7, 74.6, 70.7, 70.2, 70.0, 65.8, 65.5, 64.9  
Note: 13C shifts determined from HSQC/HMBC 
31P NMR (242 MHz, D2O) δ 3.71, -11.14 (d, J = 23.2 Hz), -11.27 (d, J = 22.1 Hz). 
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HRMS (ESI) m/z calcd for C25H35N10O20P3 ([M-H]-) 887.1169, found 887.1175. 
  
 1H 13C 31P 
I-Ado 1’ 6.00 (d, J = 5.9 Hz) 87.3  
I-Ado 2’ 4.67 74.7  
I-Ado 3’ 4.47 (dd, J =5.2, 3.5 Hz) 70.7  
I-Ado 4’ 4.38 84.5  
I-Ado 5’a 4.22 65.5  -11.27 (d, J = 22.1 Hz) I-Ado 5’b 4.22 
    
α- Rib 1’’ 5.24 (d, J = 4.2 Hz) 101.7  
α- Rib 2’’ 4.20 70.2  
α− Rib 3’’ 4.20 71.6  
α- Rib 4’’ 4.38 84.5  
α- Rib 5’’a 4.09  64.9 
 
-11.14 
(d, J = 23.2 Hz) 
α- Rib 5’’b 4.03   
    
D-Ado 1’ 6.17 (d, J = 4.0 Hz) 86.6  
D-Ado 2’ 4.67 79.7  
D-Ado 3’ 4.58 (appt, J = 5.3 Hz) 70.0  
D-Ado 4’ 4.38 84.5 
 
65.8 
 
 
3.71 D-Ado 5’a 4.09 
D-Ado 5’b 4.03   
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Chapter 4. Chemoenzymatic Synthesis of ADP-ribose Oligomers 
 
Synthesis of the ADP-ribose dimer (2-1) as described in chapter 2 was performed in 
collaboration with Dr. Matthew Brichacek.  
 
4.1 Introduction 
 The ability of the homogeneous ADP-ribose dimer (2-1) to enable otherwise challenging 
biological experiments as described in chapter 3 showed what a useful tool this compound is. 
More generally, these experiments showed the types of studies that could be performed with 
homogeneous ADP-ribose oligomers of defined chemical structure. It was imagined that could 
longer ADP-ribose oligomers and polymers be synthesized selectively and homogeneously, that 
they too could inform PAR biology. Unfortunately, the synthesis of such molecules by extension 
of the route detailed in chapter 2 was largely unsuccessful. The main obstacle inhibiting this 
route was the low yields and challenging purifications associated with solution phase 
pyrophosphate coupling reactions. One potential solution to this problem is the solid phase 
pyrophosphate formation that has been described recently1,2. However, though solid phase 
synthesis solves many of the problems associated with purification, yields for these processes are 
still generally low enough to not represent a general solution to PAR polymer synthesis. 
Therefore, we were inspired to adopt a different approach co-opting the chemical synthesis of 
substrates via controlled, enzymatic, PARP-enabled polymerization.  
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4.2 Approaches Towards Chemoenzymatic Synthesis of PAR Oligomers Using β-NAD+ 
Analogs 
 As described in chapter 1, PARPs synthesize PAR from β-NAD+ by extension of the 
polymer on the free 2’ alcohol to form long and heterogeneous PAR chains (Figure 4.1a). Others 
have shown that unnatural β-NAD+ analogs with deletion of the 2’ alcohol can modify PARP, 
but terminate extension of PAR chains3. Therefore, we reasoned that ADP-ribose polymers and 
oligomers of homogenous length could be generated from β-NAD+ analogs containing a 
removable protecting group (Figure 4.1b). It was envisioned that such oligomers would be 
incorporated by PARP and the excess substrate would be removed to afford homogeneously 
ADP-riboslyated proteins with a removable group on the 2’ alcohol. Deprotection of this group 
and addition of more substrate would result in PARP homogeneously labeled with the ADP-
ribose dimer. We envisioned this process being iterated through many rounds to afford PARP 
automodified with homogeneous PAR. Upon detachment of the polymers from the protein, 
homogeneous PAR could be obtained4. 
 
Figure 4.1. Synthesis of PAR oligomers by a) traditional methods and b) the envisioned 
chemoenzymatic approach with β-NAD+ analogs. 
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4.2.1 Synthesis of β-NAD+ Analogs for PARP Incorporation  
 It was imagined that a β-NAD+ analog that could be iterated by PARP would need to 
possess several characteristics. First, perturbation of the β-NAD+ analog from the natural 
substrate would need to be small enough that its incorporation by PARP was unaffected. Second, 
the protecting group would need to be removable under extremely mild conditions that are 
compatible with biological systems, as the growing polymer would still be protein bound when 
deprotected. Therefore, the 2-nitrobenzyl β-NAD+ analog (4-1, Figure 4.2) was selected as an 
appropriate compound for these studies as the protecting group was small and its removal could 
be effected by treatment with UV light5. Additionally, the propargyl β-NAD+ analog (4-2, Figure 
4.2) was needed because it could be used to conjugate fluorescent tags, thereby enabling the 
monitoring of PARP incorporation of analogs. Oligomers and polymers synthesized containing 
the alkyne provided by 4-2 could also allow for modification of polymers in an analogous 
fashion to the propargyl APD-ribose dimer (2-45). Finally, a deoxy β-NAD+ analog (4-3) was 
desired as it was similar to a compound that is a known substrate for PARP-13.  
 
Figure 4.2. Retrosynthetic analysis of β-NAD+ analogs 4-1, 4-2, and 4-3.  
As nicotinamide mononucleotide (NMN) is available commercially, it was envisioned 
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adenosine monophosphates with a 2-nitrobenzyl group (4-4), propargyl group (4-5), or hydrogen 
atom replacement (4-6) at the 2’ alcohol. In contrast to the synthesis of the ADP-ribose dimer (2-
1), the ultimate coupling in this case was performed without protection of the secondary alcohols 
due to the challenges of synthesis and deprotection of NMN6 and its commercial availability in 
non-protected form.     
In the forward sense (Figure 4.3), 2-nitrobenzyl adenosine monophosphate was 
synthesized by a known procedure involving treatment of adenosine with sodium hydride and 2-
nitrobenzyl bromide to afford compound 4-7 as a single isomer after precipitation7. Similarly, 
propargylation with propargyl bromide and sodium hydride gave diol 4-88. Phosphorylation to 
afford phosphates 4-4 and 4-5 was performed using phosphorous oxychloride in trimethyl 
phosphate. Imidazolide formation followed by coupling with NMN gave 2-nitrobenzyl β-NAD+ 
(4-1) and propargyl β-NAD+ (4-2). Finally, deoxy β-NAD+ was synthesized by imidazolide 
formation of commercially available deoxy adenosine monophosphate (4-6) and coupling to 
NMN to provide deoxy β-NAD+ (4-3). 
 
Figure 4.3. Synthesis of β-NAD+ analogs 4-1, 4-2 and 4-3. i. R-Br (1.3-1.5 eq), NaH (1.1-1.3 
eq), DMF, 0oC, 3 h, 52% for 4-7, 48% for 4-8. ii. POCl3 (3 eq), PO(OMe)3, 0oC, 1.5 h, reverse 
phase purification 42% for 4-4, 40% for 4-5. iii. Imidazole (16 eq), 2,2’-dipyridyldisulfide (3.2 
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eq), PPh3 (3.2 eq), Et3N (2.3 eq), DMSO, rt, 3 h. iv. NMN (0.8 eq), MnCl2 (1.5 eq), MgSO4 (2 
eq), formamide, rt, 15 h, 33% for 4-1, 50% for 4-2, 56% for 4-3.  
 
 
4.2.2 Identification of an Active PARP for Chemoenzymatic Synthesis 
 With the appropriate NAD+ analogs synthesized, an active enzyme capable of the 
synthesis of PAR oligomers was needed. Several enzymes possess PARP activity including 
PARPs-1, -2, and -3 as well as tankyrases-1 and -2 (PARPs -5a and -5b) 9. Expression of full 
length PARP-1 is known to be challenging and while occasionally performed in E. coli10, is most 
frequently performed in baculovirus systems in insect cells11. While expression of the PARP 
catalytic domain is known to proceed well in E. coli, its activity is reported to be substantially 
lower than the full length enzyme due to the requirement of the protein to bind DNA through its 
zinc finger domains12. The catalytic domain of tankyrase has been reported to have good, but 
reduced, PARP activity relative to full length PARP-113. However, for some applications the 
ease of expression of catalytic tankyrase relative to PARP-1 has overcome its reduced activity4. 
We therefore decided to obtain and assess the ability of several enzymes (and domains of 
enzymes) to both synthesize PAR from β-NAD+ as well as incorporate the unnatural analogs 
synthesized in chapter 4.2.1. 
 The catalytic domain of human tankyrase-1 was expressed in E. coli as a GST-fusion 
protein following a previously described procedure in our laboratory14. Several types of activity 
assays were performed to assess the ability of these proteins to incorporate natural β-NAD+ as 
well as the unnatural analogs synthesized in chapter 4.2.1. Human tankyrase-1 was found to have 
low levels of PAR synthesis activity when analyzed by sypro ruby staining (Figure 4.4a). Some 
PAR formation by tankyrase-1 could be seen by immunoblot (Figure 4.4b), but incorporation of 
alkyne β-NAD+ (4-2) was not observed by in-gel fluorescence after conjugation of Cy3 (Figure 
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4.4c). From these results we interpreted that while tankyrase-1 likely does produce PAR (as 
evident by immunoblot, figure 4b), such activity is likely low relative to full length PARP-1 and 
tankyrase-1 may not be able to incorporate unnatural β-NAD+ analogs.   
 
Figure 4.4. Assessment of PAR synthesis activity of the catalytic domain of tankyrase-1. a) 
Treatment of tankyrase-1 with natural β-NAD+ does not cause noticeable retardation of protein 
migration by SDS-PAGE and sypro ruby staining. b) Some PAR formation can be seen by 
immunoblot. c) Incorporation of alkyne β-NAD+ (4-2) is not seen by in gel fluorescence after 
Cy3 conjugation.  
 
 Having demonstrated low activity of tankyrase-1 and concluded that it is therefore 
unlikely to be ideal for chemoenzymatic PAR synthesis, we next assessed the ability of full-
length human PARP-1 to incorporate β-NAD+. Full-length human PARP-1 expressed in Sf21 
insect cells was purchased from Enzo Life Sciences. Though purchase of the protein was not a 
sustainable solution due to its cost (10 µg/$292), preliminary assessment of its ability to 
incorporate natural and unnatural β-NAD+ was desired. It was found that full length human 
PARP-1 robustly produced PAR as evident by retardation of migration of the protein by SDS-
PAGE and coomassie staining (Figure 4.5a). PAR formation could also be seen by 
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immunoblotting for PARP-1 (Figure 4.5b). Finally, PARP-1 was able to incorporate alkyne β-
NAD+ (4-2) as evident by in gel fluorescence (Figure 4.5c). These experiments strongly 
suggested that full length PARP-1 would be an ideal enzyme for these studies, though its 
procurement presented a greater challenge. 
 
Figure 4.5. Assessment of activity of full-length human PARP-1. a) Treatment of PARP-1 with 
natural β-NAD+ was well as a mixture with alkyne β-NAD+ (4-2) results in decreased migration 
of PARP-1 by SDS-PAGE visualized by coomassie blue staining. b) The effect of a) can be seen 
by immunblot for PARP-1. c) Incorporation of alkyne β-NAD+ (4-2) is seen by in gel 
fluorescence after Cy3 conjugation. 
  
4.3 Expression, Purification and Activity of Full-length Human PARP-1 
 With full length human PARP-1 identified as the appropriate enzyme for the controlled 
synthesis of PAR polymers, the protein needed to be expressed so that it could be obtained in 
greater quantity and at lower cost than what was obtained from commercial sources. While often 
expressed in insect cells, limited reports of expression of PARP-1 in E. coli do exist10. Upon 
obtaining an appropriate plasmid from the Ahel Lab, His6-PARP-1 was expressed and purified 
using a two step method involving Ni-NTA and subsequent Heparin chromatography10 (Figure 
4.6a,b). Upon concentration, PARP-1 expressed via this method was shown to be active both 
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towards polymerization of natural β-NAD+ (Figure 4.6c), as well as towards incorporation of 
alkyne β-NAD+ (4-2) (Figure 4.6d).   
 
Figure 4.6. Expression and purification of full length human PARP-1 a) Initial purification by 
Ni-NTA chromatography. b) Fractions from heparin chromatography containing pure protein. c) 
Ability of expressed PARP-1 to incorporate natural β-NAD+ as seen by coomassie staining. d) 
Expressed PARP-1 incorporates alkyne β-NAD+ (4-2) as seen by Cy3 in gel fluorescence. 
 
 
4.4. Attempts to Chemoenzymatically Synthesize PAR Oligomers Using Compound 4-1 
 Having chemically synthesized β-NAD+ analogs 4-1, 4-2 and 4-3, and having 
recombinantly expressed PARP-1 in acceptable yield, attempts to use these tools for the 
chemoenzymatic synthesis of short PAR oligomers were undertaken. A simple SDS-PAGE assay 
was developed to monitor β-NAD+ incorporation (Figure 4.7). In this assay, PARP-1 was 
immobilized to magnetic streptavidin beads by reacting the protein with biotin maleimide via its 
free cysteine residues. The protein was then incubated with oNB β-NAD+ (4-1) for 45 min. Next, 
excess substrate was removed by washing with buffer and the protein was treated with UV light 
to photochemically cleave the oNB protecting group on the ADP-ribosylated PARP-1. 
Subsequent treatment with β-NAD+ alkyne (4-2) should in theory lead to incorporation at the 
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newly deprotected ADP-ribose sites and formation of PARP homogenously labeled with alkyne 
containing ADP-ribose dimer. Such a spices would then be labeled with Cy3 and visualized by in 
gel fluorescence.  
Figure 4.7. Workflow for SDS-PAGE assay involving unnatural β-NAD+ analogs. 
 In practice, performance of the assay as described did not lead to robust formation of 
PARP labeled with the ADP-ribose dimer as expected. While a fluorescent band is seen when 
this process is carried out, it is also seen for the control where treatment with UV light is not 
carried out, suggesting that the fluorescent band seen is not solely due to the ADP-ribose dimer 
as expected (Figure 4.8a). While excess deoxy β-NAD+ (4-3) is capable of inhibiting 
incorporation of alkyne β-NAD+ (4-2) in a dose-dependent manner (Figure 4.8b), no conditions 
were found to elicit this effect for oNB β-NAD+ (4-1). It was therefore concluded that oNB β-
NAD+ (4-1) was a poor substrate for PARP-1 and that its inability to block incorporation of 
alkyne β-NAD+ (4-2) was the result of it not being incorporated itself. 
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Figure 4.8. Chemoenzymatic synthesis of ADP-ribose oligomers by in gel fluorescence using 
oNB β-NAD+ (4-1). a) oNB β-NAD+ (4-1) does not block incorporation of alkyne β-NAD+ (4-2). 
Alkyne β-NAD+ (4-2) incorporation can be blocked by treatment with deoxy β-NAD+. 
 
4.5 Design of a Second Generation Photocleavable β-NAD+ Analog 
 After determining that PARP-1 could not incorporate oNB β-NAD+ (4-1) as a substrate, a 
new design was needed. That propargyl β-NAD+ was incorporated by PARP-1 was encouraging, 
as it suggested that incorporation of analogs modified at 2’ position of β-NAD+ by PARP was 
possible. It was reasoned that because the propargyl group is substantially smaller than the oNB 
group, perhaps decreasing the size of the protecting group or moving it further away from the 2’-
OH of β-NAD+ could be a successful strategy. The [2(-nitrobenzyl)oxy] methyl group (nbm) was 
therefore chosen as a replacement for the orthonitrobenzyl group as used for compound 4-115. 
Upon photolysis of an analog containing this group (4-9), β-NAD+ would be generated along 
with formaldehyde (Figure 4.9). We hypothesized that the methylene spacer of this compound 
would move steric bulk away from the enzyme, facilitating better incorporation of this analog. 
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Figure 4.9. Second generation photochemical β-NAD+ analog nbm β-NAD+ (4-9) and its 
cleavage to β-NAD+ and formaldehyde upon photolysis. 
 
 In the forward sense, nbm β-NAD+ (4-9) was synthesized in a short sequence 
commencing from N-benzoyl-5’-dimethoxytrityl adenosine (Figure 4.10). Alkylation using a 
known procedure gave alcohol 4-1115. Deprotection of the dimethoxytrityl group and benzoyl 
group was accomplished in a two step process15. First, treatment with formic acid removed the 
dimethoxytrityl group, and subsequent treatment with ammonia in methanol cleaved the N-
benzoyl group to give compound 4-12. Strategically, the installation of protecting groups to give 
4-10 followed by their quick removal after alkylation to give 4-12 was less than desirable. Still, 
the protection of compound 4-11 did facilitate its purification relative to systems where the 
alkylation was performed without protecting groups and this strategy was therefore used. 
Phosphorylation of 4-12 proceeded smoothly to give 4-13 after C18 purification. Finally, 
phosphorimidazolide formation and coupling to NMN gave nbm β-NAD+ (4-9) in only trace 
yields. The yields of 4-9 in this case are poor because of hydrolysis of the imidazolide under the 
reaction conditions forms 4-13, which is challenging to separate from 4-9 even by preparative 
HPLC. However, the quantities afforded of 4-9 were sufficient to test in preliminary 
experiments. 
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Figure 4.10. Synthesis of nbm β-NAD+ (4-9). i. nbm-Cl (1.5 eq), Bu2SnCl2 (1.1 eq), EtNiPr2 (5 
eq), (CH2Cl)2, 60oC, 2 h, 49%. ii. HCO2H, CHCl3, 0oC, 1 h, 81%. iii. NH3/MeOH, rt to 40 oC, 24 
h, 66%. iv. POCl3, 0oC, 1 h, 49%. v. CDI, CH3CN, rt, 60 h. vi. NMN, MnCl2, MgSO4, 
Formamide, rt, 18 h, trace for two steps.   
  
 
4.6 Use of Second Generation nbm β-NAD+ (4-9) for Chemoenzymatic Synthesis 
 Upon accessing the second generation photocleavable β-NAD+ analog (4-9), its ability to 
perform in the chemoenzymatic synthesis assay described in section 4.4 was evaluated. 
Gratifyingly, incubation of this analog with PARP-1 was capable of blocking incorporation of 
alkyne β-NAD+ (4-2) (Figure 4.11) minimally suggesting that the new analog is a better substrate 
for PARP-1 than the original oNB β-NAD+ (4-1). Unfortunately, in contrast to what was seen in 
the oNB β-NAD+ (4-1) incorporation experiments, PARP-1 was not able to append alkyne β-
NAD+ (4-2) upon photocleavage (Figure 4.11). While the exact reason for this inability to iterate 
is unknown, we suspected that solid phase attachment of PARP-1 combined with the aldehyde 
byproducts released upon photocleavage might be responsible. 
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Figure 4.11. Chemoenzymatic synthesis of ADP-ribose oligomers by in-gel fluorescence using 
nbm β-NAD+ (4-9). 
 
4.7. Attempts to Perform Chemoenzymatic Synthesis via the in trans Activity of PARP-1  
 All previous approaches in this chapter have relied on the ability of PARP-1 to undergo 
automodification (in cis activity) and have used PARP-1 as the substrate on which PAR 
oligomers and polymers are built. Having not identified a good method by which to 
chemoenzymatically synthesize PAR oligomers via the automodification activity of PARP-1, we 
next sought to pursue an alternative chemoenzymatic synthesis strategy through PARP-1’s 
ability to modify substrates in trans. A number of proteins, most commonly histones, are known 
to be in trans substrates for PARP-111,16. Additionally, a few examples exist where short 
synthetic peptides derived from PARP-1 or other proteins have served as substrates for PAR 
synthesis mediated by PARP-117-19. We reasoned that an advantage of such an approach, in 
contrast to the solid phase, would be the utilization of PARP-1 in solution. Use of PARP-1 in 
solution could potentially lead to increased enzymatic activity relative to when appended to the 
solid phase.  
 Synthetic peptides known to be substrates for PARP-117,19 were obtained and we 
incubated them with compounds 4-2 and/or 4-3. Incorporation of these analogs was monitored 
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by LCMS. Unfortunately, these peptides were not labeled with the compounds under any 
conditions tested. While this result is somewhat surprising, literature reports suggesting that 
these peptides serve as acceptors for PARylation rarely report yields for such reactions and 
usually report automodification if it is detected by MS or immunoblot17-19. Thus, it is likely that 
the actual conversion and synthesis of PAR on these peptides is low in a preparative sense. 
 
4.8. In trans Activity of PARP-1 Using the ADP-ribose Dimer (2-1) as a “Seed” for 
Polymerization 
 With the failure of the in cis (sections 4.4 and 4.6) and in trans (section 4.7) approaches 
to chemoenzymatic synthesis, we reevaluated our approach and more extensively considered the 
process of PAR synthesis by PARP-1. While to this point much attention had been focused on 
what protein or peptide substrates PARP-1 recognizes for PARylation, we reasoned that as PAR 
polymers become increasingly long, PARP-1 likely recognizes the polymer itself and not the 
substrate protein or peptide when adding units to the polymer. Therefore, we reasoned that free, 
non-protein bound PAR oligomers in solution could serve as substrates for further PARylation.  
 To test this hypothesis, the ADP-ribose dimer (2-1) was treated with alkyne β-NAD+ (4-
2) and PARP-1 and the mixture was analyzed by LCMS (Figure 4.12). Gratifyingly, small 
amounts of formation of the propargyl ADP-ribose trimer were seen, especially when Mg2+ ions 
were omitted from the reaction buffer (Figure 4.12b). Omission of Mg2+ has been reported to 
increase the in trans activity of PARP-1, while inclusion of Mg2+ is believed to bias PARP-1 
towards automodification activity20. Attempts to optimize this reaction further by inclusion of 
putrescine in the reaction buffer were unsuccessful20.     	
	 128 
 
Figure 4.12. Formation of propargyl ADP-ribose trimer by treatment of ADP-ribose dimer (2-1) 
and propargyl β-NAD+ with PARP-1. a) Standard buffer with Mg2+. b) Buffer omitting Mg2+. 
The peak at 5.88 in b) is consistent with the mass of the propargyl ADP-ribose by mass 
spectrometry.  
 
 With the exciting result in Figure 4.12b, attention was turned to investigating the 
generality of this approach, optimizing, and extending it to a system in which natural ADP-ribose 
oligomers and polymers could be synthesized. If natural β-NAD+ could also perform this in trans 
activity and if such activity could be controlled, natural ADP-ribose oligomers could be 
produced. It was found that treatment of the ADP-ribose dimer (2-1) with β-NAD+ could, in fact, 
effect formation of the ADP-ribose trimer (Figure 4.13). This activity was found to be 
concentration dependent, as high concentrations of β-NAD+ (Figure 4.13a) failed to produce 
formation of the ADP-ribose trimer, while intermediate concentrations (Figure 4.13c) were more 
effective. The process does require PARP-1 (Figure 4.13c vs. Figure 4.13d). Additionally, the 
amount of the ADP-ribose trimer formed relative to the amount of propargyl ADP-ribose trimer 
formed in Figure 4.12 was greater, suggesting that β-NAD+ is a better substrate than the 
unnatural propargyl β-NAD+. It was also found that nbm β-NAD+ (4-9) was inactive in this 
assay, as PARP-1 was unable to synthesize an nbm ADP-ribose trimer from the ADP-ribose 
dimer (2-1) and nbm β-NAD+ (4-9)  (data not shown). These results could explain the failure of 
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the in cis approach described previously, as the unnatural β-NAD+ described above may simply 
be poor substrates for PARP-1 incorporation. Additionally, ADP-ribose dimer formation (2-1)  
could be detected from treatment of ADP-ribose with β-NAD+ (data not shown), but the 
conversion was generally lower than what could be seen for ADP-ribose dimer (2-1) conversion 
to ADP-ribose trimer. Formation of the ADP-ribose tetramer in this assay was detected but was 
minimal. This result suggests that the low concentrations of trimer present in the reaction 
coupled with the low enzymatic efficiency of PARP-1 towards this process combine to not lead 
to runaway polymerization to longer oligomers.   
 
Figure 4.13. The ADP-ribose trimer can be formed from β-NAD+ and the ADP-ribose dimer (2-
1), though not at high concentrations of β-NAD+ a) 5 mM concentration of β-NAD+ with PARP-
1 and the ADP-ribose dimer (2-1) b) 5 mM concentration of β-NAD+ and the ADP-ribose dimer 
(2-1) without enzyme c) 500 µM concentration of β-NAD+ with PARP-1 and the ADP-ribose 
dimer (2-1) d) 500 µM concentration of β-NAD+ and the ADP-ribose dimer (2-1) without 
enzyme. 
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4.9. Preparative Synthesis of ADP-ribose	Oligomers Using the “Seed” Method 
 The synthesis of the ADP-ribose trimer from the ADP-ribose dimer (2-1) as demonstrated 
in figure 4.13 was next scaled up to form meaningful quantities of the trimer and enable 
synthesis of even longer oligomers. Thirty fold scale-up of the conditions in figure 4.13 allowed 
for synthesis, purification, and isolation and characterization of the trimer by LCMS (Figure 
4.14). It was found that the trimer could be isolated as a mostly pure substance, though non-
insignificant amounts of a byproduct lacking the terminal ribose phosphate was formed. This 
product is not seen in the crude reaction (as in figure 4.13) and is likely a result of decomposition 
of the product upon concentration. Base lability of ADP-ribose oligomers as has been reported 
previously4,21. Modification of the conditions under which oligomers are isolated will likely 
resolve this decomposition issue and more cleanly provide trimer. 
 
Figure 4.14. Isolation of the ADP-ribose trimer from the chemoenzymatic route. a) HPLC trace 
showing trimer but with some cleavage product. b) MS trace of major peak showing [M-2H]2- = 
819, consistent with the ADP-ribose trimer. 
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4.10 Conclusions and Outlook 
 The chemoenzymatic synthesis of ADP-ribose oligomers as described in sections 4.8 and 
4.9 represents a promising approach for the generation of PAR oligomers and polymers. Key to 
this approach is the ability of PARP-1 to modify substrates in trans with enough efficiency to 
make the reaction synthetically useful, but not so extensively that runaway polymerization is 
seen. As previous approaches to enzymatic synthesis of PAR oligomers and polymers have not 
started with an oligomer of defined length and used it as a substrate for synthesis, this ability of 
PARP-1 has not been previously recognized.  
 How PARP-1 is able to selectively carry out this process in a controlled manner without 
runaway polymerization is still not entirely clear. One explanation is simply the math of the 
process. For instance, assume that PARP-1 conversion of the ADP-ribose dimer to the 
corresponding trimer occurs in about 30% yield (this would be consistent with figure 4.13). 
Next, assume that further conversion of the trimer to the tetramer occurs in similar yield. 
Therefore, the yield of dimer to tetramer in this process would be: 30% x 30% = 9%. This 
number is smaller than but not grossly inconsistent with the amount of tetramer observed 
experimentally upon LCMS analysis. By extension of this analysis, the yield of the pentamer 
from the dimer would be about 3%, and therefore likely barely detectable.  
In reality, the yield of the second step may be lower or higher than the yield of the first. 
The amount of trimer in solution available for automodification at 30% conversion (150 µM) is 
much reduced relative to both amount of dimer available at the beginning of the experiment (500 
µM), and the amount of dimer available at 30% conversion to trimer (350 µM). Therefore, one 
could imagine that under the experimental conditions the propensity for conversion of trimer to 
tetramer is lower. However, preliminary data (not shown) suggests that conversion of the 
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concentrated trimer to the tetramer occurs in higher yield than conversion of the dimer to the 
trimer (and both occur better than conversion of ADP-ribose to the dimer). Experimentally, the 
first factor seems to play a larger role than the second, though how this process will progress for 
longer oligomers remains to be seen. Regardless, even the selective synthesis of narrow 
distributions of PAR would have advantages over enzymatic synthesis and separation of PAR of 
all lengths between 2 and 200.   
 Homogeneous synthesis of short PAR oligomers of defined length should allow debated 
questions about PAR biology to be answered. For example, the exo vs. endo preference of PARG 
is an unresolved issue in the literature22,23. Using the approach described in sections 4.8 and 4.9 
we imagine being able to access the ADP-ribose tetramer to address this issue. If PARG is an 
enzyme with primarily endo activity, we would expect to see two molecules of the ADP-ribose 
dimer (2-1) upon PARG treatment of the tetramer. However, if PARG possesses primarily exo 
activity, we would expect to see the trimer and a molecule of ADP-ribose upon treatment. The 
use of short PAR oligomers (minimally the ADP-ribose tetramer) should resolve these questions.  
 
 
4.11 Experimental 
 
 
Expression and Purification of the catalytic domain of GST-Tankyrase-1 
 
Expression and purification was performed essentially as described previously14 with 
slight modifications. Ampicillin and chloramphenicol were used at concentrations of 100 µg/mL 
and 35 µg/mL, respectively. Expression was performed on a 1 L scale and IPTG was added at a 
concentration of 250 µM once the culture had reached OD600 of 0.85. Expression was carried out 
for 20 h at 15oC.  
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Expression and purification of full length human PARP-1 
PARP-1 was expressed and purified essentially as described10.  Briefly, the plasmid for 
full-length human PARP-1 was a gift from the Ahel Lab. The plasmid was transformed into E. 
coli Rosetta cells and grown overnight in 10 mL of LB containing 50 µg/mL and 35 µg/mL 
kanamycin and chloramphenicol, respectively. The overnight culture was added to 1 L of LB 
(also with 50 µg/mL kanamycin and 35 µg/mL chloramphenicol) and the culture was induced 
with 200 µM IPTG once it had reached an OD600 of 0.9. The expression was performed for 20 h 
at 16oC. Harvesting and lysis was performed as described. The protein was purified by Ni-NTA 
chromatography and Heparin chromatography in a 4oC room as described. The size exclusion 
step was omitted.   
 
Tankyrase Activity Assay 
To a buffered solution (100 mM Tris, 10 mM MgCl2, 1 mM DTT pH = 7.6) of β-NAD+ 
or β-NAD+ (1 mM or as indicated) was added Tankyrase-1 to a final concentration of 5 µM. The 
reaction was incubated for the indicated time and SDS-loading dye was added and the sample 
heated to 95oC for 5 min. The sample was analyzed by SDS-PAGE on a 4-20% or 12% gel. The 
gel was stained with Sypro Ruby protein stain per the manufacturer’s instructions. 
For western blotting, the sample was transferred to a PVDF membrane and blocked in 
5% milk for 1 h at room temperature. The membrane was incubated with anti-PAR primary 
antibody (1:1000 dilution in 5% milk), washed and incubated with the HRP-conjugated 
secondary antibody for 1 h. The blot was imaged using a ImageQuant LAS4010 
For in gel fluorescence experiments, the above setup was employed, but with 100 µM 
NAD+ or NAD+ analog. After the indicated time, sulfo-Cy3-azide (1.4 mM), THPTA (200 mM), 
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CuSO4 (4 mM) and sodium ascorbate (320 mM) were added and incubated for 1-2 h. The 
reactions were put through a illustra Microspin G-25 column and subjected to SDS-PAGE as 
described above. The gels were visualized using a ImageQuant LAS4010.  
 
PARP-1 Activity Assay by SDS-PAGE 
To a buffered solution (100 mM Tris, 10 mM MgCl2, 1 mM DTT pH = 7.6) of β-NAD+ 
or β-NAD+ (1 mM or as indicated) was added calf thymus DNA to a final concentration of 100 
µg/mL. Next, PARP-1 to a final concentration of 150 nM. The reaction was incubated for the 
indicated time and SDS-loading dye was added and the sample heated to 95oC for 5 min. The 
sample was analyzed by SDS-PAGE on a 4-20% or 12% gel and stained with Imperial protein 
stain per the manufacturer’s instructions.  
For western blotting, the sample was transferred to a PVDF membrane and blocked in 
5% milk for 1 h at room temperature. The membrane was incubated with anti-PARP-1 primary 
antibody (1:1000 dilution in 5% milk), washed and incubated with the HRP-conjugated 
secondary antibody for 1 h.  The blot was imaged using a ImageQuant LAS4010. 
For in gel fluorescence experiments, the above experimental conditions were employed 
and the procedure for visualization was the same as for Tankyrase-1.   
 
PARP-1 immobilization and in gel activity assay 
 PARP-1 (10 µM) was treated with biotin maleimide (100 µM) in PARP activity buffer. 
After 30 min, streptavidin magnetic beads (50 µL) were added and the reaction components (as 
above) were added. The reaction was incubated for 40 min at which point the beads were washed 
3x with PARP-1 buffer. The beads were resupsended in PARP-1 buffer and photocleaved for 40 
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min under UV light. The beads were again washed and incubated with the new reaction 
components for 30 min. The beads were washed and incubated with the click chemistry 
components as above for 1 h. The beads were washed, SDS-loading dye was added, the samples 
were heated at 95oC for 5 min and the samples were analyzed by SDS-PAGE as described above.  
 
Synthesis of ADP-Ribose Trimer from ADP-Ribose Dimer (2-1) 
 To a solution containing β-NAD+ (500 µM or as indicated) and the ADP-ribose dimer (2-
1) (500 µM) was added PARP buffer (20 mM Tris, 50 mM NaCl, 100 µM TCEP) and calf 
thymus DNA (100 µg/mL). PARP-1 (1 µM) was added and the reaction was heated at 37oC for 
48 h. The final volume of the reaction was 10 µL. For analysis, the reaction was diluted to a final 
volume of 30 µL and analyzed by LCMS.  
 For preparative reactions, this process was scaled up to a final volume of 100 µL 
(component concentrations as above) and three reactions were run in parallel. The reactions were 
purified using HPLC, and fractions containing product were concentrated. 
 
Chemical Synthesis 
 
Compound 4-7: The general procedure of Ohtuska, Tanaka and Ikehara was followed7. To a 
round bottom flask was added adenosine (1.0 g, 3.74 mmol, 1 eq) and DMF (35 mL). The 
solution was heated to 55oC for 15 min at which point it was cooled to 0oC and sodium hydride 
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(186 mg, 4.86 mmol, 1.3 eq) was added. The solution was stirred at 0oC and 2-nitrobenzyl 
bromide (1.21 g, 5.61 mmol, 1.5 eq) was added and the reaction was stirred at 0oC for 2 h. The 
reaction was poured into ice water (400 mL), filtered and washed two times with ethanol to 
provide compound 4-7 (781 mg, 52%). 
1H NMR (500 MHz, DMSO-d6) δ 8.35 (s, 1H, H-2), 8.09 (s, 1H, H-8), 7.98 (dd, J = 8.1, 1.2 Hz, 
1H), 7.65 – 7.55 (m, 2H), 7.52 – 7.45 (m, 1H), 7.35 (bs, 2H, -NH2), 6.10 (d, J = 6.1 Hz, 1H, H-
1’), 5.49 – 5.36 (m, 2H, -OH), 5.03 (d, J = 14.7 Hz, 1H), 4.86 (d, J = 14.7 Hz, 1H), 4.59 (dd, J = 
6.1, 4.7 Hz, 1H, H-2’), 4.41 (td, J = 5.0, 3.1 Hz, 1H, H-3’), 4.04 (q, J = 3.4 Hz, 1H, H-4’), 3.69 
(dt, J = 12.2, 4.2 Hz, 1H, H-5’), 3.58 (ddd, J = 12.2, 7.1, 3.6 Hz, 1H, H-5’). 
13C NMR (126 MHz, DMSO-d6) δ 156.2, 152.4, 149.0, 147.0, 139.6, 134.0, 133.6, 128.5, 124.4, 
119.4, 86.4, 86.0, 81.1, 68.9, 67.8, 61.4. 
HRMS (ESI) Calculated for C17H19N6O6 [(M+H)+] 403.1366, found 403.1365 
 
Compound 4-8: The general procedure of Madder et al. was followed and the product was 
consistent with that previously reported8. To a 0oC solution of adenosine (1.0 g, 3.74 mmol, 1 eq) 
and tetrabutylammonium iodide (303 mg, 0.82 mmol, 0.22 eq) was added sodium hydride (190 
mg, 4.97 mmol, 1.3 eq). Propargyl bromide (498 mg, 4.19 mmol, 1.1 eq, 80% solution in 
toluene) was added and the reaction was heated to 50oC for 48 h. The compound was purified by 
silica column chromatography to afford compound 4-8 (544 mg, 48%).  
1H NMR (500 MHz, DMSO-d6) δ 8.37 (s, 1H, H-2), 8.15 (s, 1H, H-8), 7.36 (s, 2H, -NH2), 6.03 
(d, J = 6.3 Hz, 1H, H-1’), 5.49 (dd, J = 7.1, 4.6 Hz, 1H, 5’-OH), 5.35 (d, J = 5.1 Hz, 1H, 3’,-
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OH), 4.70 (dd, J = 6.4, 4.8 Hz, 1H, H-2’), 4.44 – 4.31 (m, 2H, H-3’), 4.28 (dd, J = 15.9, 2.3 Hz, 
1H, CH2-CCH), 4.20 (dd, J = 15.9, 2.3 Hz, 1H, CH2-CCH), 4.01 (appq, J = 2.9 Hz, 2H, H-4’), 
3.69 (appdt, J = 12.1, 4.1 Hz, 1H, H-5’), 3.57 (ddd, J = 12.3, 7.1, 3.5 Hz, 1H, H-5’), 3.34 (t, J = 
2.5 Hz, 1H, CH2-CCH) 
13C NMR (126 MHz, DMSO-d6) δ 156.2, 152.5, 149.0, 139.8, 119.3, 86.7, 85.9, 79.7, 79.6, 
77.6, 68.9, 61.6, 56.9. 
HRMS (ESI) Calculated for C13H16N5O4 [(M+H)+] 306.1202, found 306.1207 
 
Compound 4-9: To a 0oC solution of compound 4-7 (100 mg, 0.25 mmol, 1 eq) in trimethyl 
phosphate (0.5 mL) was added POCl3 (0.070 mL, 0.746 mmol, 3 eq) and the reaction was stirred 
at 0oC for 1.5 h. The reaction was quenched with water at 4oC and purified by reverse phase 
chromatography to give compound 4-9 (50 mg, 42%). 
1H NMR (500 MHz, DMSO-d6) δ 8.52 (s, 1H, H-2), 8.16 (s, 1H, H-2), 7.89 (dd, J = 8.1, 1.3 Hz, 
1H), 7.67 (dd, J = 7.9, 1.5 Hz, 1H), 7.50 (td, J = 7.6, 1.4 Hz, 1H), 7.39 (ddd, J = 8.1, 7.4, 1.5 Hz, 
1H), 6.24 (d, J = 5.9 Hz, 1H, H-1’), 5.14 (d, J = 14.5 Hz, 1H), 4.98-4.95 (m, 1H), 4.69 (dd, J = 
5.9, 4.9 Hz, 1H, H-2’), 4.61 (dd, J = 4.9, 3.3 Hz, 1H, H-3’), 4.31-4.27 (m, 1H, H-4’), 4.12 (m, 
2H, H-5’), 3.07 (q, J = 7.3 Hz, 12H), 1.25 (t, J = 7.3 Hz, 18H). 
13C NMR (126 MHz, CD3OD) δ 157.2, 153.8, 150.7, 148.8, 141.1, 135.2, 134.5, 130.1, 129.4, 
125.4, 120.1, 87.3 (d, J = 8.9 Hz), 86.6, 84.1, 71.2, 70.1, 65.5 (d, J = 5.5 Hz), 47.1, 9.3. 
31P NMR (202 MHz, CD3OD) δ 1.91 
HRMS (ESI) Calculated for C17H20N6O9P [(M+H)+] 483.1029, found 483.1031 
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Compound 4-5: To a 0oC solution of compound 4-8 (50 mg, 0.164 mmol, 1 eq) in 
trimethylphosphate (0.33 mL) was added POCl3 (0.045 mL, 0.491 mmol, 3 eq) and the reaction 
was stirred at 0oC for 3 h. The reaction was quenched with cold water and purified by reverse 
phase chromatography to afford compound 4-5 (27 mg, 40%). 
1H NMR (500 MHz, D2O) δ 8.59 (s, 1H, H-2), 8.39 (s, 1H, H-8), 6.22 (d, J = 5.5 Hz, 1H, H-1’), 
4.72 (dd, J = 5.5, 5.1 Hz, 1H, H-2’), 4.63 (dd, J = 5.1, 3.7 Hz, 1H, H-3’), 4.36 (ddd, J = 3.7, 2.4, 
2.4 Hz, 1H, H-4’), 4.32 (dd, J = 16.1, 2.4 Hz, 1H, -CH2CCH), 4.28 (dd, J = 16.1, 2.4 Hz, 1H, -
CH2CCH), 4.16 (ddd, J = 11.7, 4.9, 2.8 Hz, 1H, H-5’a), 4.11 (ddd, J = 11.7, 5.4, 3.2 Hz, 1H, H-
5’b). 2.68 (t, J = 2.4 Hz, 1H, -CH2CCH). 
13C NMR (126 MHz, D2O) δ 149.8, 148.3, 144.7, 142.5, 118.4, 86.4, 84.8 (d, J = 8.6 Hz), 81.5, 
78.7, 76.3, 69.2, 64.41 (d, J = 5.1 Hz), 58.3. 
31P NMR (202 MHz, CD3OD) δ 0.12 
 
Compound 4-1: To a solution of compound 4-4 (50 mg, 0.104 mmol, 1 eq) in DMSO (1.2 mL) 
was added 2,2’-Dithiopyridine (73.1 mg, 0.332 mmol, 3.2 eq), triphenylphosphine (87.1 mg, 
0.332 mmol, 3.2 eq), imidazole (113 mg, 1.664 mmol, 16 eq), and triethylamine (0.033 mL, 
0.239 mmol, 2.3 eq). The reaction was stirred at room temperature for 2 h and purified by 
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reverse phase chromatography. To the isolated imidazolide (10.0 mg, 0.018 mmol, 1.2 eq) was 
added NMN (5.0 mg, 0.015 mmol, 1 eq) and formamide (0.2 mL). To the solution was added 
MnCl2 (2.8 mg, 0.0225 mmol, 1.5 eq) and MgSO4 (3.6 mg, 0.030 mmol, 2 eq). The reaction was 
stirred at room temperature for 16 h and purified by ion-pairing chromatography to give 
compound 4-1 (4.0 mg, 33%). 
1H NMR (500 MHz, D2O) δ 9.14 (s, 1H), 8.95 (d, J = 6.2 Hz, 1H), 8.68 – 8.60 (m, 1H), 8.05 – 
7.92 (m, 3H), 7.86 (s, 1H), 7.45 (d, J = 8.4 Hz, 1H), 7.29 – 7.21 (m, 1H), 7.13 – 7.06 (m, 1H), 
5.89 (d, J = 5.4 Hz, 1H), 5.69 (d, J = 7.5 Hz, 1H), 5.12 (d, J = 11.7 Hz, 1H), 5.07 (d, J = 12.1 Hz, 
1H), 4.59 – 4.42 (m, 3H), 4.37 (s, 1H), 4.33 – 4.17 (m, 3H), 4.05 (tt, J = 15.3, 4.7 Hz, 3H). 
 
Compound 4-2: To a solution of compound 4-5 (27 mg, 0.066 mmol, 1 eq) in DMSO (0.8 mL) 
was added 2,2’-Dithiopyridine (47 mg, 0.21 mmol, 3.2 eq), triphenylphosphine (56 mg, 0.21 
mmol, 3.2 eq), imidazole (72 mg, 1.06 mmol, 16 eq), and triethylamine (0.021 mL, 0.15 mmol, 
2.3 eq). The reaction was stirred at room temperature for 2 h and purified by reverse phase 
chromatography. To the isolated imidazolide (5.5 mg, 0.012 mmol, 1.2 eq) was added NMN (3.4 
mg, 0.010 mmol, 1 eq) and formamide (0.2 mL). To the solution was added MnCl2 (1.9 mg, 
0.015 mmol, 1.5 eq) and MgSO4 (2.4 mg, 0.020 mmol, 2 eq). The reaction was stirred at room 
temperature for 16 h and purified by ion-pairing chromatography to give compound 4-2 (3.5 mg, 
50%). 
1H NMR (500 MHz, D2O) δ 9.17 (s, 1H), 8.98 (d, J = 6.2 Hz, 1H), 8.67 (d, J = 8.1 Hz, 1H), 
8.31 (s, 1H), 8.06 – 7.96 (m, 2H), 5.96 (d, J = 6.3 Hz, 1H), 5.91 (d, J = 5.3 Hz, 1H), 4.64 (d, J = 
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6.2 Hz, 2H), 4.51 (dd, J = 5.3, 3.1 Hz, 1H), 4.41 – 4.35 (m, 1H), 4.32 (t, J = 5.2 Hz, 1H), 4.28 
(dt, J = 5.4, 3.2 Hz, 1H), 4.25 – 4.19 (m, 2H), 4.15 (dd, J = 9.4, 2.3 Hz, 2H), 4.13 – 4.00 (m, 4H), 
2.46 (t, J = 2.3 Hz, 1H). 
 
Compound 4-3: To a solution of 2’-deoxyadenosine 5’-monophosphate (4-6) (100 mg, 0.30 
mmol, 1 eq) in DMSO (3.5 mL) was added 2,2’-Dithiopyridine (214 mg, 0.97 mmol, 3.2 eq), 
triphenylphosphine (254 mg, 0.97 mmol, 3.2 eq), imidazole (328 mg, 4.8 mmol, 16 eq), and 
triethylamine (0.097 mL, 0.70 mmol, 2.3 eq). The reaction was stirred at room temperature for 2 
h and purified by precipitation from NaI in acetone. To the isolated imidazolide (7.3 mg, 0.018 
mmol, 1.2 eq) was added NMN (5.0 mg, 0.015 mmol, 1 eq) and formamide (0.2 mL). To the 
solution was added MnCl2 (2.8 mg, 0.0225 mmol, 1.5 eq) and MgSO4 (3.6 mg, 0.030 mmol, 2 
eq). The reaction was stirred at room temperature for 16 h and purified by ion-pairing 
chromatography. 
1H NMR (500 MHz, D2O) δ 9.30 (s, 1H), 9.10 (d, J = 6.3 Hz, 1H), 8.78 (d, J = 8.2 Hz, 1H), 
8.38 (s, 1H), 8.14 (dd, J = 8.1, 6.3 Hz, 1H), 8.11 (s, 1H), 6.40 (appt, J = 6.9 Hz, 1H), 6.05 (d, J = 
5.5 Hz, 1H), 4.71 (dt, J = 6.3, 3.2 Hz, 1H), 4.51 (t, J = 2.6 Hz, 1H), 4.46 (t, J = 5.3 Hz, 1H), 4.40 
(dd, J = 5.1, 2.7 Hz, 1H), 4.32 (ddd, J = 12.0, 4.2, 2.3 Hz, 1H), 4.28 – 4.24 (m, 1H), 4.23-4.09 
(m, 3H), 2.80 (ddd, J = 13.8, 7.5, 6.0 Hz, 1H), 2.54 (ddd, J = 14.1, 6.4, 3.4 Hz, 1H). 
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Compound 4-11: To a solution of compound 4-10 (500 mg, 0.742 mmol, 1 eq) in 1,2-
dichloroethane (7 mL) was added EtNiPr2 (0.65 mL, 3.71 mmol, 5 eq) and Bu2SnCl2 (248 mg, 
0.816 mmol, 1.1 eq). The reaction was stirred at room temperature for 1 h. After 1 h, 1-
((chloromethoxy)methyl)-2-nitrobenzene (224 mg, 1.1 mmol, 1.5 eq) was added and the reaction 
was stirred at 60 oC for 1 h. The solution was quenched with saturated aqueous ammonium 
chloride, extracted three times with chloroform, dried through sodium sulfate and concentrated. 
The crude reaction was purified by silica column chromatography to afford compound 4-11 (305 
mg, 49%). 
1H NMR (500 MHz, CDCl3) δ 8.94 (s, 1H), 8.62 (s, 1H), 8.16 (s, 1H), 8.02 (ddd, J = 8.7, 5.2, 
1.5 Hz, 3H), 7.66 – 7.58 (m, 1H), 7.56 – 7.50 (m, 3H), 7.49 – 7.37 (m, 4H), 7.34 – 7.30 (m, 4H), 
7.25 – 7.15 (m, 1H), 6.86 – 6.75 (m, 4H), 6.24 (d, J = 5.2 Hz, 1H), 5.12 (t, J = 5.1 Hz, 1H), 4.99 
(s, 2H), 4.87 (d, J = 14.9 Hz, 1H), 4.81 (d, J = 14.8 Hz, 1H), 4.55 (q, J = 4.4 Hz, 1H), 4.29 (q, J 
= 3.9 Hz, 1H), 3.77 (s, 6H), 3.53 (dd, J = 10.6, 3.5 Hz, 1H), 3.42 (dd, J = 10.6, 4.1 Hz, 1H), 2.82 
(d, J = 4.5 Hz, 1H). 
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Compound 4-14: To a 0 oC solution of compound 4-11 (280 mg, 0.33 mmol, 1 eq) in 
chloroform (3.3 mL) was added formic acid (3.3 mL). The reaction was stirred at 0 oC for 2 h. 
The compound was purified by silica column chromatography to afford compound 4-14 (145 
mg, 81%). 
1H NMR (500 MHz, CD3OD) δ 8.63 (s, 1H), 8.51 (s, 1H), 8.13 – 8.05 (m, 2H), 7.95 (dd, J = 
8.2, 1.3 Hz, 1H), 7.68 (t, J = 7.4 Hz, 1H), 7.59 (t, J = 7.7 Hz, 2H), 7.50 (td, J = 7.6, 1.4 Hz, 1H), 
7.40 – 7.28 (m, 2H), 6.26 (d, J = 6.5 Hz, 1H), 5.01 (dd, J = 6.5, 4.9 Hz, 1H), 4.97 (d, J = 7.1 Hz, 
1H), 4.91 (d, J = 7.0 Hz, 1H), 4.67 (d, J = 15.1 Hz, 1H), 4.62 (d, J = 15.0 Hz, 1H), 4.50 (dd, J = 
5.0, 2.7 Hz, 1H), 4.21 (q, J = 2.8 Hz, 1H), 3.90 (dd, J = 12.4, 3.0 Hz, 1H), 3.80 (dd, J = 12.4, 3.0 
Hz, 1H). 
 
Compound 4-12: To a solution of compound 4-14 (131 mg, 0.244 mmol, 1 eq) in methanol (3 
mL) was added ammonia in methanol (3.5 mL of a 7M solution). The reaction was heated to 40 
oC and stirred for 24 h. The solution was concentrated and purified by silica column 
chromatography to afford compound 4-12 (70 mg, 66%). 
1H NMR (500 MHz, d6-DMSO) δ 8.30 (s, 1H), 7.98 (s, 1H), 7.96 (dd, J = 8.2, 1.3 Hz, 1H), 7.56 
(td, J = 7.5, 1.3 Hz, 1H), 7.48 – 7.43 (m, 1H), 7.30 (dd, J = 7.8, 1.6 Hz, 1H), 7.24 (s, 1H), 6.02 
(d, J = 6.5 Hz, 1H), 4.84 – 4.78 (m, 2H), 4.74 (d, J = 6.9 Hz, 1H), 4.71 (d, J = 14.6 Hz, 1H), 4.52 
(d, J = 14.5 Hz, 1H), 4.29 (dd, J = 4.9, 2.8 Hz, 1H), 3.97 (appq, J = 3.3 Hz, 1H), 3.64 (dd, J = 
12.3, 3.7 Hz, 1H), 3.52 (dd, J = 12.2, 3.6 Hz, 1H). 
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13C NMR (126 MHz, d6-DMSO) δ 155.9, 152.3, 148.8, 146.7, 139.7, 133.7, 133.4, 128.4, 128.2, 
124.4, 119.2, 94.1, 86.4, 86.2, 78.4, 69.3, 65.6, 61.4. 
 
Compound 4-13: To a solution of compound 4-12 (20 mg, 0.046 mmol, 1 eq) in trimethyl 
phosphate (0.3 mL) was added phosphorous oxychloride (0.013 mL, 0.139 mmol, 3 eq). The 
reaction was stirred at 0 oC for 2 h and purified by reverse phase chromatography to afford 
compound 4-13 (14 mg, 49%). 
1H NMR (500 MHz, CD3OD) δ 8.57 (s, 1H), 7.99 – 7.90 (m, 2H), 7.53 (td, J = 7.6, 1.3 Hz, 1H), 
7.44 – 7.37 (m, 1H), 7.29 (dt, J = 7.9, 1.1 Hz, 1H), 6.21 (d, J = 6.8 Hz, 1H), 5.01 (d, J = 7.0 Hz, 
1H), 4.92-4-88 (m, 2H), 4.68 (d, J = 15.2 Hz, 1H), 4.61 (d, J = 15.2 Hz, 1H), 4.54 (dd, J = 5.0, 
2.1 Hz, 1H), 4.30 – 4.21 (m, 1H), 4.15 – 4.07 (m, 2H). 
31P NMR (202 MHz, CD3OD) δ 1.98 
 
Compound 4-9: To a solution of compound 4-13 (7.0 mg, 0.011 mmol, 1 eq) in formamide (0.2 
mL) was added carbonyldiimidazole (5.5 mg, 0.034 mmol, 3 eq). The reaction was stirred at 
room temperature for 2 h and quenched with 0.5 mL of 1% Et3N in MeOH (v/v). The solution 
was concentrated and evaporated three times with dry acetonitrile. The solution was dissolved in 
formamide (0.2 mL) and NMN (3.8 mg, 0.011 mmol, 1 eq) was added. MnCl2 (2.2 mg, 0.017 
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mmol, 1.5 eq) and MgSO4 (2.7 mg, 0.023 mmol, 2 eq) were added and the reaction was stirred at 
room temperature for 48 h. The product was purified by preparative HPLC. A small amount was 
isolated and a 1 mM solution was formed based on absorbance compared to compound 4-1. 
LCMS:  
 
β-NAD+ analogs fragment with loss of nicotinamide by ESI m/z = 705.  
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Chapter 5. Mode of Action Studies of the Small Molecule Raptinal 
 
Portions of this chapter are reprinted with permission from: Palchaudhuri, R.; Lambrecht, M.J.; 
Botham, R.; Partlow, K.; van Ham, T.J.; Putt, K.S.; Nguyen, L.T; Kim, S.; Peterson, R.T.; Fan, 
T.; Hergenrother, P.J.; A Small Molecule that Induces Intrinsic Pathway Apoptosis with 
Unparalleled Speed. Cell Rep. 2015, 13, 2027-2036. The contributions of others are mentioned 
throughout.  
 
5.1 Introduction to Raptinal 
 The induction of apoptosis is a major mechanism through which chemotherapeutics kill 
cancer cells1 and the misregulation of apoptosis is a hallmark of cancer2. As such, new molecules 
that induce apoptosis often present promising leads for the treatment of cancers. Also of 
significant importance is the discovery of novel mechanisms of action and phenotypes through 
which to trigger apoptosis. Such discoveries could potentially lead to new classes of 
chemotherapeutics or inform understanding of apoptotic processes. 
 
Figure 5.1. The chemical structure of Raptinal, an unusually fast inducer of apoptosis. 
 The small molecule Raptinal (Figure 5.1) was discovered in a high throughput screen of 
the UIUC Heritage Library by Dr. Karson Putt and shown by Dr. Rahul Palchaudhuri to be an 
unusually rapid inducer of apoptotic cell death. Still, how exactly Raptinal induces apoptosis was 
CHOOHC
Raptinal (5-1)
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not (and even today is not) entirely clear. The experiments herein were performed to elucidate 
the mode of action of Raptinal.  
 
5.2 Raptinal Exists Primarily as a Hydrate in Aqueous Solution 
 While aldehydes and ketones are in equilibrium with their corresponding gem-diol 
(hydrate) species in aqueous solution, generally the equilibrium favors the non-hydrated structure 
in the absence of strong electron withdrawing substituents3. However, it was imagined that the 
dialdehyde structure of Raptinal might lend itself to hydration as is seen for structurally similar 
dialdehyde molecules such as o-phthalaldehyde4. To test this hypothesis, Raptinal was incubated 
in solutions containing d6-DMSO and increasing concentrations of D2O. It was found that 
Raptinal converted to a new species by 1H NMR spectroscopy (Figure 5.2) and that this 
conversion was quite rapid at high concentrations of D2O (Figure 5.3). Two-dimensional NMR 
spectroscopy was used to confirm that the new species formed were the hydrates of Raptinal and 
enabled the assignment the resonances in figure 5.2. Particularly striking is the disappearance of 
the aldehyde resonance (A, figure 5.2) and the corresponding appearance of the hemiacetal 
resonance (9, figure 5.2) in its place. Additionally, due to the cis or trans disposition of the -OH 
groups on the hydrate, two hydrated isomers are formed and the aryl rings on the fluorene of 
each isomer become magnetically non-equivalent.  
The NMR-based approach to monitoring Raptinal hydration only allowed for D2O to 
comprise 25% of the solution, above which point reasonable NMR signals could not observed 
due to the lack of solubility and the millimolar concentrations of compound necessary for 
detection by NMR spectroscopy. However, for cell culture experiments where water contents are 
much higher (generally 99% H2O and 1% DMSO with Raptinal concentrations of 10 µM) 
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hydration is likely even faster and the hydrate is likely the predominant species in solution. The 
ability of the pre-formed hydrate to induce rapid apoptotic cell death was assessed and compared 
to non-hydrated Raptinal which was added to cells as a DMSO solution. It was found that both 
treatments caused > 80% cell death at 2 h as assessed by flow cytometry and that they had 
identical 24 h IC50 values (840 nM) in U-937 cells as determined by the MTS assay. 
 
Figure 5.2. Hydration of Raptinal as seen by 1H NMR Spectroscopy. Only the major hydrated 
isomer is annotated for clarity of the figure, though the minor isomer can be seen.   
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Figure 5.3. Conversion of Raptinal to hydrate as measured by 1H NMR spectroscopy. 
Quantification was performed by comparison of integration of signal E of the dialdehyde form to 
signal 7 of the hydrate form (Figure 5.2) as these were cleanly resolved from other resonances.  
 
5.3 The Synthesis and Biological Evaluation of Analogs of Raptinal 
  With the desire to perform traditional target identification studies5 of Raptinal via a 
compound-tagged approach, analogs were synthesized (Figure 5.4) to develop a structure-
activity relationship profile. Raptinal itself was synthesized via a known6 two-step procedure on 
multigram scale. Additionally, Raptinal could be used as a substrate for reduction to form 5-3 or 
to form oxime 5-4. Treatment of the olefin 5-5 with sodium metal with trapping of carbon 
dioxide afforded the diacid 5-6 from which the anhydride 5-7 and methyl ester 5-8 were 
synthesized. Synthesis of brominated (5-9) and chlorinated (5-10) analogs was performed by the 
method used to synthesize Raptinal. Also, ketone (5-11) and trifluoromethyl ketone (5-12) 
analogs were prepared. 
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Figure 5.4. Synthesis Raptinal (5-1) and analogs. i. Ethyl formate (2.5 eq), KOMe (2 eq), Et2O, 
reflux, 30 min. ii. SOCl2, Et2O, reflux, 3 h, 30% (2 steps). iii. NaBH4 (8.5 eq), EtOH, rt, 45 min, 
80%. iv. H2NOCH3.HCl (2.5 eq), pyridine, rt, 44 h, 70%. v. Na (4.3 eq), Et2O, rt 48 h, then: CO2, 
rt, 15 min, 33%. vi. Ac2O, 70oC, 2 h, 35%. vii. Me3SiCHN2 (3 eq), MeOH, rt, 2 h, 50%. viii. 
KOMe (2 eq), ethyl formate (2.5 eq), Et2O, reflux, 1.5 h. ix. SOCl2, Et2O, reflux 17 h, 8% (2 
steps for 5-9), 29% (2 steps for 5-10). x. KOtBu (2 eq), RCO2Et (1.5 eq), THF, relux, 4 h (56% 
for R = CH3, 64% for R = CF3). xi. SOCl2, reflux, 24 h (34% for R = CH3). xii. Cu powder, 
benzene, reflux, 20 h (38% for R = CH3, 13% for R = CF3 for 2 steps).  
 
 Upon accessing these compounds, they were assessed by Rachel Botham for their ability 
to induce cell death in U-937 cells (Table 5.1). Cell death assays were performed at both the 2 h 
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and 24 h time points in an effort to determine the potency of these analogs relative to Raptinal, 
but also to observe if they retain the rapid cell death phenotype of the parent molecule. These 
experiments reveal that few of these compounds display any measurable activity against U-937 
cells in the 24 h assay. Those compounds that do, specifically 5-9 and 5-10, show greatly 
reduced activity at 2 h relative to Raptinal. From this data we concluded that the aldehyde moiety 
of Raptinal is absolutely essential for biological activity, and its removal leads to compounds that 
are non-cytotoxic. Compounds 5-14, 5-15, and 5-16 show that the presence of the 1,4-dialdehyde 
is not sufficient to induce cytotoxicity, as these compounds were unable to induce cell death at 
similar concentrations as Raptinal.  
As most modifications slowed or abolished the phenotype of Raptinal, we concluded that 
derivative synthesis and pull-down experiments would be unlikely to further elucidate the 
mechanism of the compound. A further complication of derivative synthesis and pull-down was 
the challenges associated with synthesizing dialdehyde Raptinal derivatives. Such compounds 
were found to be unstable to silica column chromatography. Additionally, byproducts from 
synthesis were challenging to remove by chromatography on florisil, a medium on which they 
were stable. Purification by reverse phase chromatography rarely produced clean separation due 
to the hydration phenomenon described previously.   
Compound 24 h IC50 (µM) 24 h IC50 Curve 
% Cell Death at 2 h 
(10 µM treatment) 
 
Raptinal (5-1) 
0.7 ± 0.3 
 
84.9 ± 17.7 
Table 5.1. Evaluation of cell death induced by Raptinal derivatives at 2 h and 24 h in U-937 
cells. Experiments performed by Rachel Botham. 	
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5-3 
33 ± 7 
 
N.D. 
 
5-4 
> 100 
 
N.D. 
 
5-5 
> 100 
 
N.D. 
 
5-6 
> 100 
	
N.D. 
 
5-7 
> 100 
	
N.D. 
 
5-8 
> 100 
 
N.D. 
 
5-9 
6.5 ± 1.6 
 
6.3 ± 0.8 
Table 5.1. (continued) 
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5-10 
4.6 ± 0.9 
	
7.6 ± 1.9 
 
5-11 
> 100 
 
N.D. 
 
5-12 
> 100 
	
N.D. 
 
5-13 
> 100 
 
N.D. 
 
 
 
5-14 
> 100 
 
N.D. 
 
 
5-15 
38 ± 12 
 
N.D. 
 
 
5-16 
> 100 
 
N.D. 
Table 5.1. (continued) 
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5.4 RNAi as a Method for Target Identification and Validation of Raptinal 
 Whole genome shRNA screens have confirmed protein targets of small molecules with 
known modes of action7. While this approach had not previously been reported in de novo target 
identification of small molecules, Dr. Rahul Palchaudhuri performed such an experiment for 
Raptinal with the hope that this method would uncover its mode of action. For this work, cells 
were transfected with shRNA and then treated with Raptinal; the assumption is that cells that 
survive treatment are able to do so because of knockdown of a gene essential in Raptinal-induced 
cell death. Upon performing this shRNA screen for Raptinal, 142 genes with >40 fold 
enrichment for Raptinal and 45 that were enriched >5 fold with two or more transcripts per gene 
were identified. In addition to these 187 (142 single transcirpt + 45 two or more transcripts) an 
additional 58 genes known to be associated with apoptosis were selected for follow-up (for a 
total of 142 + 45 + 58 = 245). For follow-up, siRNAs were selected (single siRNA per gene) and 
their ability to prevent Raptinal-induced caspase-3 activity in a cell-lysate caspase-3/-7 activity 
assay using a fluorescent substrate was determined. Dr. Palchaudhuri performed the initial 
rescreen of siRNAs and found 44 “rehits,” or siRNAs that resulted in <40% of maximal caspase 
activation using the fluorescence assay.   
 With 44 rehits protecting from Raptinal-induced cell death to varying degrees, we sought 
to understand which of these RNAs were specifically protecting from Raptinal and which were 
more generally protective from apoptosis, but were not necessarily specific to Raptinal’s 
mechanism.  To interrogate this, a co-screen was conducted of these rehits compared to 
staurosporine (STS) and doxorubicin, two inducers of apoptosis that we expected to 
mechanistically induce apoptosis in different ways than Raptinal (Figure 5.5). Very few RNAs 
were found that were selective for Raptinal over both STS and doxorubicin, suggesting that 
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many of the siRNAs in the collection were protecting generally from apoptosis and less from a 
specific aspect of Raptinal’s mode of action. Additionally, we were disappointed to find that the 
magnitude of protection for most siRNAs was small compared to the robust protection seen by 
those for apoptotic proteins such as caspase-3, diablo, and APAF-1. If a given protein was 
directly involved in Raptinal’s mode of action, we would expect its knockdown by siRNA would 
nearly quantitatively protect from induction of caspase-3 activity. The large degree of protection 
from RNAs for apoptotic proteins such as caspase-3, APAF-1, and diablo was further support for 
Raptinal-induced apoptosis being highly consistent with the intrinsic pathway.   
 
Figure 5.5. Percent caspase-3 activity after treatment with Raptinal, doxorubicin (Dox), or 
staurosporine (STS) for 44 follow-up siRNAs in MIA PaCa-2 cells. These experiments were 
performed with assistance from Dr. Kathy Partlow.  
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5.5 Small Molecule Cytoprotectants to Inform Raptinal’s Mode of Action 
   In addition to RNAi as a method through which to specifically target genes (and 
therefore proteins) to find targets important in Raptinal’s mode of action, small molecules with 
known biological activity were tested for their ability protect from Raptinal-induced cell death 
(Figure 5.6). The strongest protection was seen from agents that affect the electron transport 
chain. For instance, inhibitors of complex I (rotenone), complex III (anitmycin A), complex IV 
(sodium azide and potassium cyanide) and ATP synthase (oligomycin) all provided high levels 
of protection as did a mitochondrial respiration uncoupler (FCCP). These results are consistent 
with previous reports of oligomycin protecting from cytochrome c release in apoptosis8 and the 
importance of the mitochondrial proton pump in apoptosis9. While the exact mechanisms of how 
these reagents affecting the mitochondrial electron transport chain protect from apoptosis is not 
entirely clear, it is reasonable given the important role of cytochrome c in both processes. 
 
Figure 5.6. Raptinal-induced cell death can be protected by treatment with various small 
molecule cytoprotectants. All experiments were performed with 2 h pretreatment with 
cytoprotectants at optimized concentrations and with 2 h treatment of Raptinal at 10 µM in U-
937 cells. Cell death was assessed by flow cytometry. Data for certain compounds was 
contributed by Dr. Rahul Palchuldhuri and Rachel Botham.  
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5.6. Conclusions and Outlook on Raptinal 
 The small molecule Raptinal is especially unique among small molecules given its ability 
to induce rapid and clean apoptosis across many cell lines. While the exact mechanism by which 
it triggers induction of the apoptotic cascade is not entirely clear, the data in figures 5.5 and 5.6 
clearly supports that it is entirely consistent with the intrinsic (mitochondrial) pathway of 
apoptosis. Given the flat SAR of Raptinal as described in section 5.3, genetic approaches to 
target identification similar to the shRNA screen/siRNA follow-up will likely be the most fruitful 
going forward. The challenge with such approaches is distinguishing candidate targets from 
proteins that are identified as hits because they are generally protective from apoptosis processes 
rather than specific to a given molecule. In the future, an experiment such as the shRNA screen 
should be done with co-screening with mechanistically similar molecules to Raptinal such as 
STS. While Dr. Palchaudhuri did some triaging and comparison of Raptinal shRNAs with those 
for DNQ, the mechanistic dissimilarities between the two compounds (DNQ induces cell death 
through a ROS-based mechanism inconsistent with apotosis) makes such analyses less useful 
than had they been done for agents that directly induce apoptosis.      
 
5.7 Experimental 
Cell culture conditions 
All cells were grown in RPMI 1640, DMEM or EMEM media supplemented with 10% 
FBS, 1% penicillin-streptomycin and incubated at 37 ºC in 5% CO2, 95% humidity incubator. 
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MTS assay for suspension cells 
Serial dilutions of compound in 100% DMSO were added in triplicate (2 µL to each well) 
to empty wells of a 96-well plate. Suspension cells (HL-60, U-937, SKW 6.4, Jurkat WT, Jurkat 
CASP8-/-, Jurkat FADD-/-, Jurkat Bcl-2) cells in RPMI 1640 media were added to 96-well plates 
(198 µL containing 4 x 104 cells) and the cells incubated for 24 hours. A solution containing the 
soluble tetrazolium salt ((3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt; MTS) and the electron coupling reagent, phenazine 
methosulfate (PMS) was prepared according to the manufacturer’s instructions (Promega) and 20 
µL added to each well. The plates were incubated at 37 ºC for 15-45 min and the absorbance at 
490 nm was measured using a SpectraMax Plus 384 well plate reader (Molecular Devices, 
Sunnyvale CA). The mean IC50 values and standard deviations were determined from three 
independent experiments. 
 
Protection assays using small molecule inhibitors 
For protection assays, U-937 cells (0.5 x 106 cells/mL) were pretreated with the 
prospective protective agents for 2 hours at the following concentrations: Sodium fluoride (1 
mM), cyclosporine A (10 µM), oligomycin A (10 µM), FCCP (10 µM), cycloheximide (10 µM), 
TTFA (1 mM), atpenin A5 (1 µM), actinomycin D (2 µM), rotenone (200 µM), potassium 
cyanide (1 mM), sodium azide (1 mM) antimycin A (100 µM), sodium pyruvate (5 mM), tempol 
(400 µM), granzyme B inhibitor I (50 µM), calpain inhibitor I (50 µM), MnTBAP (20 µM), DPI 
(10 µM), allopurinol (1 mM), dicoumarol (50 µM), tiron (10 mM), Ru360 (10 µM), NAC (10 
mM), DIDS (2 mM), and Q-VD-OPh (50 µM). The cells were then co-treated with Raptinal at 
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10 µM for 2 hours prior to analysis by propidium iodide/FITC-annexin V staining and flow 
cytometry. 
 
Transfection and screening of siRNA constructs 
All RNA interference reagents were purchased from Life Technologies (Carlsbad, CA). 
The optimal transfection conditions (i.e., siRNA concentration, time, cell number, etc.) were 
determined using the KDalert GAPDH Assay Kit according to the manufacturer’s instructions.  
Human Silencer Select siRNA was purchased for gene targets of interest and diluted in DEPC 
water. The siRNA (5 nM final conc.) was complexed in OptiMEM media with RNAiMAX 
lipofectamine (0.3 µL lipofectamine/pmol siRNA) for 5 min in the well prior to addition of cells. 
MIA PaCa-2 cells were trypsinized, washed in PBS, resuspended at 50 cells/µL in OptiMEM 
containing 4% FBS, added to the well (100 µL/96-well or 2.5 mL/6-well), and grown for 4 days.  
Silencer® Negative Control siRNA was used in control wells. After silencing, fresh OptiMEM 
with 4% FBS was supplied to the cells (half immediately and half at time of compound addition). 
 
Chemistry  
General 
Compounds 5-5, 5-13, 5-14 and 5-15 are commercially available, were purchased and 
were used as received. All reactions were run in flame or oven dried glassware under an 
atmosphere of dry nitrogen unless otherwise noted. Acetonitrile, tetrahydrofuran, methanol and 
methylene chloride used in reactions were obtained from a solvent dispensing system. Diethyl 
ether was distilled from sodium metal. 4 Å molecular sieves were dried at 200 °C on high 
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vacuum overnight. Pyridine was distilled from CaH2 and stored on 4 Å molecular sieves. All 
other reagents were of standard commercial purity and were used as received.  
 Analytical thin-layer chromatography was performed on EMD Merck silica gel plates 
with F254 indicator. Plates were visualized with UV light (254 nm) or staining with p-
anisaldehyde. Silica gel for column chromatography was purchased from Sorbent Technologies 
(40-75 µm particle size).   
 Unless otherwise indicated, 1H, 13C, 19F, and 31P NMR spectra were recorded at 500, 125, 
470 and 203 MHz, respectively. 1H and 13C NMR spectra were referenced to tetramethylsilane or 
the residual solvent peak. 19F NMR spectra were referenced using C6F6 as an internal standard (-
164.9 ppm). Chemical shifts are reported in ppm and multiplicities are reported as s (singlet), d 
(doublet), t (triplet), q (quartet), p (pentet), h (hextet), hep (heptet), m (multiplet), and b (broad). 
Mass spectrometry analysis was performed by the University of Illinois Mass Spectrometry 
Center.  
 
Procedures for Chemical Synthesis 
 
Raptinal (5-1): A modified version of the procedure of Curtin and co-workers was followed6. 
To a solution of fluorene (5-2) (4.4 g, 26.4 mmol, 1 eq) and potassium methoxide (3.7 g, 52.8 
mmol, 2 eq) in diethyl ether (50 mL) was added ethyl formate (5.3 mL, 66.0 mmol, 2.5 eq) and 
the reaction was heated at reflux for 30 min. The reaction was poured into 1M KOH, and the 
organic layer removed. The aqueous layer was acidified with concentrated HCl until the solution 
CHO
CHOOHC
KOMe (2 eq)
Ethyl formate (2.5 eq)
Et2O, reflux, 30 min
SOCl2/Et2O (1/3)
reflux, 3 h
30% (2 steps)
Raptinal
Fluorene (5-2)
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tested acidic to pH paper (at which time a white precipitate was formed). The solution was 
extracted with diethyl ether, dried through Na2SO4, and concentrated. The crude material was 
dissolved in diethyl ether (25 mL), thionyl chloride (8 mL) was added and the solution was 
heated to reflux for 3 h. The reaction was quenched by careful addition to ice water. The solution 
was extracted three times with methylene chloride, washed with water and saturated aqueous 
NaCl, dried through Na2SO4, and concentrated. The crude material was recrystallized from acetic 
acid, the crystals were collected and washed with water until the washing solution tested neutral 
to pH paper, affording Raptinal (5-1) as white crystals (1.52 g, 30%).   
1H NMR (500 MHz, CDCl3) δ 9.89 (s, 2H), 7.53 (dt, J = 7.6, 1.0 Hz, 4H), 7.33 (td, J = 7.5, 1.1 
Hz, 4H), 7.16 – 7.06 (m, 4H), 6.97 (bd, J = 7.8 Hz, 4H). 
13C NMR (125 MHz, CDCl3) δ 197.6, 142.5, 139.6, 129.2, 127.2, 126.8, 119.9, 71.2. 
HRMS (ESI): m/z 387.1381, [calculated for C28H19O2 (M+H)+: 387.1385] 
 
 
Compound 5-3: To a solution of Raptinal (5-1) (32 mg, 0.0828 mmol, 1 eq) in EtOH (0.8 mL) 
was added NaBH4 (27 mg, 0.714 mmol, 8.6 eq) and the reaction was stirred for 45 min. The 
reaction was quenched by careful addition of 1M HCl. The reaction was extracted three times 
with CHCl3, dried through Na2SO4, and concentrated. The compound was purified by silica 
column chromatography to give compound 5-3 (26 mg, 80%) as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.54 (d, J = 7.5 Hz, 4H), 7.27 (t, J = 7.5 Hz, 4H), 7.07 (t, J = 7.5 
Hz, 4H), 6.96 (bs, 4H), 4.10 (s, 4H), 3.45 (bs, 2H). 
CHOOHC
NaBH4 (8.6 eq)
EtOH, rt, 45 min
80%
CH2OHHOH2C
5-3Raptinal
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13C NMR (125 MHz, CDCl3) δ 145.3, 141.3, 127.9, 126.6, 125.1, 119.7, 67.0, 60.4. 
HRMS (ESI): m/z 413.1510, [calculated for C28H22O2Na (M+Na)+: 413.1512] 
 
 
Compound 5-4: To a solution of Raptinal (5-1) (32 mg, 0.083 mmol, 1 eq) in pyridine (0.8 mL) 
was added methoxyamine hydrochloride (17 mg, 0.207 mmol, 2.5 eq) and the reaction was 
stirred at room temperature for 44 h. The reaction was diluted with chloroform and washed twice 
with 1M HCl. The organic layer was dried through Na2SO4, concentrated, and purified by silica 
column chromatography to afford compound 5-4 (26 mg, 70%) as a white foam.  
1H NMR (500 MHz, CDCl3) δ 8.35 (s, 2H), 7.45 (d, J = 7.6 Hz, 4H), 7.25 (t, J = 7.7 Hz, 4H), 
7.06 (t, J = 7.0 Hz, 4H), 6.83 (s, 4H), 3.88 (s, 6H). 
13C NMR (125 MHz, CDCl3) δ 150.1, 143.0, 141.2, 128.2, 126.3, 126.3, 119.4, 62.1, 60.8. 
HRMS (ESI): 445.1912 [calculated for C30H25N2O2 (M+H)+ 445.1916] 
 
 
Compound 5-6: To a solution of compound 5-5 (100 mg, 0.304 mmol, 1 eq) in diethyl ether (6 
mL) was added sodium metal (30 mg, 1.30 mmol, 4.3 eq). The solution was stirred at room 
temperature for 48 h, at which point CO2 (g) was bubbled through the solution. The crude 
reaction was poured into 2.5% NaOH, and washed once with diethyl ether. The aqueous layer 
CHOOHC
H2N-OCH3.HCl (2.5 eq)
Pyridine, rt, 44 h
70%
5-4
NOMeMeON
Raptinal
COOHHOOC
a. Na (4.3 eq)
Et2O, rt, 48 h
b. CO2, rt, 15 min
33%
5-5 5-6
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was acidified until complete precipitation at which point it was extracted three times with 
methylene chloride and once with diethyl ether. The organic extracts were combined, dried 
through Na2SO4, concentrated and purified by silica column chromatography (with 1% formic 
acid) to afford compound 5-6 (42 mg, 33%).  
1H NMR (500 MHz, CD3OD) δ 7.42 (d, J = 7.5 Hz, 4H), 7.23 (t, J = 7.5 Hz, 4H), 7.08 (bs, 4H), 
7.00 (t, J = 7.5 Hz, 4H) 
13C NMR (125 MHz, CD3OD) δ 174.7, 143.9, 143.1, 129.2, 128.6, 126.9, 119.8, 67.7. 
HRMS (ESI): m/z 417.1125, [calculated for C28H17O4 (M-H)-: 417.1127] 
 
 
Compound 5-7: To a reaction vial was added compound 5-6 (50 mg, 0.12 mmol, 1 eq) and 
acetic anhydride (2 mL). The reaction was heated to 70 °C for 2 h, after which the solvent was 
evaporated. The compound was purified by silica column chromatography to give 16.6 mg 
(35%) of compound 5-7.  
1H NMR (500 MHz, CDCl3) δ 7.58 (d, J = 8 Hz, 4H), 7.39 (bt, J = 8 Hz, 4H), 7.20 (bs, 8H) 
13C NMR (125 MHz, CDCl3) δ 169.9, 141.7, 138.4, 130.3, 127.8, 124.7, 120.9, 68.1 
HRMS (ESI): m/z 423.1008, [calculated for C28H16O3Na (M+Na)+: 423.0997] 
 
 
COOHHOOC O
O
O
Ac2O (neat)
70oC, 2 h
35%
5-6 5-7
COOHHOOC COOMeMeOOC
Me3SiCHN2 (3 eq)
MeOH, rt, 2 h
50%
5-6 5-8
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Compound 5-8: To a room temperature solution of compound 5-6 (10 mg, 0.0239 mmol, 1 eq) 
in methanol (0.3 mL) was added TMS-diazomethane (0.036 mL of a 2M solution in diethyl 
ether, 0.717 mmol, 3 eq) at room temperature. The reaction was stirred at room temperature for 2 
h. The reaction was concentrated and purified by silica column chromatography to afford 
compound 5-8 (5.3 mg, 50%) as a white solid. 
1H NMR (500 MHz, CDCl3) δ 7.39 (dd, J = 7.6, 1.2 Hz, 4H), 7.25 (dd, J = 7.8, 6.6 Hz, 4H), 
7.08 – 7.01 (m, 4H), 6.97 (bd, J = 7.9 Hz, 4H), 3.77 (s, 6H). 
13C NMR (125 MHz, CDCl3) δ 171.8, 141.7, 141.5, 128.6, 127.4, 126.7, 126.3, 119.0, 66.4, 
52.9. 
HRMS (ESI) 447.1603 [calculated for C30H23O4 (M+H)+ 447.1596] 
 
Compound 5-9: To a solution of 2,7-dibromofluorene (5-17) (500 mg, 1.5 mmol, 1 eq) and 
potassium methoxide (210 mg, 3.0 mmol, 2 eq) in diethyl ether (10 mL) was added ethyl formate 
(0.3 mL, 3.75 mmol, 2.5 eq) and the reaction was heated to reflux for 1.5 h. The reaction was 
poured into water and washed with diethyl ether. The aqueous layer was acidified with 
concentrated HCl until precipitation was observed. The aqueous layer was extracted twice with 
diethyl ether, washed once with water, dried through Na2SO4 and concentrated. To the crude 
material was added diethyl ether (10 mL) and thionyl chloride (1 mL) and the reaction was 
heated at reflux for 17 h. The product was precipitated and washed with diethyl ether to afford 
compound 5-9 (42 mg, 8%).  
KOMe (2 eq)
Ethyl formate (2.5 eq)
Et2O, reflux, 1.5 h
Br Br Br
Br
OH
SOCl2/Et2O (1/10)
reflux, 17 h
8% (2 steps)
CHOOHC
BrBr
Br Br
5-9
5-17
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1H NMR (500 MHz, CDCl3) δ 9.80 (s, 2H), 7.49 (d, J = 6.6 Hz, 4H), 7.37 (d, J = 8.1 Hz, 4H), 
7.03 (bs, 4H). 
13C NMR (125 MHz, CDCl3) δ 196.2, 141.0, 140.8, 133.4, 130.6, 121.9, 121.8, 71.5. 
HRMS (ESI) 724.7595, [calculated for C28H14O2Br4Na (M+Na)+ 724.7581] 
 
 
Compound 5-10: To a solution of 2,7-dichlorofluorene (5-18) (1.0 g, 4.25 mmol, 1 eq) and 
potassium methoxide (1.0 g, 14.2 mmol, 3.3 eq) in diethyl ether (30 mL) was added ethyl 
formate (1.6 mL, 19.8 mmol, 4.7 eq) and the reaction was heated to reflux for 2.5 h. The reaction 
was poured into water and extracted twice with hexane. The aqueous layer was acidified with 
concentrated HCl until precipitation was observed. The aqueous layer was extracted three times 
with ethyl acetate, the combined organic extracts were washed with saturated aqueous NaCl, 
dried through Na2SO4 and concentrated. The crude product was dissolved in diethyl ether (5 mL) 
and thionyl chloride (0.62 mL) was added. The reaction was heated at reflux for 12 h. The 
precipitate was collected and washed with diethyl ether to give compound 5-10 (76 mg, 29%). 
1H NMR (500 MHz, CDCl3) δ 9.82 (s, 2H), 7.44 (d, J = 8.1 Hz, 4H), 7.36 (d, J = 8.2 Hz, 4H), 
6.91 bs, 4H). 
13C NMR (125 MHz, CDCl3) δ 196.2, 140.9, 140.4, 133.9, 130.5, 127.7, 121.5, 71.3. 
HRMS (ESI) 522.9849 [calculated for C28H15O2Cl4 (M+H)+ 522.9826] 
 
KOMe (3.3 eq)
Ethyl formate (4.7 eq)
Et2O, reflux, 1.5 h
Cl Cl Cl
Cl
OH
SOCl2/Et2O (1/10)
reflux, 12 h
29% (2 steps)
CHOOHC
ClCl
Cl Cl
5-10
5-18
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Compound 5-19: The procedure of Borowiecki and co-workers was followed and the product 
matches the known compound 10. To a 50 mL round-bottom flask was added fluorene (5-2) (1.0 
g, 6.02 mmol), and potassium t-butoxide (1.01 g, 9.03 mmol, 1.5 eq). The solids were dissolved 
in THF (20 mL) and ethyl acetate (0.89 mL, 9.03 mmol, 1.5 eq) was added dropwise to the 
solution. The reaction was heated at reflux under nitrogen for 4 h. The reaction mixture was 
poured into a saturated solution of NH4Cl and which was extracted three times with diethyl ether. 
The combined ether extracts were washed with a saturated NaCl solution, dried over Na2SO4, 
and concentrated in vacuo. The compound was purified by silicia column chromatography to 
give compound 5-19 as a yellow solid (699 mg, 56%).  
1H NMR (500 MHz, CDCl3) δ 7.82 (d, J=8 Hz, 2H), 7.51 (d, J=7.5 Hz, 2H), 7.46 (t J=7.5 Hz, 
2H), 7.35 (t, J=7.5 Hz, 2H), 4.80 (s, 1H), 1.62 (s, 3H). 
13C NMR (125 MHz, CDCl3) δ 207.1, 142.6, 141.6, 128.9, 128.2, 125.6, 120.9, 64.0, 25.6 
HRMS (ESI): 209.0970 [calculated mass for C15H13O (M+H)+ 209.0966] 
 
 
Compound 5-20: A modified version of the procedure of Greenhow and co-workers was 
followed11. To a 10 mL round bottom flask containing compound 5-19 (1.0 g, 4.8 mmol) was 
added thionyl chloride (4 mL). The reaction was heated at reflux for 24 h. Following removal of 
thionyl chloride, the product was purified by silica column chromatography (10:1 hexane/ethyl 
KOtBu (2 eq)
EtOAc (1.5 eq)
THF, reflux, 4 h
56%
O
5-19
Fluorene (5-2)
O
5-19
SOCl2 (neat)
reflux, 24 h, 34%
O
5-20
Cl
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acetate) and recrystallized from ethanol, affording compound 5-20 (395 mg, 34%).  
1H NMR (400 MHz, CDCl3) δ 7.76 (d, J=7.2 Hz, 2H), 7.51 (d, J=7.2 Hz, 2H), 7.49 (td, J=7.6 
Hz, 0.8 Hz, 2H), 7.39 (td, J=7.6 Hz, 1.2 Hz, 2H), 1.770 (s, 3H) 
13C NMR (125 MHz, CDCl3) δ 198.8, 144.2, 141.0, 130.8, 129.4, 125.6, 121.3, 110.0, 24.9 
HRMS (ESI): 265.0399 [calculated mass for C15H11OClNa (M+Na)+ 265.0396] 
 
 
Compound 5-11: A modified version of the procedure of Greenhow and co-workers was 
followed 11. To a 25 mL round bottom flask containing 5-20 (169 mg, 0.69 mmol, 1 eq) was 
added 274 mg of copper powder and 15 mL of benzene. The reaction was heated at reflux for 20 
h, the copper was filtered and the solvent was evaporated. The product was purified by silicia 
column chromatography (10:1 hexane/ethyl acetate) to give compound 5-11 (55.3 mg, 38%). 
Note: NMR analysis of the product at room temperature resulted in very poor NMR signal, 
presumably due to limited rotation about the C9-C9’ single bond. NMR spectroscopic analysis 
was therefore carried out at -40 °C. 
1H NMR (500 MHz, CDCl3, -40oC) δ 8.24 (d, J = 7.5 Hz, 2H), 7.56 (d, J = 7.3 Hz, 2H), 7.53 – 
7.41 (m, 4H), 7.29 (d, J = 7.7 Hz, 2H), 7.04 (t, J = 7.5 Hz, 2H), 6.63 (t, J = 7.5 Hz, 2H), 5.86 (d, 
J = 7.8 Hz, 2H), 1.71 (s, 6H). 
13C NMR (125 MHz, CDCl3, -40oC) δ 206.4, 144.4, 143.4, 141.3, 141.1, 129.7, 128.9, 128.1, 
127.1, 126.1, 125.4, 119.8, 118.9, 72.9, 29.0. 
HRMS (ESI): 415.1690 [calculated mass for C30H23O2 (M+H)+ 415.1698] 
O
5-20
Cl
Cu powder
Benzene, reflux, 20 h
38%
COCH3H3COC
5-11
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Compound 5-21: To an oven-dried 50 mL round-bottom flask with a stir bar was added fluorene 
(5-2) (1.0 g, 6.02 mmol) and potassium t-butoxide (1.01 g, 9.03 mmol, 1.5 eq). The solids were 
dissolved in THF (25 mL) and ethyl trifluoroacetate (1.1 mL, 9.03 mmol, 1.5 eq) was added 
dropwise. The reaction was heated at reflux under nitrogen for 20 h. The reaction mixture was 
poured into a saturated NH4Cl solution and extracted three times with diethyl ether. The 
combined ether extracts were washed with water, dried over Na2SO4, and the solvent was 
removed in vacuo to give a yellow oil which slowly solidified. The compound was purified by 
silicia column chromatography (6:1 hexanes/ethyl acetate) to give compound 5-21 (1.002 g, 
64%).  
1H NMR (500 MHz, CDCl3) δ 7.83 (d, J=7.5 Hz, 2H), 7.50 (m, 4H), 7.37 (t, J=7 Hz, 2H), 5.25 
(s, 1H).  
13C NMR (125 MHz, CDCl3) δ 190.4 (q, J=33.9 Hz), 142.8, 139.1, 129.6, 127.6, 125.7, 121.2, 
116.2 (q, J=292.1 Hz), 57.3. 
19F NMR (470 MHz, CDCl3, C6F6) δ: -78.30 
HRMS (ESI): m/z 263.0691 [calculated mass for C15H10OF3 (M+H)+ 263.0684] 
 
 
KOtBu (2 eq)
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Compound 5-12: To a 50 mL round bottom flask containing compound 5-21 (500 mg, 1.91 
mmol) was added thionyl chloride (20 mL). The reaction was heated at reflux for 48 h. The 
thionyl chloride was removed. 1H NMR spectroscopy showed a compound consistent with the α-
chloro trifluoromethyl ketone with partial conversion to the desired dimer. The crude material 
(426 mg) was added to a 10 mL round bottom flask containing copper powder (827 mg) and 
benzene (40 mL). The reaction was heated at reflux for 15 h after which the copper was filtered 
and the solvent evaporated. The product was purified by silica column chromatography (20:1 
hexane/ethyl acetate) to give compound 5-12 (63.4 mg, 13%).  
1H NMR (500 MHz, CDCl3) δ 8.23 (bs, 2H), 7.55-7.49 (m, 8H), 7.10 (bs, 2H), 6.66 (bs, 2H), 
5.76 (bs, 2H) 
13C NMR (125 MHz, CDCl3) δ 144.5, 142.2, 140.3, 136.6, 130.2, 129.7, 129.4, 127.7, 126.4, 
125.6, 120.3, 119.4, 115.7 (q, J = 294.5 Hz), 70.0. 
19F NMR (470 MHz, CDCl3, C6F6) δ -74.80 
HRMS (ESI) 523.1140 [calculated for C30H17F6O2 (M+H)+ 523.1133] 
 
Compound 5-16: A modified version of the procedure of Boudif and Momenteau was 
followed12. Briefly, POCl3 (0.33 mL) was added dropwise to DMF (0.5 mL) at 0oC and stirred 
for 1 h. Next, 2,5-dimethyl-1H-pyrrole (5-22) (100 mg, 1.05 mmol, 1 eq) was added at room 
temperature and heated to 50oC for 2 h. The reaction was cooled to room temperature and slowly 
quenched by addition to H2O. The reaction was extracted three times with EtOAc and washed 
with saturated aqueous NaCl. The solution was dried through Na2SO4, concentrated and purified 
by silica column chromatography to afford compound S14 (16.4 mg, 10%) as a white solid.  
H
N
CHOOHC
5-16
H
N a. POCl3, DMF, 0oC
b. H2O, rt
10%5-22
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1H NMR (500 MHz, d6-Acetone) δ 10.26 (s, 2H), 2.50 (s, 6H). 
13C NMR (125 MHz, d6-Acetone) δ 186.5, 137.9, 120.4, 11.1. 
HRMS (ESI) 152.0716 [calculated for C8H10NO2 (M+H)+ 152.0712] 
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